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Abstract 
 
The objective of this research was to investigate the possibility that Photorhabdus 
luminescens produces glycoproteins and thus contains a protein glycosylation system. 
P. luminescens is a pathogen of insects and a symbiont of soil nematodes. Adhesion and 
invasion are very important in the life cycle of the organism and it is speculated that the 
bacteria may produce glycoproteins to facilitate infection of the host. 
 
Proteins from P. luminescens were analysed using lectins for the presence of 
glycoproteins. Many potential glycoproteins were isolated using lectin affinity 
chromatography (LAC) and one such protein was identified conclusively using mass 
spectrometry to be an outer membrane porin, OmpN. No glycoproteins have previously 
been identified in P. luminescens. The ompN gene was cloned and expressed in both 
Escherichia coli and P. luminescens. It was found that OmpN purified from P. 
luminescens was capable of binding the lectins WGA and GSL I, while OmpN purified 
from E. coli was not. 
 
Campylobacter jejuni is the most extensively studied bacteria in terms of protein 
glycosylation. It contains a pgl locus encoding enzymes involved in the glycosylation of 
many of its proteins. Orthologues of some Pgl proteins were discovered in P. 
luminescens. The gene that encodes one of these proteins, wblK, was mutated. LAC was 
used to examine the effect of this mutation on the glycoproteins produced by the 
organism. It was found that the glycosylation of at least two proteins was affected by 
the wblK mutation. These proteins were isolated by LAC using WGA agarose from the 
wblK mutant strain but not from the wildtype strain. One of the altered proteins was 
identified as plu3611. It was found to exist in at least two different glycoforms. The 
results provided evidence that P. luminescens is capable of glycosylating OmpN and 
plu3611 and so contains a protein glycosylation system. 
Chapter 1 
Introduction 
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1.1 Glycobiology and glycosylation 
 
1.1.1 Glycobiology 
 
Glycobiology is the study of the structure, biosynthesis and biology of carbohydrates 
i.e. sugar chains or glycans. This includes the study of glycoconjugates, glycan 
biosynthesis enzymes and glycan recognition proteins such as lectins. Glycobiology is 
one of the most rapidly growing fields in biological science. However, to date the 
current understanding of the area is relatively limited.  
 
The complete set of sugars in an organism, whether they are free or present in more 
complex forms is known as its glycome. The glycome of an organism can be extremely 
complex compared to its proteome. Proteins are synthesised as an identical copy from 
an mRNA template encoded in the genome. However, glycan synthesis is not a template 
driven process but instead glycans are assembled through a series of individual 
enzymatic reactions linking together different monosaccharide units. Not only can 
different monosaccharides combine together to form different glycans but they can also 
be combined in various ways through different glycosidic linkages. Glycans can also be 
assembled in branched structures leading to many possible combinations of just a few 
monosaccharides (Taylor and Drickamer 2006).  For example the number of theoretical 
combinations of three monosaccharides to produce a trisaccharide is 38,016 compared 
to just 64 possible permutations of four nucleotides in a three base codon (Laine 1997). 
Glycans therefore have an inherent capacity and potential for encoding enormous 
amounts of biological information. Another important point to note is that a 
glycoprotein can be modified with heterogeneous glycans. Glycoproteins with the same 
peptide chain but different glycan moieties are called glycoforms. Each glycoform can 
have different and distinct biological properties and characteristics (Taylor and 
Drickamer 2006, Campbell and Yarema 2005). 
 
This degree of complexity makes it very difficult to assign functional roles to glycans.  
Many functions of glycans can be found by observing what occurs when glycans are no 
longer synthesised correctly by an organism. It is known that glycans are an essential 
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component of all living things. Incorrect glycan formation plays a role in many diseases 
in humans such as rheumatoid arthritis, Alzheimer’s disease and certain cancers (Taylor 
and Drickamer 2006, Ambrosi et al. 2005). Diseases belonging to a group known as 
congenital disorders of glycosylation (CDG) are known to be directly caused by defects 
in the synthesis of glycans and are reviewed by Grünewald et al. (2002). The disorders 
are caused by a deficiency in enzymes involved in the glycan synthesis pathway. The 
disorders most commonly begin in infancy. The symptoms of CDG vary from stroke to 
psychomotor retardation to the fragile skin seen in progeroid syndrome. Often 
individuals affected by CDG do not survive infancy (Aebi and Hennet 2001). 
Congenital muscular dystrophy, a progressive disease that causes muscle degeneration, 
is a CDG where the protein α-dystroglycan which is normally modified with O-linked 
mannose is not correctly glycosylated (Nakamura et al. 2010). 
 
Other known functions of glycans include stabilisation and solubilisation of proteins. 
They also play a vital role in many biological processes such as cell recognition and 
adhesion and cell signalling. They are known to provide structural components such as 
cell walls. (Taylor and Drickamer 2006).  
 
1.1.2 Glycosylation 
 
Glycosylation is a term used to describe the addition of a glycan to a protein or a lipid 
via a covalent glycosidic linkage. The sugar groups are synthesised in the organism by 
various sugar biosynthesis enzymes and then transferred to the growing sugar chain by 
enzymes called glycosyltransferases (GTs). When the desired glycan has been 
synthesised it is then further processed by various processing enzymes such as flippases, 
polymerases and chain length determinant enzymes to yield the functional glycolipid or 
glycoprotein (Samuel and Reeves 2003).  
 
In eukaryotes both glycoproteins and glycolipids are found in the plasma membrane of 
the cell at its surface. The extracellular matrix surrounding eukaryotic cells comprises 
glycoproteins and they are also secreted in biological fluids such as serum (Taylor and 
Drickamer 2006). Around 70% of all proteins in eukaryotes are believed to be 
glycosylated (Apweiler et al. 1999, Dell et al. 2010). The majority of genes involved in 
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protein glycosylation in humans have been identified and account for about 2% of the 
total human genome (Campbell and Yarema 2005).  
 
In bacterial systems, glycosylation occurs in lipopolysaccharide (LPS), 
lipooligosaccharide (LOS) and capsular polysaccharide (CP) biosynthesis pathways. It 
is now well known that many bacteria are also capable of producing glycoproteins and 
this will be discussed further in section 1.3. 
 
There are five different classes of glycosylation, N-linked, O-linked, P-linked, C-linked 
and G-linked. All five classes occur in eukaryotes but so far only N-linked and O-linked 
protein glycosylation has been discovered in prokaryotes. In P-linked glycosylation 
phospho-glycans are linked to a protein via the phosphate of a phosphoserine. C-linked 
glycosylation occurs when glycans are attached to a carbon on a tryptophan side chain. 
G-linked glycosylation occurs in glycosylphosphatidylinositol (GPI)-anchored proteins. 
GPI is a glycolipid which acts as an anchor between cell surface proteins and the 
phospholipid bilayer in a eukaryotic cell membrane. A G-linkage is found between the 
glycan and the lipid in GPI (Pandhal and Wright 2010, Böhme and Cross 2002). N-
linked and O-linked glycosylation occur most commonly and will now be discussed 
briefly in eukaryotic systems and in more depth in prokaryotic systems. 
 
1.2 Eukaryotic protein glycosylation 
 
Eukaryotic glycoprotein synthesis takes place in the rough endoplasmic reticulum (ER) 
and Golgi apparatus of the cell (Taylor and Drickamer 2006, Weerapana and Imperiali 
2006). It is a highly complex process involving step by step enzymatic conversions and 
hundreds of gene products. The process is sensitive to the availability of enzymes, 
nutrients and nucleotide sugar donors, therefore the glycoproteins produced are highly 
dependent on the overall metabolic state of the cell (Taylor and Drickamer 2006, Marth 
and Grewal 2008). Despite this complexity, well defined pathways have been identified 
for the synthesis of N- and O-linked glycoproteins. Table 1.1 shows the most common 
monosaccharides found in eukaryotic N- and O-linked glycoproteins. 
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Table 1.1 Monosaccharides commonly found in eukaryotic glycoproteins 
Monosaccharide Abbreviation 
3-D Chair 
Projection 
β-D-Glucose Glc 
 
β-D-Mannose Man 
 
β-D-Galactose Gal 
 
β-D-N-Acetylglucosamine GlcNAc 
 
β-D-N-Acetylgalactosamine GalNAc 
 
β-D-Xylose Xyl 
 
α-N-Acetylneuraminic acid 
(sialic acid) 
NeuNAc 
 
β-D-Glucuronic acid GlcA 
 
α-L-Iduronic acid IdoA 
 
α-L-Fucose Fuc 
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1.2.1 N-linked eukaryotic protein glycosylation 
 
The N-linked protein glycosylation pathway in eukaryotes is the best understood 
glycosylation system. Eukaryotic N-linked glycans are synthesised through a common 
biosynthetic pathway and therefore all consist of a common pentasaccharide core 
structure of three mannose residues and two GlcNAc residues (Man3GlcNAc2). The 
glycan is attached to the protein via a β-glycosidic linkage between GlcNAc and the 
amide nitrogen (N-linked) of an asparagine residue within an Asn-X-Ser/Thr consensus 
sequence. The X in the Asn-X-Ser/Thr consensus sequence can be any residue apart 
from proline (Taylor and Drickamer 2006, Weerapana and Imperiali 2006, Geyer and 
Geyer 2006). 
 
N-glycans can be differentiated into three groups according to the monosaccharides 
attached to the pentasaccharide core structure. The three groups are high mannose, 
hybrid and complex glycans (Geyer and Geyer 2006). Figure 1.1 shows an example of 
each. 
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Figure 1.1 The three eukaryotic N-Linked glycan component classes  
Examples of core mannose (a), hybrid (b) and complex (c) N-linked glycans (Taylor and Drickamer 2006, 
Geyer and Geyer 2006).  
 
Figure 1.1 shows that all eukaryotic N-linked glycans contain the Man3GlcNAc2 core 
pentasaccharide. Core mannose glycans typically contain between five and nine 
mannose residues. They contain unsubstituted terminal mannose residues (figure 1.1 
(a)). Hybrid glycans contain both unsubstituted mannose residues and substituted 
mannose residues with GlcNAc (figure 1.1 (b)). In complex glycans, all terminal 
residues of a high mannose glycan have been replaced with GlcNAc. In complex 
glycans mannose residues are only present in the core pentasaccharide (figure 1.1 (c)). 
 
= Man 
 
= GlcNAc 
 
= Gal 
 
 
= NeuNAc 
 
 
= Fuc 
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GlcNAc structures added to the glycan core are called “antennae” therefore figure 1.1 
(b) is a biantennary glycan and figure 1.1 (c) is a tetraantennary glycan. In both complex 
and hybrid glycans other monosaccharides can be transferred to the terminal GlcNAc of 
the growing glycan structure. Complex glycans usually terminate with sialic acid. 
Complex glycans can be further modified with a bisecting GlcNAc or a core fucose 
residue can be attached to the innermost GlcNAc residue (Taylor and Drickamer 2006, 
Geyer and Geyer 2006). 
 
N-linked glycosylation in eukaryotes is a co-translational process that occurs in three 
stages. Firstly a precursor oligosaccharide is formed on a lipid carrier. Next the 
oligosaccharide is transferred to the polypeptide and finally the glycan is processed i.e. 
residues are removed and new ones added to yield the final glycoprotein (Taylor and 
Drickamer 2006). 
 
The lipid carrier on which the precursor glycan is assembled is called dolichol and is 
found in the membrane of the ER. Seven sugar residues (Man5GlcNAc2) are attached to 
dolichol at the cytoplasmic side of the membrane of the ER. Single mannose and 
glucose residues are also bound to other dolichol molecules in the ER. The 
oligosaccharide/dolichol and monosaccharide/dolichol structures are flipped into the 
lumen of the ER. In the lumen, GTs transfer the single sugar residues from the dolichol 
molecule to the growing oligosaccharide. A tetradecasaccharide, Glc3Man9GlcNAc2 
(figure 1.2) is synthesised on dolichol. The synthesis of this dolichol linked 
tetradecasaccharide is known as the dolichol pathway (Weerapana and Imperiali 2006). 
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Figure 1.2 The tetradecasaccharide Glc3Man9GlcNAc2 
Structure of Glc3Man9GlcNAc2, the glycan transferred to a polypeptide in eukaryotic N-linked 
glycosylation in the lumen of the ER. The glycan can then be further processed in the ER and Golgi 
apparatus to yield the final glycoprotein (Weerapana and Imperiali 2006). 
 
Glc3Man9GlcNAc2 is then transferred by an oligosaccharyltransferase (OT) to the 
polypeptide via a GlcNAc-Asn linkage. The protein is still being translated by the 
ribosome in the ER during this process. Released dolichol molecules are flipped back to 
face the cytoplasm (Taylor and Drickamer 2006, Weerapana and Imperiali 2006). 
 
Still in the ER, the three glucose residues and one of the mannose residues are removed 
by glycosidases and the protein undergoes correct folding. The Man8GlcNAc2 bound 
protein is transferred to the Golgi apparatus. Here, through the action of various 
glycosidases and GTs the glycan is further processed to yield glycans similar to those 
shown in figure 1.1. 
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1.2.2 O-linked eukaryotic protein glycosylation 
 
The most common type of O-linked glycosylation is where the glycan is attached to the 
protein through the oxygen atom (O-linked) of the hydroxyl group of a serine or 
threonine residue. There is no consensus sequence required for O-linked glycosylation. 
The most prevalent O-linked glycans in vertebrates are the mucin-type glycans. They 
contain an initial GalNAc residue α-glycosidically linked to serine or threonine (Taylor 
and Drickamer 2006, Geyer and Geyer 2006). Mucins are glycoproteins expressed in 
high abundance in epithelial cells such as the surface of the digestive and genital tracts 
and in the respiratory system. These surfaces are not sealed by moisture impermeable 
layers as is the case with the skin. Mucins serve to retain moisture, lubricate and protect 
from the invasion of microorganisms. They contain large numbers of clustered O-
glycans especially sialylated glycans resulting in regions of strong negative charge 
allowing mucins to bind large amounts of water (Taylor and Drickamer 2006, Varki 
1999). Mucin type glycans contain one of eight core structures. The four most common 
of these core structures are shown in figure 1.3. 
 
 
Figure 1.3 Common core structures of eukaryotic mucin-type O-linked glycans 
The core structures all contain GalNAc linked to serine or threonine and additional Gal and/or GlcNAc 
residues. 
 
Most mucin type O-glycans contain the core 1 or core 2 structure. Mucin type O-
glycans vary dramatically in size and structure. They can contain merely a single 
residue bound to the polypeptide or the core structure can be extended to produce long 
chain glycans with variable termini that can be similar to the termini of N-glycans 
 
= Gal 
 
= GalNAc 
 
= GlcNAc 
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(Lamblin et al. 2001). O-glycans are generally not as branched as N-glycans, with the 
most common structures being biantennary (Varki 1999). 
 
Although mucins are the most common O-glycosylated proteins in vertebrates other O-
glycans do occur. For example many nuclear and cytoplasmic proteins contain O-linked 
GlcNAc (Varki 1999). O-linked fucose and glucose are found in epidermal growth 
factor-like domains (Haltiwanger and Stanley 2002). O-linked mannose is found in 
dystroglycan and other nervous system glycoproteins (Endo 1999). Galactose O-linked 
to hydroxlysine is found in collagen (Anttinen and Hulkko 1980). Many proteins in 
yeast are O-glycosylated with mannose (Geyer and Geyer 2006, Varki 1999). 
 
Because of the lack of a common protein-glycan linkage in O-linked glycosylation, 
unlike N-linked glycosylation, a common biosynthetic pathway can not be defined. As 
previously stated there are some terminal glycan structures common to both N-linked 
and O-linked glycans suggesting that there may be some enzymes common to both 
biosynthesis processes (Taylor and Drickamer 2006). 
 
In contrast to N-linked glycosylation, O-linked glycosylation is a post-translational 
event that occurs in the Golgi apparatus. There is no precursor oligosaccharide 
transferred to the protein, instead all of the sugar units are directly covalently added, one 
at a time to the protein molecule. In mucin glycosylation this process begins with the 
addition of a GalNAc residue to a serine or threonine residue. The GalNAc is initially 
linked to an undecaprenyl pyrophosphate (UDP) lipid carrier and is transferred to the 
protein by UDP-N-acetylgalactosyl transferase (GalNAcT). In N-linked glycosylation 
the glycan is attached to the protein by a single OT, however in O-linked glycosylation 
numerous GalNAcT enzymes exist (there are at least twelve mammalian GalNAcT 
enzymes) that can transfer the first GalNAc. The enzyme used depends on the amino 
acid sequence of the protein. The glycan is subsequently elongated by several other GTs 
(Taylor and Drickamer 2006, Lamblin et al. 2001).  
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1.3 Prokaryotic protein glycosylation 
 
Up until the 1970s many scientists believed that protein glycosylation was restricted to 
eukaryotic systems. This was believed to be the case because prokaryotes lack the 
cellular organelles required in eukaryotic protein glycosylation (the ER and Golgi 
apparatus) and also because of the relatively short life span of prokaryotes (Upreti et al. 
2003). But now there is overwhelming evidence to prove that protein glycosylation does 
occur in prokaryotes and in fact due to the diversity of prokaryotic glycoproteins 
discovered in recent years, protein glycosylation in prokaryotes is now considered the 
norm rather than the exception. Protein glycosylation in prokaryotes appears to be even 
more complex than in eukaryotes. Prokaryotes are capable of synthesising a wider 
variety of sugars compared to eukaryotes and therefore the variations in prokaryotic 
glycoproteins exceed those found in eukaryotes (Benz and Schmidt 2002, Szymanski 
and Wren 2005, Schmidt et al. 2003).  
 
So far only N-linked and O-linked protein glycosylation has been observed in 
prokaryotes. As in eukaryotes, with N-linked glycosylation the glycan is most 
commonly attached to an asparagine residue and in O-linked glycosylation the glycan is 
attached to a serine, threonine or tyrosine residue (Szymanski and Wren 2005, Hitchen 
and Dell 2006). In some bacterial species a distinct consensus sequence is required for 
N-glycosylation to occur (Nita-Lazar et al. 2005) which will be discussed later. Four 
distinct major glycosylation pathways have so far been discovered in prokaryotes. These 
are (i) OT mediated N-linked glycosylation, (ii) stepwise cytoplasmic N-linked 
glycosylation, (iii) OT mediated O-linked glycosylation and (iv) stepwise O-linked 
glycosylation (Dell et al. 2010). Type (i) is similar to the normal N-linked glycosylation 
found in eukaryotes (see section 1.2.1). This type of glycosylation is abundant in 
archaea but has only been discovered in certain bacterial species. Types (ii) and (iii) 
have so far only been found in the bacterial domain. Type (iv) is similar to the standard 
O-linked glycosylation pathway found in eukaryotes (section 1.2.2). This type of 
glycosylation is common in bacteria but very little of this type of glycosylation has been 
discovered in the archaeal domain (Dell et al. 2010). 
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Protein glycosylation has been most extensively studied in pathogenic bacteria 
(Szymanski and Wren 2005, Power and Jennings 2003). Many proteins associated with 
pathogenesis such as pili and flagella have been shown to be glycosylated. In recent 
years protein glycosylation has also been discovered in Bacteroides spp., one of the 
most abundant genera of commensals found in the human colon (Dell et al. 
2010)(Schmidt et al. 2003). Although huge strides have been made in recent years in 
research of prokaryotic protein glycosylation, it is believed that the area has been 
largely unexplored. It is still not very well understood in many organisms and details of 
the glycosylation processes, the roles of glycosylation and the genes involved still 
remain to be discovered. 
 
1.3.1 Glycosylation of prokaryotic S-layer proteins – a novel discovery 
 
The earliest example of protein glycosylation in prokaryotes was found by Strominger 
and co-workers in the Gram-negative halophile Halobacterium salinarum, a member of 
the domain archaea (Upreti et al. 2003, Mescher et al. 1974, Mescher and Strominger 
1976). A 194 kDa glycosylated surface-layer (S-layer) protein accounting for 40 to 50% 
of the total cell envelope proteins was found in this organism (Benz and Schmidt 2002, 
Mescher et al. 1974). Around the same time protein glycosylation was observed in the 
Gram-positive thermophiles Clostridum thermosaccharolyticum and Clostridium 
thermohydrosulfuricum, the first instance of protein glycosylation reported in eubacteria. 
They both contain a glycosylated S-layer protein with a molecular weight of 140 kDa 
(Sleytr and Thorne 1976). 
 
Glycosylated S-layer proteins are commonly found in archaea and in Gram-positive 
bacteria. According to Schäffer and Messner (2004), up to 20% of total protein 
synthesis in these organisms may be devoted to the production of S-layer glycoproteins. 
To date only about 40 different S-layer glycoprotein structures have been elucidated but 
already the diversity of S-layer glycan structures and glycosidic linkages observed 
exceeds those in eukaryotic glycans (Weerapana and Imperiali 2006). In bacteria, linear 
or branched glycans with 20-50 identical repeating units are generally observed while in 
archaea the glycans tend to be short and do not contain repeating units. S-layer 
glycoproteins in Gram-positive bacteria are analogous to LPS in Gram-negative bacteria 
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with regard to their overall structure and constituent sugars. Some rare sugars found in 
LPS are also observed in S-layer glycoproteins in Gram-positive bacteria. The major 
difference between LPS and S-layer glycoproteins is that the lipid A in LPS is replaced 
with a protein in S-layer glycoproteins. O-linked glycans have been observed on both 
archaeal and bacterial S-layer glycoproteins while N-linked S-layer glycoproteins have 
only been seen in archaea (Schaffer and Messner 2004). 
 
S-layer glycoproteins have a unique feature in that they form two-dimensional 
crystalline arrays on the cell wall of the organism. The cell surface is completely 
covered with S-layer glycoproteins and the carbohydrate moiety of the protein projects 
from the cell surface, as is also the case with LPS (Schaffer and Messner 2004, 
Whitfield 1995). 
 
1.3.2 Protein glycosylation in bacteria 
 
Since the discovery of glycosylated S-layer glycoproteins, many other glycosylated 
proteins have been discovered in important medically relevant pathogenic bacteria such 
as Campylobacter spp., Neisseria spp. and Pseudomonas spp. to name a few and 
recently in Bacteroides spp. (Dell et al. 2010). As previously stated four glycosylation 
pathways have been discovered in bacteria. These will now be discussed with examples 
representing each pathway. 
 
1.3.2.1 Type (i): Oligosaccharyltransferase mediated N-linked glycosylation 
 
As previously stated, it was discovered in 1976 that the S-layer protein from the 
archaeal prokaryote, H. salinarum contained asparagine linked glycans. N-glycosylation 
was then found to be common in the S-layers of many archaea. In the early 2000s much 
research was being carried out on the human pathogen Campylobacter jejuni and it was 
found that it was also capable of N-glycosylation (Young et al. 2002, Wacker et al. 
2002). The pathway that C. jejuni uses to do this is very similar to those that eukaryotes 
and archaea use for N-linked protein glycosylation. 
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• N-linked protein glycosylation in C. jejuni 
 
C. jejuni is the best studied bacterium in terms of N-linked protein glycosylation. C. 
jejuni is a human-gut mucosal pathogen that is involved in enterocolitis, the symptoms 
of which are acute abdominal pain and inflammatory diarrhoea (Weerapana and 
Imperiali 2006, Ketley 1997). Because this organism is so problematic there has been a 
lot of interest in studying its pathogenic mechanisms. 
 
Szymanski et al. (1999) provided evidence that a general protein glycosylation system 
exits in C. jejuni. In 2002, this general protein glycosylation system was shown to be 
involved in glycosylation of two glycoproteins, PEB3 and CgpA, The lectin Soybean 
agglutinin (SBA), which has affinity for GalNAc was used to purify putative 
glycoproteins from C. jejuni and, following trypsin digestion the two glycoproteins 
were identified using mass spectrometry (Linton et al. 2002). Shortly afterwards, Young 
et al. (2002) proved that the PEB3 glycan was N-linked. This was the first confirmed 
report of an N-linked protein glycosylation system in a bacterial system. To date over 65 
proteins have been identified in C. jejuni that are glycosylated by the general N-linked 
glycosylation system (Nothaft and Szymanski 2010). Many of these proteins were also 
isolated using SBA (Power and Jennings 2003, Young et al. 2002, Feldman et al. 2005). 
The N-linked glycan structure modifying these proteins was determined by mass 
spectrometry and nuclear magnetic resonance (NMR) spectroscopy to be a 
heptasaccharide consisting of GalNAc-α1,4-[Glcβ1,3-]Gal-NAc-α1,4-GalNAc-α1,4-
GalNAc-α1,4-GalNAc-α1,3-Bac-β1,N-Asn-X, where Bac is bacillosamine (2,4-
diacetamido-2,4,6-trideoxyglucopyranose) (Young et al. 2002).  
 
In C. jejuni it appears that a specific consensus sequence is needed for N-glycosylation 
to occur. Like in eukaryotic systems the glycan is attached to an asparagine from the 
sequence Asn-X-Ser/Thr (Hitchen and Dell 2006, Nita-Lazar et al. 2005, Young et al. 
2002). Recently it has been discovered that the N-glycosylation consensus sequence in 
C. jejuni also requires a glutamic acid or aspartic acid residue upstream of the Asn-X-
Ser/Thr residues making the extended consensus sequence Glu/Asp-Z-Asn-X-Ser/Thr 
where neither Z nor X can be proline (Kowarik et al. 2006b). 
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The genes involved in this C. jejuni N-glycosylation pathway are found in a 17 kb gene 
locus called the ‘pgl gene cluster’. It contains twelve genes called pglA, pglB etc. to 
pglK and galE (Power and Jennings 2003, Szymanski et al. 2003, Linton et al. 2005). 
 
These genes are significantly homologous to the genes encoding enzymes involved in 
bacterial LPS and CP biosynthesis and were originally thought to be involved in the 
biosynthesis of LPS and CP. However, mutagenesis of these genes did not affect LPS or 
CP biosynthesis suggesting that the proteins encoded by the pgl gene cluster functioned 
independently from the known LPS and CP biosynthetic pathways (Weerapana and 
Imperiali 2006, Szymanski et al. 1999). The pgl gene locus is highly conserved among 
strains of C. jejuni and Campylobacter coli (Power and Jennings 2003).  
 
According to Szymanski (2003) the key enzyme in the pgl gene locus is PglB. This 
enzyme is very similar to the staurosporine- and temperature sensitive yeast protein 3 
(STT3) subunit of the N-linked OT complex of Saccharomyces cerevisiae. STT3 is 
important for recognition and/or catalysis in the OT complex. There are many 
orthologues to STT3 in eukaryotes and archaea. In archaea the orthologue is called 
AglB (Abu-Qarn et al. 2008). STT3 proteins are large proteins (700-970 amino acids), 
contain 10-12 membrane-spanning regions. STT3 orthologues have a conserved C-
terminal catalytic motif (WWDYG) of which the second and third amino acids are 
essential. These properties are seen in PglB and AglB suggesting they act as OTs. It is 
believed to be responsible for the transfer of the oligosaccharide to the Asn residue. 
Campylobacter was the first bacterial genus to be shown to have an OT (Szymanski and 
Wren 2005, Nita-Lazar et al. 2005, Power and Jennings 2003, Szymanski et al. 2003, 
Wacker et al. 2006). 
 
A proposed model for the biosynthesis of N-linked glycoproteins in C. jejuni is outlined 
in Szymanski (2003) and shown in figure 1.4.  
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Figure 1.4 The N-linked protein glycosylation system in C. jejuni 
A proposed model for the biosynthesis of N-linked glycoproteins in C. jejuni (Szymanski et al. 2003). 
 
In this model it is proposed that nucleotide activated sugars are sequentially assembled 
on a lipid carrier, UDP, the same lipid carrier that is used in eukaryotic O-linked protein 
glycosylation. This occurs at the cytoplasmic side of the membrane (Feldman et al. 
2005). The first residue, GlcNAc is attached to the lipid carrier by PglC. It is then 
sequentially modified by PglF (a dehydratase), PglE (an aminotransferase) and PglD (an 
acetyltransferase) to form bacillosamine. PglA is a GT that is believed to add the α-1,3-
linked GalNAc to bacillosamine. PglH and PglJ are GTs that are both believed to be 
involved in transferring the next four α-1,4-linked GalNAc residues. The final GT, PglI 
adds the only branched residue, glucose. It is unsure whether this addition of the glucose 
occurs in sequence or after all five GalNAc residues have been added. The UDP-linked 
heptasaccharide is shown in figure 1.5. Once the lipid-linked heptasaccharide is 
assembled, it is flipped across the inner membrane into the periplasm by PglK, an ABC 
transporter. PglB, the most important enzyme in the process, the OT, transfers the 
glycan to the asparagine residue of the Glu/Asp-Z-Asn-X-Ser/Thr consensus sequence 
(Upreti et al. 2003, Szymanski et al. 2003, Weerapana et al. 2005, Karlyshev et al. 
2005a). 
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Figure 1.5 The C. jejuni UPD-linked heptasaccharide 
The UDP-linked heptasaccharide, GalNAc-α1,4-[Glcβ1,3-]Gal-NAc-α1,4-GalNAc-α1,4-GalNAc-α1,4-
GalNAc-α1,3-Bac-α1-UDP. The heptasaccharide is the glycan donor in N-linked protein glycosylation in 
C. jejuni catalyzed by the pgl gene cluster (Weerapana et al. 2005). 
 
There are some key differences between type (i) OT mediated N-linked glycosylation in 
prokaryotes compared to eukaryotes. In prokaryotes transfer of the oligosaccharide by 
OT takes place in the periplasm (in bacteria) or on the cell surface (in archaea). Because 
of this the protein must be fully folded, since protein folding occurs in the cytoplasm. In 
contrast, in eukaryotes oligosaccharides are transferred to nascent proteins which have 
not yet been folded. Another difference is that as yet there is no evidence to suggest that 
the oligosaccharide sequence seen in prokaryotes is conserved as is the conserved 
Glc3Man9GlcNAc2 sequence found in all higher eukaryotes. Finally, unlike in 
eukaryotes, prokaryotic glycans do not appear to be further processed following flipping 
by PglK (Dell et al. 2010). 
 
• N-linked protein glycosylation in other Epsilonproteobacteria 
 
OT genes are ubiquitous in the eukaryotic and archaeal domains and consequently N-
linked protein glycosylation is very common in both of these domains. However, very 
few bacteria actually contain OT genes and so only a limited number of bacterial 
species undergo N-linked protein glycosylation (Nothaft and Szymanski 2010). When 
pglB, the first known bacterial OT gene, was discovered in C. jejuni, it was thought that 
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its occurrence was unique in the bacterial domain. Scientists postulated that C. jejuni 
acquired this gene through lateral gene transfer from either archaea or eukarya. 
However, recent searches of bacterial genomes have uncovered that other bacteria from 
the epsilon subdivision of proteobacteria (of which the Campylobacter genus is a 
member) also contain pglB genes. Some of these bacteria include Wolinella 
succinogenes DSM 1740, Sulfurovum sp. NBC37-1, Nitratirutor sp. SB155-2, 
Caminibacter mediatlanticus TB-2, Helicobacter pullorum and Desulfovibrio 
desulfuricans subsp. desulfuricans G20 (Dell et al. 2010, Nothaft and Szymanski 2010). 
The structures of the N-linked glycans modifying H. pullorum and W. succinogenes 
glycoproteins have been elucidated using mass spectrometry and are shown in figure 1.6 
along with the C. jejuni N-linked heptasaccharide. 
 
Figure 1.6 Structural representation of bacterial N-linked glycans 
Like in C. jejuni, the glycan modifying W. succinogenes N-linked glycoproteins contains bacillosamine as 
its first residue. It is a hexasaccharide containing one branched hexose. In H. pullorum the first sugar of 
the pentasaccharide is an N-Acetylhexosamine (HexNAc). It contains no branched sugars. Some of the 
sugar units belonging to the W. succinogenes and H. pullorum glycans have not yet been identified (Dell 
et al. 2010). 
 
Because the machinery for N-linked protein glycosylation in bacteria has so far only 
been found in Epsilonproteobacteria, some scientists now believe that the OT gene was 
transferred to them from archaea. This is because in primordial deep sea vents, where 
many archaea are found, the majority of bacteria living there are Epsilonproteobacteria 
(Dell et al. 2010).  
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1.3.2.2 Type (ii): Stepwise cytoplasmic N-linked glycosylation 
 
In 2008 a novel N-linked protein glycosylation system was discovered by Gross and co-
workers in the Gram-negative Gammaproteobacterium Haemophilus influenzae that 
involved sequential transfer of sugars to the glycoprotein rather than the block transfer 
of an oligosaccharide seen in type (i) (see section 1.3.2.1) (Gross et al. 2008). The 
modification is the only one of this kind to be discovered so far and occurs on the high-
molecular-weight adhesin 1 (HMW1) protein. HMW1 adhesin is modified at 31 Asn 
residues. All but one of the Asn residues that are modified are part of the consensus 
sequence Asn-X-Ser/Thr. The modifications that occur are either monohexoses or 
dihexoses with the hexoses being Gal or Glc. The enzyme responsible for stepwise N-
linked glycosylation in this organism is called HMW1C. This appears to be the only 
enzyme necessary for this process. It acts as an OT, transferring Glc/Gal to asparagine 
residues but also has a GT function as it generates the hexose-hexose bonds when the 
modification is a dihexose. As yet the mechanism for this pathway has not been defined. 
Orthologues to this protein have been found in other bacterial species and so it is likely 
the H. influenzae is not the only bacterium capable of stepwise cytoplasmic N-linked 
glycosylation (Dell et al. 2010, Nothaft and Szymanski 2010, Gross et al. 2008). 
 
1.3.2.3 Type (iii): OT mediated O-linked glycosylation 
 
In recent years a general O-linked protein glycosylation system has been discovered in 
some bacterial species. This system is very similar to the type (i) pathway mentioned 
earlier (section 1.3.2.1). It was first discovered in pathogenic bacteria. The pili of 
Neisseria spp. and Pseudomonas aeruginosa were shown to be O-glycosylated by this 
mechanism. However, even more recently this type of glycosylation has been observed 
in Bacteroides spp. This type of glycosylation has only been discovered in Gram-
negative bacteria. This does not come as a surprise since the pathway is analogous to 
LPS biosynthesis (Dell et al. 2010). 
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• OT mediated O-linked glycosylation of Neisseria proteins 
 
Neisseria bacteria are members of the class Betaproteobacteria and are Gram-negative 
diplococci. Two very important species of Neisseria are Neisseria. gonorrhoeae and 
Neisseria meningitidis. Both of these organisms are pathogenic. N. meningitidis is one 
of the most common causes of bacterial meningitis and also causes meningococcal 
septicaemia. N. gonorrhoeae is the causative agent of the human disease gonorrhoea 
(Power and Jennings 2003). It has been shown that these species are capable of 
glycosylating their pili with O-linked glycans. Pili are found in many Gram-negative 
pathogenic bacteria. They are fibrous polymeric proteins composed primarily of 
thousands of pilin subunits (Power et al. 2000). Pili protrude from the bacterial surface 
and are utilised by the organism for adhesion to and colonisation of the host cell (Power 
et al. 2000, Virji et al. 1991). 
 
The structure and nature of pilin glycosylation in N. meningitidis was first determined in 
strain C311. It was shown that the pilin was glycosylated at serine 63. The glycan 
molecule was an unusual molecule, O-linked Gal(β1,4)-Gal(α1,3)-2,4-diacetamido-
2,4,6-trideoxyhexose (Gal(β1,4)-Gal(α1,3)-DATDH) (Power et al. 2000, Stimson et al. 
1995). N. gonorrhoeae strain MS11 is also glycosylated at the same region of its pilin 
molecules, however the modification is not the same. In N. gonorrhoeae the glycan is 
an O-linked disaccharide Gal(α1,3)-GlcNAc (Power et al. 2000, Parge et al. 1995). It 
has also been reported that this disaccharide rather than the trisaccharide may also be 
found in certain strains of N. meningitidis (Power et al. 2000, Marceau et al. 1998). 
Figures 1.7 and 1.8 show the structures of these glycans. 
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Figure 1.7 Gal(β1,4)-Gal(α1,3)-DATDH  
The structure of the glycan Gal(β1,4)-Gal(α1,3)-DATDH which modifies N. meningitidis strain C311 pili 
at serine 63 of the pilin subunit (Power and Jennings 2003). 
 
 
Figure 1.8 Gal(α1,3)GlcNAc  
The structure of the glycan Gal(α1,3)GlcNAc which modifies N. gonorrhoeae strain MS11 pili at serine 
63 of the pilin subunit (Power and Jennings 2003). 
 
Jennings et al. (1998) identified the first gene involved in pilin glycosylation in N. 
meningitidis, called pglA. PglA is homologous to type 1 GTs and is proposed to transfer 
galactose to DATDH via the α1,3 linkage. PglA also catalyses the addition of the 
Gal(α1,3) residue in the disaccharide found in N. gonorrhoeae strain MS11 (Power and 
Jennings 2003). After the discovery of pglA, more pgl genes that were responsible for 
O-linked pilin glycosylation in Neisseria were found and it was shown that they were 
clustered together on a locus called the pgl gene locus. The pgl pilin glycosylation locus 
has been studied in several strains of N. meningitidis, for example strain NMB (Kahler 
et al. 2001) and strain C311#3 (Power et al. 2003a). The locus is polymorphic, 
containing between four and nine genes depending on the strain (Power and Jennings 
2003). The locus in strain C311#3 contains four genes. Included in these four genes is a 
gene encoding PglF and three genes encoding proteins involved in the biosynthesis and 
transfer of DATDH, PglC (an aminotransferase), PglD (a dehydratase) and PglB 
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(believed to be bifunctional with acetyltransferase and GT domains) (Power et al. 
2003a). PglF is a membrane spanning protein and is believed to be a flippase whose 
function is to flip the UDP-linked sugar from the cytoplasmic to the periplasmic side of 
the inner membrane (Power et al. 2006). 
 
Polymorphisms that have been found include a 2 kb insertion that has been added to the 
locus. The insertion contains two additional genes called pglG and pglH that are 
homologous to GTs. An insertion-deletion in pglB is another polymorphism that has 
been found in some strains (Power and Jennings 2003, Kahler et al. 2001). There have 
also been two further genes found that are involved in the biosynthesis of the 
trisaccharide. However, these genes are not found in the glycosylation locus. PglI is 
believed to be an acetlyltransferase involved in biosynthesis of DATDH and PglE is a 
type 2 GT that transfers the galactose to the trisaccharide. pglE contains many copies of 
a heptanucleotide repeat CAAACAA which mediates phase variation allowing the 
switching between expression of the disaccharide and trisaccharide structures in the 
organism at different stages of its life cycle (Power et al. 2003a).  
 
Some of the proteins encoded by genes from the pgl locus in N. meningitidis display 
significant homology to Pgl proteins involved in the N-linked protein glycosylation 
pathway in C. jejuni. For example PglA from N. meningitidis displays 52% sequence 
similarity with PglA from C. jejuni subsp. jejuni 81-176 over the entire protein 
sequence. PglB from N. meningitidis displays 68% sequence similarity with PglC from 
C. jejuni over 47% of the protein sequence. PglC from N. meningitidis displays 52% 
sequence similarity with PglE from C. jejuni over 70% of the protein sequence. PglD 
from N. meningitidis displays 54% sequence similarity with PglF from C. jejuni over 
the entire protein sequence. Homology searches were carried out using BLASTP from 
NCBI (see section 2.12). Research has shown that the OT mediated O-linked 
glycosylation pathway in Neisseria has similarities to the OT mediated N-linked protein 
glycosylation pathway in C. jejuni. In each case the glycan is assembled on a lipid 
carried, flipped across the cytoplasmic membrane and then transferred to the protein by 
an OT enzyme (Abu-Qarn et al. 2008). 
 
Bioinformatic and site-directed mutagenesis studies led to the discovery of the OT gene 
in Neisseria spp. It is called pglL in N. meningitidis and pglO in N. gonorrhoeae 
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(Nothaft and Szymanski 2010, Power et al. 2006, Faridmoayer et al. 2007). PglL/PglO 
OTs are responsible for the glycosylation of type IV pili, not just in Neisseria species 
but in a wide range of pathogenic bacteria. In 2009 it was discovered that in Neisseria 
this general O-linked protein glycosylation system was utilised to not only decorate 
pilin proteins with glycans but also a broad range of other proteins produced by the 
organism (Vik et al. 2009). 
 
• OT mediated O-linked glycosylation of P. aeruginosa pili 
 
P. aeruginosa is a Gram-negative opportunistic pathogen of humans and plants. It is the 
leading cause of nosocomial pneumonia in immuno-compromised individuals. The 
organism produces pili to aid in infection by allowing it to adhere to and colonize the 
cells and they also mediate motility across surfaces (Horzempa et al. 2006, Mattick 
2002). P. aeruginosa strain 1244 pili are modified by glycosylation. The modification is 
an attachment of the trisaccharide α5NβOHC47NFmPse (β2,4)-Xyl (β1,3)-FucNAc 
(β1,3)- to the N-terminal serine residue (O-linked glycosylation) (Power and Jennings 
2003, Castric 1995). Comer et al. (2002) demonstrated that the pilin glycosylation site 
was residue 148 of the protein. Figure 1.9 shows the structure of this trisaccharide. 
 
 
 
Figure 1.9 α5NβOHC47NFmPse (β2,4)-Xyl (β1,3)-FucNAc (β1,3)-  
Structure of the glycan α5NβOHC47NFmPse (β2,4)-Xyl (β 1,3)-FucNAc (β 1,3)-, which glycosylates P. 
aeruginosa strain 1244 pili (Castric et al. 2001). 
 
This trisaccharide is identical to the O-antigen repeating unit found in the LPS produced 
by this strain. This suggests that there is a common origin for the pathways involved in 
the biosynthesis of O-antigen and the glycosylation of pili in this organism (Castric et 
al. 2001). This has been proved by the fact that in mutants of strain 1244, where O-
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antigen biosynthesis is defective, glycosylated pili are also not made (DiGiandomenico 
et al. 2002, Smedley III et al. 2005). 
 
Castric (1995) identified the genes involved in the synthesis of the trisaccharide and 
also another gene, pilO, which is essential for pilin glycosylation. PilO is a membrane 
protein and the transmembrane profile of PilO shows that it contains 13 membrane 
spanning regions. PilO is homologous to PglL/PglO in Neisseria species. PilO is not 
present in P. aeruginosa strains that do not produce glycosylated pili (Power and 
Jennings 2003). The pilO gene is found in the same operon as the pilin structural gene, 
pilA. It encodes an OT that transfers the O-antigen repeating unit to the pilin (Smedley 
III et al. 2005). When this operon was cloned into a P. aeruginosa strain that normally 
does not glycosylate its pili, it produced glycosylated pili. Also when pilO is mutated in 
strain 1244, it results in non-glycosylated pili proving that PilO is the only other 
glycosylation factor required for pilin glycosylation besides those genes also involved in 
the O-antigen biosynthesis pathway (DiGiandomenico et al. 2002, Smedley III et al. 
2005). 
 
• General OT mediated O-linked glycosylation in Bacteroides spp. 
 
Bacteroides are the most abundant genus of commensal bacteria found in the human 
intestine. Members of this genus produce a huge array of glycan structures including 
different CPs, some of which contain terminal fucose residues (Krinos et al. 2001). 
Further investigation into fucose utilization by these bacteria showed that it uses 
exogeneous L-fucose from the host and incorporates it not only into its CP but also into 
oligosaccharides that are bound to proteins (Nothaft and Szymanski 2010, Krinos et al. 
2001). 
 
A consensus sequence for O-linked glycosylation was determined in Bacteroides 
fragilis as Asp-Ser/Thr-Ala/Ile/Leu/Val/Met/Thr where the final amino acid required a 
methyl group. The gene locus responsible for O-linked glycosylation in Bacteroides 
fragilis was discovered and was termed lfg (Fletcher et al. 2009). It contained a putative 
flippase gene (wzx) and five putative GT genes. However no candidate gene has been 
identified so far to be the putative OT. Other Bacteroides spp. were shown to contain 
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similar genetic loci and also produce O-linked glycoproteins (Fletcher et al. 2009). A 
pathway for O-linked glycosylation in Bacteroides has not yet been defined but it is 
proposed that the GTs are responsible for assembling the oligosaccharide on a lipid 
carrier on the cytoplasmic face of the inner membrane and Wzx flips the lipid linked 
oligosaccharide into the periplasm where the oligosaccharide is then attached to the 
protein at its consensus sequence (Dell et al. 2010). 
 
O-fucosylated fimbriae have been discovered in Porphyromonas gingivalis. This is not 
a human commensal but in fact an oral mucosal pathogen. However, it is a member of 
the order Bacteroidales, the same order to which Bacteroides spp. belong. So far the 
glycan sequences of its glycoproteins have not been fully determined but initial analysis 
has shown that they are likely to be quite complex. As well as fucose, a range of other 
monosaccharides having already been detected (Zeituni et al. 2010). 
 
1.3.2.4 Type (iv): Stepwise O-linked glycosylation 
 
In eukaryotes all O-linked glycosylation is stepwise or progressive. The first step in the 
process is the attachment of the initial monosaccharide to the protein via a serine or 
threonine residue. Stepwise O-linked glycosylation has also been well characterised in 
some bacterial species especially the flagellar glycosylation systems of Campylobacter 
spp., Clostridium spp. and Pseudomonas spp. 
 
• C. jejuni flagella glycosylation 
 
One of the earliest reports of protein glycosylation in C. jejuni was described by Doig et 
al. (1996). They concluded that C. jejuni flagella were glycosylated because they were 
sensitive to periodate oxidation (a test for carbohydrates) and they bound to the lectin, 
Limax flavus agglutinin (LFA), which has affinity for terminal sialic acid. The 
modification was believed to be O-linked as flagellin glycosylation occurred even in the 
presence of an N-linked glycosylation inhibitor. The study showed that C. jejuni flagella 
are extensively modified with glycans. Approximately 10% of the total mass of the 
flagellin glycoprotein is attributed to carbohydrate. Studies following this on C. jejuni 
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strain 81-176 revealed that the terminal residue in the glycan is not sialic acid but 
instead a nine-carbon related sugar of sialic acid, 5,7-diacetamido-3,5,7,9-tetradeoxy-L-
glycero-L-manno-nonulosonic acid (pseudaminic acid, Pse5Ac7Ac) or one of its 
derivatives such as 7-acetamido-5-acetimidoyl-3,5,7,9-tetradeoxy-L-glycero-L-manno-
nonulosonic acid (legionaminic acid, Pse5Am7Ac). (Benz and Schmidt 2002, Power 
and Jennings 2003, Szymanski et al. 2003, Logan et al. 2002, Thibault et al. 2001). 
Pseudaminic acid and legionaminic acid are shown in figure 1.10. 
  
Figure 1.10 (a) Pseudaminic acid and (b) Legionaminic acid 
The structure of (a) pseudaminic acid, a nine carbon related sugar of sialic acid and its derivative (b) 
legionaminic acid which modify C. jejuni flagella (Schmidt et al. 2003). 
 
C. jejuni flagella are modified by pseudaminic acid or its derivatives at 19 sites. The 
modification occurs on serine/threonine residues in the central domain of the protein 
that is surface exposed (Thibault et al. 2001). Studies on C. jejuni strain NCTC 11168 
(Szymanski et al. 2003) revealed that it contains a flagellar glycosylation gene locus 
containing about 50 genes. The gene cluster contains genes involved in the biosynthesis 
of pseudaminic acid and pseudaminic acid derivatives. Some of the genes encode the 
flagellin structural proteins FlaA and FlaB. Other genes encoded in the O-linked 
glycosylation locus of C. jejuni strain NCTC 11168 include hypothetical genes that are 
thought to encode proteins of two paralogous gene families, the 1318 motility accessory 
factor (1318/maf) family and the 617 family. These two gene families account for about 
50% of the genes in the locus. There have been no known orthologues of the 617 family 
found in any other bacterial species and the functions of the proteins encoded by these 
genes are unknown (Szymanski et al. 2003). At this time the mechanism for O-
glycosylation of flagella in C. jejuni is unknown. A very surprising characteristic of the 
flagellar glycosylation locus is that there have been no characterised GTs found in the 
locus (Szymanski and Wren 2005). Perhaps the organism uses GT genes from other 
pathways to transfer the sugar units to its flagella. 
(a) (b) 
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Table 1.2 summarizes the differences between the key features of the O-linked and N-
linked protein glycosylation pathways in C. jejuni that have been discussed. 
 
Table 1.2 Summary of the key differences between the O- and N-linked protein  
glycosylation systems in C. jejuni (adapted from Szymanski et al. (2003)) 
 
Feature N-linked O-linked 
Nature of glycan Heptasaccharide Monosaccharide or disaccharide 
Glycan structure GalNAc2(Glc)GalNAc3Bac- Pseudaminic acid- 
Target proteins >65 secreted proteins FlaA and possibly others 
Size of gene loci 17 kb Variable, ~50 genes 
Target sequence Glu/Asp-Z-Asn-X-Ser/Thr Ser/Thr 
 
• P. aeruginosa flagella glycosylation 
 
P. aeruginosa is also capable of glycosylating its flagella (Arora et al. 2001). There are 
two major flagellin types found in P. aeruginosa, type A and type B flagella. Both types 
are known to be glycosylated. P. aeruginosa flagella consist primarily of a FilC subunit. 
A gene locus adjacent to the flagellin biosynthesis genes was found by Arora et al. 
(2001). The locus contains up to 14 genes required for the O-glycosylation of type A 
flagella. Experiments were carried out by Arora et al. where the first and last genes in 
the locus, orfA and orfN were inactivated. Inactivation of either of these genes 
completely abolished flagellin glycosylation. 
 
OrfA is homologous to PglC from N. meningitidis and PglE form C. jejuni (both 
aminotransferases), while OrfN is homologous to PglE from N. meningitidis and PglI 
form C. jejuni (both GTs) (Power and Jennings 2003, Arora et al. 2001). The 
glycosylation moiety attached to A-type flagella in two P. aeruginosa strains (PAK and 
JJ692) have been determined by Schirm et al. (2004). Their flagella are O-glycosylated 
at two sites. In both strains the glycosyl moiety is linked through a rhamnose residue. In 
strain JJ692 the flagella are glycosylated with only a single rhamnose but in strain PAK 
the glycan can contain up to 10 additional monosaccharides (Schirm et al. 2004). The B 
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type flagellin in P. aeruginosa PAO1 is modified at two nearby serine residues with a 
single deoxyhexose residue that can be linked to a unique modification with a mass of 
209 Da that is known to include a phosphate moiety (Verma et al. 2006). 
 
• Clostridium spp. flagella glycosylation 
 
Several Clostridia spp. have been shown to contain an O-linked protein glycosylation 
system responsible for the glycosylation of its flagella (Twine et al. 2009). In 
Clostridium botulinum the flagella are modified with a derivative of legionaminic acid 
called 7-acetamido-5-(N-methyl-glutam-4-yl)-amino-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-nonulosonic acid (αLeg5GlunMe7Ac) and with di-N-acetylhexuronic acid. 
Seven Ser/Thr sites in each protein subunit are modified (Twine et al. 2008).  
 
Clostridium difficile 630 flagella are also modified at seven sites but the modification is 
a HexNAc moiety. Mutants lacking this HexNAc moiety showed defected flagellum 
formation and loss of motility. Hypervirulent strains of C. difficile that have been 
recently isolated from outbreaks have been shown to contain O-glycans on their flagella 
containing HexNAc-linked oligosaccharides with at least five sugars in the chain 
including HexNAc, deoxyhexose, methylated deoxyhexose and heptose residues. These 
are the most complex flagellin-linked O-glycans that have been discovered so far. 
Analysis of the genome of these organisms have shown that the locus involved in 
flagellin glycosylation varies greatly to the C. difficile 630 strain (Dell et al. 2010, 
Nothaft and Szymanski 2010, Twine et al. 2009). 
 
• O-mannosylation in Gram-positive Actinomycetes 
 
A recent review by Lommel (2009) discusses how protein O-mannosylation is a process 
that is conserved in all three domains of life. O-mannosyl glycans are very common in 
fungi and yeast while only a limited number of proteins are O-mannosylated in 
mammals. O-mannosyl glycans similar to those found in yeast and fungi have been 
discovered in bacteria, namely Gram-positive Actinomycetes including Mycobacterium 
spp. and Streptomyces spp. (Lommel and Strahl 2009). The first glycoprotein of this 
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kind to be characterised was in Mycobacterium tuberculosis. A 45 kDa secreted protein, 
MPT 32, was shown to be glycosylated at threonine residues with a single α-D-
mannose, mannobiose or mannotriose (with α1-2 linkages between mannose residues) 
(Dobos et al. 1996). The mannosyltransferase (MT) responsible for this glycosylation 
has been discovered and has structural similarity to eukaryotic protein MTs (Dell et al. 
2010).  
 
In Streptomyces coelicolor, its phosphate binding protein PstS is O-glycosylated. The 
glycan is a trihexose and the MT responsible is a membrane bound lipoprotein, Pmt 
(Wehmeier et al. 2009). O-mannosylation appears to be a general pathway common to 
all Actinomycetes as orthologues to MT genes have been found in many other genera. 
As well as requiring MT enzymes, a lipid carrier is also needed similar to what is seen 
in Neisseria and Pseudomonas pilin glycosylation but as Actinomycetes are Gram-
positive, they do not have a periplasm, therefore the lipid-linked oligosaccharide would 
be flipped to the surface of the outer membrane with the transfer of the glycan to the 
protein occurring on the outer surface of the cell (Nothaft and Szymanski 2010). 
 
• O-Linked heptoses in Gram-negative Escherichia coli 
 
Autotransporter proteins are the most common type of secreted proteins in Gram-
negative bacteria. In pathogenic E. coli strains, three glycosylated autotransporter 
proteins have been discovered, namely, AIDA-I, TibA and Ag43.  These proteins are 
associated with virulence phenotypes such as biofilm and aggregate formation. The 
modification is an O-linked heptose on the proteins’ passenger domains (Benz and 
Schmidt 2001, Lindenthal and Elsinghorst 1999, Sherlock et al. 2006). These glycans 
are derived from ADP-linked glycans recruited from the LPS pathway in the organism. 
Glycosylation of these proteins appears to aid in pathogenesis by enhancing the 
attachment of the bacterium to human cells. Glycosylation is also required for activity 
of these proteins (Dell et al. 2010, Schmidt et al. 2003). 
 
The examples discussed in sections 1.3.1 and 1.3.2 is by no means a complete overview 
of all known incidences of prokaryotic protein glycosylation but it does include the best 
understood pathways of prokaryotic protein glycosylation to date. Table 1.3 shows a 
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summary of some of the properties of bacterial proteins that are known to be 
glycosylated, including some from organisms that have not been discussed here. 
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Table 1.3 Overview of some characterised bacterial glycoproteins 
Organism Protein Linked glycan 
# Sugar 
residues/ 
glycan 
N-/O-
linked 
# Modification 
sites/protein 
Transfer of 
sugars 
Biological effect of 
modification Reference 
C. jejuni subsp. Multiple, 
secreted GalNAc2(Glc)GalNAc3Bac 7 N 1-3 Block 
competence, animal 
colonisation, adherence/ 
invasion, protein 
antigenicity 
Young et al. (2002), 
Szymanski et al. (1999) 
C. coli VC167 FlaA flagellin 
Pseudaminic acid, 
acetamidino, deoxypentose 
and Pse/PseAm 
1-2 O 16 Sequential 
Flagella assembly, 
bacterial motility, 
protein antigenicity 
Logan et al. (2002) 
C. jejuni 81-176 FlaA flagellin 
Pseudaminic acid, 
acetamidino, O-
acetylacetamidino, 
dihydroxyproprionyl 
1 O 19 Sequential 
Flagella assembly, 
bacterial motility, 
protein antigenicity 
Thibault et al. (2001) 
Helicobacter 
pylori FlaA, FlaB Pseudaminic acid 1 O 7, 10 Sequential 
Flagella assembly, 
bacterial motility Schirm et al. (2003) 
N. meningitidis Pilin Gal(β1,4)-Gal(α1,3)-DATDH 2-3 O 1 Block Complement mediated killing Stimson et al. (1995) 
N. gonorrhoeae Pilin Gal(α1,3)-GlcNAc 2-3 O 1 Block Correlation with disease Parge et al. (1995) 
P. aeruginosa 
PAK Flagellin 
Up to 11 sugars linked through 
rhamnose including 4-amino 
4,6-dideoxyhexose viosamine 
Up to 11 O 2 Sequential 
Role in virulence-
adhesion/invasion/ 
colonisation 
Schirm et al. (2004) 
P. aeruginosa 
JJ692 Flagellin Rhamnose 1 O 2 Sequential 
Role in virulence-
adhesion/invasion/ 
colonisation 
Schirm et al. (2004) 
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Organism Protein Linked glycan 
# Sugar 
residues/ 
glycan 
N-/O-
linked 
# Modification 
sites/protein 
Transfer of 
sugars 
Biological effect of 
modification Reference 
P. aeruginosa 
1244 Pilin 
Hydroxybutyryl-formyl-
pseudaminic acid with xylose 
and N-acetylfucosamine 
3 O 1 Block Adherence/Virulence/ Colonisation 
Castric et al. (2001), 
Smedley III et al. (2005) 
P. aeruginosa LecB _ _ N 1 _ 
Localisation of the 
protein in the outer 
membrane 
Bartels et al. (2011) 
E. coli H10407 TibA 
adhesin Heptoses _ O _ Sequential Adherence/Invasion 
Lindenthal and Elsinghorst 
(1999) 
E. coli 2787 AIDA-1
1
 
adhesin Heptoses 1 O 19 Sequential Adherence Benz and Schmidt (2001) 
M. tuberculosis MPT 32 α(1-2) linked D-mannose/ 
mannobiose/mannotriose 1-3 O 4 Sequential Pathogenesis Dobos et al. (1996) 
Mycobacterium 
bovis 
MBP83 
antigen (1,3)-linked mannose 3 O 2 Sequential Pathogenesis Michell et al. (2003) 
C. difficile 630 Flagellin HexNAc 1 O 7 Sequential Formation of flagellin/ 
motility Twine et al. (2009) 
H. influenzae HMW1
2
 
adhesin Gal, Glc 1-2 N 31 Sequential 
Protein 
stability/adherence Grass et al. (2003) 
                                               
1
 Adhesin involved in diffuse adherence 
2
 High molecular weight protein adhesin 
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1.3.3 The use of glycan-specific genes in multiple pathways 
 
Capsular polysaccharide (CP) is found on the cell surface of many bacterial species. It 
consists of a think mucous-like layer of polysaccharide and functions in adherence and 
infection and prevents the bacteria from drying out. CP is composed of repeating 
monosaccharides joined by glycosidic linkages. They polymers can be homo- or 
heterologous. CP is very diverse. It differs from organism to organism with regard to 
the sugar units found in the molecule and also the linkages between these sugars 
(Roberts 1996). 
 
Lipopolysaccharide (LPS) and lipooligosaccharide (LOS) are both major constituents of 
the outer surface of Gram-negative bacteria. As the name suggests LPS consists of a 
polysaccharide covalently linked to a lipid and LOS contains an oligosaccharide linked 
to a lipid. LPS contains three regions, the lipid, an oligosaccharide core and a sequence 
of repetitive subunits called the O-antigen (Caroff and Karibian 2003). The core 
consists of sugars such as glucosamine, glucose, galactose, L-glycero-D-manno-heptose 
or 3-deoxy-oct-2-ulosonic-acid (KDO). In LOS there is no third region, only the core 
oligosaccharide consisting of the same sugars found in LPS bound to the lipid. LPS 
containing O-antigen is sometimes called smooth LPS and LOS is sometimes called 
rough LPS (Szymanski and Wren 2005, Caroff and Karibian 2003).  
 
O-antigens are highly variable and occur in multiple forms. There is considerable 
variation of O-antigens between and even within different species (Samuel and Reeves 
2003). The variation occurs in the nature, order and linkage of the different sugars. For 
example there has been 186 different O-antigens reported in E. coli strains and 54 in 
Salmonella enterica and only three of these are identical between the two species 
(Samuel and Reeves 2003). 
 
Figure 1.11 shows a schematic representation of a typical enterobacterial Gram-negative 
cell envelope and the structures of LOS and LPS. 
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Figure 1.11 The typical structure of the Gram-negative cell envelope, LPS and LOS 
LOS (rough LPS) contains only the lipid bound to the sugar core. Semi-rough LPS contains one O-
antigen subunit. Smooth LPS contains multiple O-antigen subunits (Caroff and Karibian 2003). 
 
The genes involved in O-antigen biosynthesis are usually found clustered together on 
the chromosome in a gene locus (Samuel and Reeves 2003). There are three major 
groups of genes found in the gene cluster. The first group is genes that encode proteins 
involved in the biosynthesis of the nucleotide precursors of the O-antigen. The second 
group encodes GTs. These transfer the synthesised precursor sugars to the lipid carrier, 
UDP. The UDP-linked oligosaccharide is positioned at the cytoplasmic side of the inner 
membrane. The final group of genes encode O-antigen processing proteins. These 
include flippases, that translocate the O-antigen across the membrane, polymerases and 
chain length determining enzymes (Samuel and Reeves 2003). Figure 1.12 outlines the 
synthesis of O-antigens and shows the three different groups of proteins involved. 
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Figure 1.12 Representation of typical O-antigen biosynthesis 
Nucleotide sugar precursor biosynthesis genes are shown in red, GT genes are in blue and antigen 
processing genes are in pink. Sugar biosynthesis and sequential transfer to the growing sugar chain occurs 
in the cytoplasm and processing and polymerisation of O-antigens occurs at the periplasmic face of the 
inner membrane (Samuel and Reeves 2003). 
 
Many bacteria have evolved to use the same carbohydrate biosynthetic genes for 
different pathways i.e. bacteria that produce glycoproteins, LPS, LOS or CP often use 
the same carbohydrate specific genes for more than one of these pathways. Because of 
this bacterial genomes are extremely compact and usually do not contain any redundant 
genes (Szymanski and Wren 2005). It can be seen that the genes involved in the 
biosynthesis of LPS, LOS and CP are very similar to those involved in protein 
glycosylation. The three groups of enzymes used for O-antigen biosynthesis described 
above are the same types of enzymes that are used for protein glycosylation in many 
bacteria. 
 
Some examples of prokaryotes using carbohydrate biosynthesis or GT genes in more 
than one pathway have already been discussed. For example, common enzymes are used 
in P. aeruginosa strain 1244 for both pilin glycosylation and O-antigen production 
(section 1.3.2.3). Mutation of the genes wbpM or wbpL inhibits production of both O-
antigens and glycosylated pili (Horzempa et al. 2006, DiGiandomenico et al. 2002). 
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Another example of bacteria using a carbohydrate specific gene for more than one 
pathway can be seen in C. jejuni. It produces ADP-heptose to modify its LOS and GDP-
heptose to modify its CP. A common phosphatase enzyme is used in both pathways 
(Szymanski and Wren 2005, Karlyshev et al. 2005). C. jejuni also produces the protein 
GalE. This is a bifunctional epimerase that converts glucose to galactose and GlcNAc to 
GalNAc (Bernatchez et al. 2005). When the galE enzyme is inactivated it affects three 
important pathways. It results in truncation of LOS and lack of modification of CP and 
N-linked proteins by GalNAc (Szymanski and Wren 2005, Bernatchez et al. 2005, Fry 
et al. 2000). When the same enzyme (galE) is mutated in N. meningitidis, this causes 
truncation of LOS and the pilin trisaccharide Gal(β1,4)-Gal(α1,3)-DATDH (Szymanski 
and Wren 2005, Stimson et al. 1995). In H. influenzae, the enzyme phosphoglucomutase 
is involved in both LOS production and glycosylation of HMW1 (Szymanski and Wren 
2005, Grass et al. 2003). 
 
It has also been found that in some cases genes involved in protein glycosylation may 
be very similar to genes in different organisms that are involved in LPS, LOS or CP 
production. Power et al. (2006) showed that pilin glycosylation in N. meningitidis 
occurs by a very similar pathway to wzy-dependent O-antigen biosynthesis in E. coli. 
The N-glycosylation system that has been proposed in C. jejuni has a lot of similarities 
to the O-antigen or O-polysaccharide polymerase dependent synthesis pathway seen in 
many Gram-negative bacteria (Feldman et al. 2005, Bugg and Brandish 1994). 
 
1.3.4 Significance of bacterial glycosylation  
 
Glycosylation has been demonstrated to alter the function of both eukaryotic and 
prokaryotic proteins. Many studies have been conducted on eukaryotic proteins and the 
specific effects of many the modifications on the functions of the proteins have been 
determined (Upreti et al. 2003). Some of these functions include maintenance of protein 
conformation and stability, cell adhesion, modulation of viscosity, solubility and surface 
charge, proteolytic processing, mediation of biological activity and embryonic 
development (Upreti et al. 2003, Paulson 1989).  
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At present there is not a great deal known about the specific function of the 
glycosylation of many bacterial glycoproteins but it is believed to have similar functions 
to eukaryotic glycosylation (Upreti et al. 2003). This area requires much further 
exploration. For some prokaryotic glycoproteins the function of the modification has 
been characterised. For example a lot of knowledge has been obtained from studies on 
S-layer glycoproteins and more recently, glycosylated surface appendages such as 
flagella and pili. Because many glycosylated proteins are surface exposed in the 
organism this suggests that glycosylation plays an important role in pathogenicity 
(Szymanski and Wren 2005). 
 
Glycoproteins have been proven to directly function in pathogenicity in some 
organisms. For example in Mycobacterium smegmatis glycosylation of proteins with an 
acyl or glucosyl moiety inhibits the major histocompatibility complex (MHC) from 
presenting peptides to T-cells (Upreti et al. 2003, Baumeister and Lembcke 1992). 
Glycoproteins on the cell surfaces of bacteria are important for pathogenicity in terms of 
cell-cell interactions between the bacteria and host cell. They can be important for 
facilitating adhesion of the bacteria and invasion into the host cell. Glycosylation of cell 
surface structures may also stabilize attachment of the bacteria to the host cell 
containing the proper receptor for the glycan (Upreti et al. 2003).  
 
Glycosylation often functions in pathogenesis by aiding in immune evasion. Many 
examples of this are seen in pathogenic bacteria. One such example is in Neisseria spp. 
It produces an O-glycosylated outer membrane protein called AniA, a nitrate reductase. 
Glycosylation of this protein protects the organism against killing by the human 
immune response. The protein is glycosylated at its carboxyl terminus. As the protein is 
an outer membrane protein it is surface exposed and immunogenic. The carbohydrate 
modification shields the substrate recognition domain of AniA and therefore protects it 
from immune recognition (Ku et al. 2009). 
 
Some examples have been discussed already where bacteria O-glycosylate their flagella. 
This modification seems not only to be important for cell-cell interactions but also for 
facilitating correct formation of the flagellar filament and motility of the organism as 
seen in H. pylori (Schirm et al. 2003) and C. jejuni. (Logan et al. 2002, Thibault et al. 
2001). Mutation of flagellar glycosylation genes in C. jejuni results in non-motile 
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phenotypes with no flagellar filament so O-linked glycosylation in C. jejuni is required 
for complex protein assembly (Szymanski and Wren 2005, Goon et al. 2003). 
 
The exact function of N-linked protein glycosylation in C. jejuni is not fully understood. 
It is known that N-linked glycosylation functions in adherence and invasion of the host. 
Disruption of the N-linked glycosylation pathway produces cells that have reduced 
ability to adhere and invade in vitro eukaryotic cell cultures and show reduced 
colonisation in the intestines of chicken and mice (Szymanski et al. 2002). 
 
Glycoproteins on cell surfaces can contribute to the structural integrity of the cell and 
thus aid in cell adhesion. An example of this is the glycoproteins on the surface of 
Halobacterium spp. They function in maintaining the rod shape of the bacterial cell. 
When addition of the glycan to the protein is inhibited the cells are changed to spherical 
cells (Upreti et al. 2003). Another example can be seen in Thermoplasma acidophilum 
where carbohydrates attached to the membrane proteins trap water molecules and 
immobilize them to form a mesh like network which gives the plasma membrane 
rigidity and stability (Upreti et al. 2003).  
 
Other important biological functions have also been attributed to glycosylation. 
Glycosylation of S-layer proteins can facilitate the organism to survive in hostile 
environments. The glycans can be found clustered together in domains on the protein, 
restricting the folding of the protein and leading to an extended conformation. If the 
glycans are added at β-turns in the protein, the turn conformation is masked and the 
protein can be protected from proteolysis. Removal of these glycans exposes protease 
cleavage sites in increases the sensitivity of the protein to proteolytic cleavage (Upreti et 
al. 2003, Beeley 1977). 
 
Many bacterial enzymes are glycosylated. It is believed that the glycosylation does not 
affect the catalytic activity of the enzyme but may function in recognition and binding 
of the enzyme to the substrate, allowing the enzyme to bind with higher affinity and 
thereby increase the effectiveness of the enzyme (Kawamura and Shockman 1983). 
Glycosylation can also increase the thermostability of the enzyme. It has been shown in 
Bacillus amyloliquefaciens and Bacillus macerans that glycosylated enzymes had a 
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longer half life at higher temperatures compared to their non-glycosylated forms (Upreti 
et al. 2003). 
 
Glycosylation of proteins in Bacteroides spp. by fucose residues is believed to aid in the 
survival of the organism in the mammalian intestine. Because many mammalian 
proteins are glycosylated with fucose Bacteroides are able to disguise themselves and 
become immunologically inert (Fletcher et al. 2009). 
 
1.4 Identification and characterisation of glycoproteins – 
glycoproteomics  
 
1.4.1 Gel electrophoresis 
 
There are a wide variety of techniques available for the identification and 
characterisation of glycoproteins. A combination of the available techniques is needed 
to adequately identify the carbohydrate moiety attached to the protein. Often the first 
step for the isolation and analysis of proteins is gel electrophoresis for example sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing 
(IEF) or 2-dimensional (2-D) gel electrophoresis, which is a combination of both SDS-
PAGE and IEF. Glycoproteins sometimes exhibit aberrant migration in a gel compared 
to their non glycosylated counterpart (Hitchen and Dell 2006). The protein bands or 
spots obtained by these gels can be very broad because the glycoprotein is usually a 
heterogeneous mix of different glycoforms so complete separation of the different 
glycoforms can be difficult. Another drawback of electrophoresis is that often 
membrane glycoproteins are difficult to detect. This is because these proteins are 
hydrophobic and so do not solubilise well in the non-ionic detergents used in IEF. 
Another problem is that they do not stain very well with conventional dyes because of 
their high carbohydrate content. So other approaches are used for the isolation of 
membrane glycoproteins such as blue native electrophoresis or SDS-PAGE in 
conjunction with nano-high performance liquid chromatography (HPLC). Capillary 
electrophoresis has a very high resolving potential for different glycoprotein isoforms 
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but does not give any information on the nature of the attached glycan (Geyer and 
Geyer 2006). 
 
A useful way to distinguish between glycoproteins and non-glycosylated proteins 
separated by gel electrophoresis is by the periodic acid-Schiff stain. This stains 
carbohydrates a pink colour but does not stain proteins. The periodic acid oxidises the 
carbohydrate to form an aldehyde, which undergoes a condensation reaction with the 
Schiff base and a chromagen or indicator enzyme to form a pink colour (Benz and 
Schmidt 2002). It is important to confirm that the carbohydrate is actually covalently 
linked to the protein and not just associated with it. This can be confirmed by genetic, 
chemical or enzymatic means. For example treatment of the glycoprotein with 
trifluoromethanesulphonic acid breaks the covalent bond and so the migration of the 
protein in a gel will be altered (Benz and Schmidt 2002, Sojar et al. 1987). Treatment of 
glycoproteins with the enzyme PNGaseF completely removes all N-linked 
glycoproteins. Treatment of glycoproteins using the β-elimination reagent completely 
removes all O-linked glycans. 
 
1.4.2 Lectins 
 
One of the most useful methods of detecting and identifying glycoproteins is the use of 
lectins. Lectins are defined as carbohydrate binding proteins which lack enzymatic 
activity and are not produced as a result of an immune response i.e. they are not 
antibodies (Ambrosi et al. 2005, Barondes 1988, Gabius et al. 2011). Lectins react non-
covalently with carbohydrates. They bind mono- and oligosaccharides. The reaction is 
reversible and relatively specific. An important property of lectins is that they exhibit 
di- or polyvalency, meaning that they contain two or more carbohydrate binding sites. 
This property means that when they react with sugars on the surface of cells such as 
erythrocytes or on glycoproteins they cause cross-linking of the cells or molecules 
which leads to their agglutination or precipitation. This property of lectins is used for 
their detection and characterisation. The agglutination and precipitation reactions of 
lectins are inhibited by the sugars for which the lectin is specific (Lis and Sharon 1998). 
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Lectins are found in most living organisms from viruses to animals (Ambrosi et al. 
2005). The first demonstration of lectin activity was shown in around 1860 by the use of 
rattlesnake venom to agglutinate red blood cells (Ambrosi et al. 2005, Kilpatrick 2002). 
Sumner isolated the first pure lectin, Concanavalin A (Con A) from jack beans in 1919 
(Ambrosi et al. 2005, Sumner 1919). He also demonstrated the sugar specificity of the 
lectin (Sumner and Howell 1936). Nowadays lectins are readily purified from their 
source using techniques such as affinity chromatography with immobilised 
carbohydrates. Recombinant DNA technology is also used to produce pure lectins (Lis 
and Sharon 1998). 
 
1.4.2.1 Carbohydrate specificity 
 
Lectins are classified into five main groups based on the monosaccharide for which they 
have highest affinity. These groups are mannose, galactose/GalNAc, GlcNAc, fucose 
and sialic acid. The structures of these monosaccharides were shown previously in table 
1.1. 
 
This list ignores some important monosaccharides but the six monosaccharides listed 
are the most common monosaccharides found in eukaryotic glycans. These sugars are 
all in the D-configuration apart from fucose which is in the L-configuration (Lis and 
Sharon 1998). Although the affinity of lectins is very weak for monosaccharides the 
specificity is very high (Gabius et al. 2011). This means that in general lectins specific 
for galactose do not react with glucose or mannose even though the structures are so 
similar (galactose is the 4 epimer of glucose and mannose is the 2 epimer of glucose). 
Those specific for mannose do not bind galactose. Also except for wheat germ 
agglutinin (WGA), lectins specific for GlcNAc do not bind GalNAc and vice versa. 
This high selectivity is not always the case. For example many lectins tolerate variations 
at C-2 of the pyranose ring and so for this reason many lectins that bind galactose also 
bind GalNAc and so they are put in the same specificity group (Ambrosi et al. 2005). In 
some cases lectins bind preferentially to a particular anomer of a glycan. Sometimes the 
properties of the aglycan (the non-sugar part of a molecule) can have an effect on the 
binding of the lectin. For example Con A binds to aromatic glycosides more strongly 
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than aliphatic glycosides. This is because of the hydrophobic region that is in close 
proximity to the carbohydrate binding site (Poretz and Goldstein 1971).  
 
Nowadays this method for classifying lectins is becoming obsolete because of the 
differences in specificities of lectins in a single category and also many lectins do not 
have a high specificity to simple saccharides (Ambrosi et al. 2005). Many lectins can be 
up to 1000 times more specific for di- tri- and tetrasaccharides than they are for 
monosaccharides and some lectins only interact with oligosaccharides. This is because 
oligosaccharides are the most likely ligands of lectins to be found in nature (Lis and 
Sharon 1998). 
 
1.4.2.2 Structural features 
 
Now lectins tend to be grouped according to their sequences and structural features. 
There are three main categories for defining lectins in this way. These are simple, 
mosaic (or multidomain) and macromolecular assemblies (Lis and Sharon 1998). 
Simple lectins have several subunits, each below ~40 kDa in size which are not 
necessarily identical. Each subunit contains a carbohydrate binding site. Simple lectins 
include most known plant lectins and most of the galectins. Galectins (formerly known 
as S-lectins) are animal lectins specific for β-galactoside. The legumes family is the 
largest and most comprehensively studied family of simple lectins of which Con A is a 
member. In 1998 there were over 100 characterised legume lectins. Almost all of these 
lectins have been isolated form the seeds of the plants (Lis and Sharon 1998, Sharon 
and Lis 1990, Konami et al. 1995). 
 
Mosaic lectins are composite molecules consisting of several domains. Only one 
domain contains a carbohydrate binding site. Many of these lectins are monovalent but 
act like multivalent lectins because they are embedded in membranes. Included in the 
mosaic lectin group are diverse proteins from a range of sources such as viral 
hemagglutinins and C-, P- and I- type animal lectins (Lis and Sharon 1998). 
 
Macromolecular assemblies are lectins commonly found on bacterial surfaces. These 
lectins are filamentous and heteropolymeric, 3-7 nm in diameter and 100-200 nm in 
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length. They consist of several subunits called pilins that are helically arranged and 
assembled in a well defined order (Gaastra and Svennerholm 1996). 
 
Lectins may be used in a number of ways to isolate and characterise glycoproteins. 
They may be used to probe glycoproteins that are immobilised on the surface of a chip 
or a plate. The lectins are often labelled with a molecule such as biotin. Anti-biotin 
antibodies can then be used to detect lectins that have bound to glycoproteins. They may 
be used in the same way in western blots. Lectins can be covalently bound to matrices 
like sepharose or agarose (in lectin affinity columns), membranes or magnetic beads to 
allow the separation, fractionation and characterisation of glycoproteins. Depending on 
the requirement, lectins with broad specificities or very specific lectins can be used. 
Using broad range lectins an entire pool of glycoproteins can be isolated but glycoforms 
can be differentiated in greater detail using specific lectins or specific eluting sugars 
(Geyer and Geyer 2006). Recently, multi-lectin affinity chromatography columns have 
been developed which simultaneously allow an almost complete enrichment of 
glycoproteins from the sample as well as their fractionated displacement from the 
column (Geyer and Geyer 2006, Wang et al. 2006). Lectin microcolumns have also 
been developed which allow high pressures to be used and can be coupled online to 
mass spectrometry equipment allowing semi-automated, sensitive profiling of 
glycoproteins (Madera et al. 2006). Lectin arrays have been developed containing over 
35 different lectins which provides a fast, sensitive, high throughput detection method 
for glycoproteins (Kuno et al. 2005). All of these techniques are valuable tools for the 
future to gain a better understanding of the glycoprotein structures found in prokaryotes. 
 
1.4.3 Mass spectrometry 
 
Once gel electrophoresis or lectin-based methods have been used to isolate 
glycoproteins analytical methods such as mass spectrometry (MS) are extremely useful 
for identifying the protein and determining the carbohydrate structure attached to it. MS 
can analyse large numbers of proteins in complex mixtures with very high sensitivity 
and accuracy. In MS the sample is converted to gas-phase ions. The ions are accelerated 
out of the ionization source into a mass analyser. Inside the mass analyser the ions are 
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separated according to their mass to charge ratio and detected to produce a mass 
spectrum (Hitchen and Dell 2006). 
 
Matrix assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) 
MS are considered the best methods available for protein identification using MS. 
MALDI or ESI describe the method that is used to generate the gas-phase ions. These 
methods can be used to analyse large biological molecules and do not degrade them. A 
technique known as peptide mass fingerprinting (PMF) is commonly used for protein 
identification. This involves cleaving the protein into peptides using an enzyme such as 
trypsin, which cleaves the protein only at specific residues. The mass of each peptide is 
determined by the mass spectrometer (mass mapping) and the information is inputted 
into a search engine that uses an algorithm to identify what protein the peptides belong 
to (Henzel et al. 1993). MALDI-MS is an unsurpassed method for this type of analysis. 
This type of analysis for the identification of proteins is called “bottom-up” proteomics. 
One disadvantage of PMF is that it cannot be used for complex samples with more than 
two or three proteins present. It requires relatively pure protein samples. 
 
PMF alone is sometimes not enough to identify a protein conclusively. ESI-MS can be 
used to determine the exact molecular weight of the intact protein. This will confirm the 
identification of the protein. MS is also very useful for peptide or protein sequencing. 
For this type of analysis tandem mass analysers (MS/MS) are needed. The first analyser 
traps the peptide or molecular ions of interest. The ions are fragmented by collision with 
an inert gas and broken up into fragments or individual amino acids. The second 
analyser separates the fragmented ions which can then be detected.  A program is used 
that takes the mass data from the fragments and uses it to deduce the sequence of the 
original precursor ion.  
 
MS/MS may also be used in the same way to determine the sequence of 
monosaccharides in a glycan on a glycopeptide. It cannot give information on the 
conformation of the monosaccharides or the type of linkage between sugar units, only 
their mass. Glycans can also be analysed separately from a protein by first releasing the 
glycan from the protein by chemical or enzymatic means. The cleaved glycans can be 
easily separated from the much larger protein using centrifugal filters with a lower 
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molecular weight cut off point than the molecular mass of the protein (North et al. 
2009). 
 
The quadropole orthogonal acceleration time of flight (Q-TOF) mass spectrometer is the 
most common type of MS/MS instrument. It has the ability to perform MS/MS 
experiments on line in real time (Hitchen and Dell 2006). Nowadays tandem mass 
spectrometer configurations such as MALDI-Q-TOF are commonly used. This type of 
instrument combines the advantages of both MALDI and Q-TOF i.e. it can carry out 
mass mapping of the protein as well as being able to sequence it (Medzihradszky et al. 
2000).  Protein and glycan sequencing done is this way is quite time consuming and so 
this method is not suitable for high-throughput analysis. 
 
A new technique known as “top-down” proteomics is emerging as an alternative 
method for protein and glycoprotein identification using MS. For this analysis usually 
ESI is used. There is no requirement for cleaving the protein into peptides prior to 
analysis, instead the ionised protein is subjected to gas-phase fragmentation in the mass 
analyser. The sizes of the fragments generated are determined and the protein sequence 
can be obtained. Top-down proteomics is very useful because it enables post-
translational modifications on a protein to be located and characterised (Siuti and 
Kelleher 2007). For example, different forms of a protein can be isolated from different 
cell states, with the proteins having the same amino acid sequence but varying post 
translational modifications (PTMs). Top-down proteomic analysis allows variations in 
protein size to be detected and hence the type of modifications attached to the protein 
can be elucidated. Because the protein is fragmented into single amino acids, the 
location of the PTMs can also be found. 
 
1.4.4 Nuclear magnetic resonance (NMR) spectroscopy for glycan analysis 
 
NMR spectroscopy is an extremely useful technique for obtaining detailed information 
about the glycan structures on a glycoprotein. It can determine the conformation of the 
monosaccharides and the types of linkages between monosaccharides. Certain atomic 
nuclei have magnetic properties and in a magnetic field they absorb and re-emit 
electromagnetic energy. The energy is at a specific resonance frequency which is 
 47 
determined by the strength of the magnetic field applied and the magnetic properties of 
the nucleus of the atom. NMR spectroscopy uses the resonance frequency values to 
determine the physical and chemical properties of that molecule. NMR spectroscopy is 
a very powerful method of analysis but requires relatively large amounts of pure glycan 
(10-100 ng). HLPC coupled to NMR spectroscopy can be used in order to separate out 
different glycans first. The equipment required for NMR spectroscopy is very expensive 
and highly trained operators are required to use it (Evans 1995, Keeler 2005). 
 
1.5 Exploitation of prokaryotic protein glycosylation systems for 
industrial applications 
 
Over 70% of human therapeutic proteins are modified with N-linked glycans (Pandhal 
and Wright 2010). Correct glycosylation of these products is essential to ensure that 
these products exhibit desirable pharmacokinetic properties and to prevent unwanted 
immune responses to the therapeutic. Currently the majority of complex glycoprotein 
based therapeutics are expressed in mammalian cells for example Chinese hamster 
ovary cells. This is because unlike yeast and bacterial cells, mammalian cells add 
human like glycans to the glycoprotein product (Hamilton and Gerngross 2007, Walsh 
and Jefferis 2006). However many technical difficulties can arise with the use of 
mammalian cell culture for the expression of glycoproteins. As previously stated, 
glycosylation is linked to the overall metabolic state of the cell and so can be influenced 
by a number of different factors such as nutrient availability, media composition, pH 
and oxygen levels and other conditions within the fermentation tank. If the correct 
conditions are not optimised and maintained this can lead to aberrant glycosylation of a 
significant percentage of the glycoprotein product. Incorrect glycosylation can 
significantly alter the properties of the glycoprotein, such as stability, solubility and half 
life, leading to a great deal of wasted product and increased production costs (Walsh 
and Jefferis 2006, Werner et al. 2007). 
 
Expression systems that are based in bacterial cells is a far more desirable option due to 
the relative ease with which bacteria can be grown and maintained compared to animal 
cells. Expression in bacteria results in much lower costs and higher yields in a shorter 
time compared to animal cells. It is also much easier to genetically modify a bacterial 
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cell compared to an animal cell. Since the discovery of N-linked protein glycosylation 
systems in bacteria, glycoengineering within bacterial cells for the production of human 
therapeutics has become a real possibility for the future (Pandhal and Wright 2010, 
Langdon et al. 2009). 
 
A significant breakthrough in this area came in 2002 when Wacker and co-workers 
successfully transferred the pgl gene locus from C. jejuni responsible for N-linked 
protein glycosylation (section 1.3.2.1) into E. coli and were able to produce N-
glycosylated proteins in E. coli (Wacker et al. 2002). PglB, the OT enzyme from the C. 
jejuni N-linked system shows relaxed substrate specificity compared to its eukaryotic 
counterpart and it was shown that various glycan structures could be added to proteins 
in E. coli instead of just the normal heptasaccharide (Linton et al. 2005). In 2005, 
purified Pgl enzymes (C, A, J, H and I) from the C. jejuni N-linked protein 
glycosylation system were used to synthesise the heptasaccharide that modifies C. jejuni 
proteins in vitro in a single reaction, on a the lipid carrier, UDP (Glover et al. 2005).  In 
C. jejuni N-linked protein glycosylation occurs independently of protein translation 
(Kowarik et al. 2006a). This means that glycans synthesised in vitro could be 
transferred onto fully folded proteins using purified OT enzyme, PglB.  
 
The OT mediated O-glycosylation system (Langdon et al. 2009) that modifies Neisseria 
and P. aeruginosa pili (section 1.3.2.3) has also been expressed in E. coli (Faridmoayer 
et al. 2007). Like PglB in C. jejuni, the OT enzymes (PglL in Neisseria and PilO in P. 
aeruginosa) show relaxed glycan specificity. PilO can only transfer short lipid-linked 
oligosaccharides, however, PglL can transfer very diverse lipid-linked polysaccharides. 
In fact it was able to transfer sugars found in peptidoglycan onto E. coli pili 
(Faridmoayer et al. 2007). This shows the potential for these O-linked systems to be 
used for glycoengineering purposes. 
 
1.6 Project aims and objectives 
 
The primary objective of this research project was to investigate the possibility that the 
Gram-negative Gammaproteobacterium, Photorhabdus luminescens produces 
glycoproteins and thus contains a protein glycosylation system. An introduction into the 
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life cycle of P. luminescens is provided in section 1.7. Using various bioinformatic tools 
a number of orthologues to genes known to be involved in protein glycosylation in other 
organisms such as C. jejuni were identified in P. luminescens. 
 
In order to investigate whether P. luminescens produces glycoproteins, lectins were 
employed in various ways, for example in enzyme linked lectin assays, western blots 
and bound to affinity matrices in order to isolate and characterise glycoproteins from the 
organism. Isolated potential glycoproteins were then identified using MS techniques. 
Potential putative genes involved in protein glycosylation were mutated by insertional 
inactivation and the changes in the glycome of the mutant compared to the wildtype 
were examined. 
 
1.7 P. luminescens – life cycle 
 
P. luminescens is a motile, Gram-negative, Gammaproteobacteria belonging to the 
family Enterobacteriaceae. This bacterium has an extremely interesting and complex 
life cycle. It is a symbiont of soil nematodes belonging to the family Heterorhabditidae 
(Forst et al. 1997, Forst and Nealson 1996). P. luminescens is found in the gut of 
nematodes during its non-feeding infective stage and is an insect pathogen. The 
nematode enters the digestive tract of the insect in its larval stage and penetrates the 
hemocoel of the insect and releases the bacteria into the heomolymph. After infection 
death of the insect usually occurs within about 48 hours. 
 
Within the hemocoel of the insect many generations of both bacteria and nematode are 
produced. The bacteria reassosiates with the nematode near the final stages of its 
development inside the insect. After about a week the insect cadaver bursts open and 
releases hundreds of thousands of nematodes ready to complete the life cycle all over 
again. Figure 1.13 shows an example of an insect cadaver that has burst open releasing 
hundreds of thousands of nematodes. 
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Figure 1.13 An insect cadaver one week after infection with P. luminescens  
Thousands of nematodes containing P. luminescens in their gut emerge from the insect cadaver (USDA 
Agricultural Research Service). 
 
To date, free living forms of P. luminescens have not been isolated from soil or water 
sources suggesting that the bacteria may not be able to survive in the soil outside of the 
nematode (Waterfield et al. 2009). In return, the bacteria are required for the killing of 
the insect larva which provides nutrients for the nematode in order for it to complete its 
life cycle (Forst et al. 1997, Kaya and Gaugler 1993). 
 
P. luminescens is capable of undergoing phase variation. There are two distinct phases 
in the life cycle of the organism, phase I and phase II. Phase I is the normal form of the 
bacterial cells when the bacteria associates with the infective juvenile nematode. Inside 
the hemolymph of the insect, P. luminescens switches to phase II of its life cycle. In 
phase II many genes are expressed and proteins are produced that are not present in 
phase I. It secretes extracellular products including lipases, phospholipases, proteases 
and broad spectrum antibiotics during its stationary phase. The enzymes break down the 
macromolecules of the insect cadaver to provide nutrients and the antibiotics prevent the 
growth of other microorganisms on the cadaver and so prevent putrefaction of the 
cadaver (Forst et al. 1997).  
 
The complete genome sequence of P. luminescens strain TTO1 was published in 2003. 
The genome is 5,688,987 base pairs in size and contains 4,839 predicted protein coding 
genes. Other proteins encoded in the genome of P. luminescens include adhesins, toxins 
and hemolysins which all play a roll in adhesion of the bacteria to the host cell, 
infection and killing of the insect (Duchaud et al. 2003). One of the toxins produced by 
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P. luminescens is toxin complex A (TcaA). The tobacco horn worm Manduca sexta is 
generally resistant to bacterial infection but this toxin shows very high oral toxicity for 
the insect. Figure 1.14 shows an image of Manduca sexta infected with luminescent P. 
luminescens. 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Manduca sexta  
The tobacco horn worm Manduca sexta infected with luminescent P. luminescens (University of Bath, 
2004). 
 
P. luminescens strain TTO1 encodes many fimbrial genes. According to Duchaud et al. 
(2003) there are 11 fimbrial gene loci in the organism. Some of the fimbrial gene loci 
encode proteins similar to type IV pili from other organisms. This large repertoire of pili 
is likely to be very important for colonisation in nematode gut and invasion of the 
insect. The organism also produces proteins important in host cell interactions including 
lectins (Duchaud et al. 2003). However, to date, the cell surface properties of P. 
luminescens have not been well studied. 
 
Homology searches of the genome of P. luminescens have identified a number of 
orthologues to genes involved in protein glycosylation in other organisms, namely C. 
jejuni subsp. This will be discussed further in chapter 5. Protein glycosylation has been 
shown to play an important role in pathogenesis of other organisms. Because adhesion 
to the nematode and insect is so important in the life cycle of P. luminescens, it is likely 
that it produces glycoproteins to aid in cell recognition and adhesion. No proteins from 
P. luminescens have previously been shown to be glycosylated. 
Chapter 2 
Materials and methods
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2.1 Bacterial strains, plasmids and primer sequences 
 
Table 2.1 Bacterial strains 
Strain Genotype Features Source 
    
Escherichia coli   
XL1-Blue 
endA1, recA1, relA1, 
gyrA96(nalR), thi-1, lac, 
glnV44, hsdR17(rk-, mk+), 
supE44, F′ [proAB+ 
lacIqZ∆M15 
::Tn10(TetR)] 
Cloning strain, TetR Stratagene 
XL10-Gold ∆(mcrA)183, ∆(mcrCB-
hsdSMR-mrr)173, 
endA1, recA1, relA1, 
glnV44, gyrA96, supE44, 
thi-1 lac, F′ [proAB 
lacIqZ∆M15 
::Tn10(TetR Amy CmR)] 
High transformation 
efficiency, TetR, 
CmR, Expression host 
Stratagene 
   
Photorhabdus luminescens   
TTO1 Wildtype RifR Dr. David 
Clarke (UCC) 
wblK Mutant TTO1 wblK::kan RifR, KanR This Study 
    
Campylobacter jejuni   
NCTC 11168 Wildtype  Dr. Cyril 
Carroll (N.U.I. 
Galway) 
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Table 2.2 Plasmids 
Plasmid Description Source/Reference 
   
pBR322 TetR, AmpR, rop, pMB1 origin Bolivar et al. (1977) 
pBBR1MCS-5 Broad host range cloning vector, 
GmR, mob (Figure 2.1) 
Kovach et al. (1995) 
pRK600 Provides transfer functions, CmR Finan et al. (1986) 
pJQ200sk+ Suicide vector, GmR, mob, sacB 
from Bacillus subtilis, p15a 
origin (Figure 2.2) 
Quandt and Hynes 
(1993) 
pUK4K Source of KanR cassette, AmpR 
(Figure 2.3) 
Amersham Pharmacia 
  
pBBR1MCS-5 derived plasmids  
pMF1.2 C B/H pBBR1MCS-5 encoding C-
terminally histidine tagged 
OmpN for expression 
This Study 
 
pJQ200sk+ derived plasmids 
pMF2.0 B/P pJQ200sk+ vector containing 2 
kb B/P fragment encoding 5′ end 
of wblK for mutagenesis 
This Study 
pMF2.1 P/X pMF2.0 B/P containing 2 kb P/X 
fragment encoding 3′ end of 
wblK for mutagenesis 
This Study 
pMF2.2 P KanR cassette insertion in 
pMF2.1 P/X 
This Study 
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GmR 
mob 
rep 
 
 
Figure 2.1 pBBR1MCS-5 vector (Kovach et al. 1995) 
The pBBR1MCS-5 broad host range plasmid, showing the multiple cloning site (MCS) with restriction 
enzyme sites (single restriction sites in blue, and double restriction sites in red), the gentamicin resistance 
gene in red, the origin of replication in light blue and the mobilization site in pink. 
 
 
Ori T 
Ori V 
traJ 
sacB 
GmR 
 
 
Figure 2.2 pJQ200sk+ vector (Quandt and Hynes 1993) 
The suicide vector, pJQ200sk+, showing the gentamicin resistance gene in red and the sacB gene in blue. 
The mobilization site (OriT) and the origin of replication (OriV) are shown. The multiple cloning site is 
located between bases 972 and 1074. Selected restriction enzyme sites are indicated (unique sites are 
highlighted in blue while enzymes cutting twice are highlighted in red). 
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AmpR 
KanR 
 
 
Figure 2.3 pUK4K vector (Amersham Pharmacia) 
The pUK4K vector is the source of the kanamycin resistance cassette for mutagenesis. The kanamycin 
resistance gene is shown in brown. The gene is flanked by common restriction sites for excision of the 
cassette. The ampicillin resistance gene is highlighted in green. 
 
Table 2.3 Primer sequences (synthesised by Sigma-Aldrich, UK) 
Name Primer sequence (5′→3′) Tm (°C) 
 
Primers for cloning 
ompN_F1 GTCAGTAAGCTTATGAGGGTAATAATAATGATGAAA 60 
ompN_R2 GTCAGTGGATCCTTAGTGATGGTGATGGTGATGGAATT
GGTAAATCATACCTACG 
60 
 
Primers for mutagenesis 
wblK_F1 ACGTGACATGGATCCTTCCATGCTTCCTAAAGTAC 56 
wblK_R1 ACGTGACATCTGCAGATATTGCGCAAAATCTTGTTC 56 
wblK_F2 ACGTGACATCTGCAGTTAGGTTCCGATGTTGAAGC 58 
wblK_R2 ACGTGACATCTCGAGTAGCGTTCTATAGATAAATCTTG 60 
  
Notes:  Non-binding bases are in bold type 
Restriction sites are underlined and in red 
Melting temperatures were calculated using the formula )(2)(4 TACGTm +++=  
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2.2 Microbiological media 
 
Bacteriological agar, tryptone and yeast extract were supplied by Lab M Ltd. All Oxoid 
media were supplied by Fannin Healthcare. BBL Brucella broth was supplied by Becton 
Dickinson UK Ltd. All other chemicals were supplied by Sigma-Aldrich Co. All media 
were sterilised by autoclaving at 121°C and 15 lb/in2 for 20 minutes. 
 
• Lysogeny broth/agar (LB) 
 
Used for the culturing of E. coli strains and P. luminescens strains 
Tryptone  10 g/L 
NaCl   10 g/L 
Yeast extract   5 g/L 
pH   7.0 
For LB agar, 15 g/L bacteriological agar was included.  
 
• Nutrient broth/agar 
 
Used for the culturing of P. luminescens strains 
 Oxoid nutrient broth  13 g/L 
 Oxoid nutrient agar  28 g/L 
 
• Campylobacter selective agar 
 
Used for the culturing of C. jejuni 
Oxoid Campylobacter Blood-Free Selective Agar Base 45.5 g/L 
Once autoclaved and cooled to 55°C, one vial of Oxoid CCDA Selective Supplement 
that had been reconstituted in 1 ml of sterilised distilled water was aseptically added per 
500 ml of agar. 
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• BBL brucella broth 
 
Used for the culturing of C. jejuni 
BBL brucella broth  28 g/L 
 
• SB broth 
  
Tryptone  30 g/L 
 Yeast extract  20 g/L 
 MOPS   10 g/L 
 pH   7.0 
Once sterilised and cooled to 55°C, 20% (w/v) glucose and 1 M MgCl2 solutions that 
had been filter sterilised were added to final concentrations of 0.4% and 10 mM 
respectively. 
 
• SOB medium 
 
 Tryptone  20 g/L 
 Yeast extract  5 g/L 
 NaCl   0.5 g/L 
 KCl   2.5 mM 
 pH   7.0 
The solution was sterilised and allowed to cool to 55°C. Filter sterilised solutions of 1 
M MgCl2 and 1 M MgSO4 were added to final concentrations of 10 mM each. 
 
• SOC medium 
 
After  making SOB medium as described above, filter sterilised 50% glucose was added 
to a final concentration of 20 mM. 
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2.3 Solution and buffers 
 
• TE buffer 
  
Tris-HCl  10 mM 
 Na2-EDTA  10 mM 
 pH   8.0 
 
• TAE buffer (50X) 
 
Tris   242 g/L 
Glacial acetic acid 5.71% (v/v) 
 EDTA   50 mM (from 0.5 M stock) 
 pH   8.0 
The solution was diluted to 1X with dH2O before use 
 
• Solutions for 1, 2, 3 method of plasmid preparation (Birnboim and Doly 1979) 
 
Solution 1 
  
Glucose  50 mM 
 Na2-EDTA  10 mM (from 0.5 M stock) 
 Tris-HCl  25 mM (from 1 M stock) 
 pH   8.0 
 
Solution 2 
  
NaOH   200 mM (from 1 M stock) 
 SDS   1% (w/v) 
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Solution 3 
  
Potassium acetate 3M 
 pH   4.8 
To 60 ml of 5 M potassium acetate, 11.5 ml of glacial acetic acid and 28.5 ml of dH2O 
was added. The resulting solution was 3 M with respect to potassium and 5 M with 
respect to acetate. 
 
• Agarose gel loading dye (6X) 
  
Bromophenol blue 0.25% (w/v) 
 Xylene cyanol 0.25% (w/v) 
 Ficoll (Type 400) 15% (w/v) 
Made in dH2O and sterilised by autoclaving. 
 
• Ethidium bromide stain 
 
A 10 mg/ml solution of ethidium bromide was stored at 4°C in the dark. For the staining 
of agarose gels, 100 µl of this stock was mixed with 1 L of dH2O. The solution was kept 
in a plastic tray and covered to protect against the light. Fresh stain was made every 1-2 
weeks. Used ethidium bromide stain was collected and ethidium bromide was removed 
by mixing with a de-staining bag (GeneChoice) overnight. The clear liquid was 
disposed of routinely, while the ethidium waste was incinerated. 
 
• TB buffer for competent cells 
 
KCl   250 mM 
CaCl2   15 mM 
PIPES   10 mM 
pH   6.7 
The pH of the solution was adjusted with KOH. MnCl2 was then added to a final 
concentration of 55 mM. The solution was then sterilised through a 0.45 µm sterile filter 
and stored at 4oC. 
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• Sodium phosphate resuspension buffer for the water lysis method (Ward et al. 
2000) 
 
A 0.5 M solution of di-sodium hydrogen orthophosphate (Na2HPO4) and a 0.5 M 
solution of sodium di-hydrogen orthophosphate (NaH2PO4) were prepared. The 0.5 M 
Na2HPO4 solution was buffered to pH 7.2 using the 0.5 M NaH2PO4 solution. This 
solution was diluted to 0.1 M with dH2O prior to use in the water lysis method. 
Mercaptoethanol was added on day of use to a final concentration of 1 mM. 
 
• Buffers for Ni-NTA purification of histidine tagged proteins 
 
Ni-NTA wash buffer 
  
NaH2PO4  50 mM 
 NaCl   300 mM 
 Imidazole  10 mM 
pH   8.0 
 
Ni-NTA elution buffer 
  
NaH2PO4  50 mM 
 NaCl   300 mM 
 Imidazole  300 mM 
pH   8.0 
  
• SDS-PAGE sample (Laemmli) buffer (5X) (Laemmli 1970) 
 
Glycerol  50% (v/v) 
2-mercaptoethanol 5% (v/v) 
SDS   2% (w/v) 
Bromophenol blue 0.1% (w/v) 
Tris-HCl, pH 6.8 62.5 mM 
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• SDS-PAGE running buffer (5X) 
  
Tris   125 mM 
 Glycine  960 mM 
 SDS   0.5% (w/v) 
 pH   8.3 
 
• Coomassie blue stain for SDS-PAGE gels 
  
Methanol  45% (v/v) 
 dH2O   45% (v/v) 
 Glacial acetic acid 10% (v/v) 
 Coomassie blue 0.25% (w/v) 
To make destaining solution for coomassie blue stained gels, the coomassie blue was 
omitted. 
 
• Schiff solution for the periodic acid-Schiff stain for glycoproteins (McGuckin 
and McKenzie 1958) 
 
8 g of potassium metabisulphite was dissolved in 10.5 ml concentrated HCl and the 
volume was adjusted to 1 litre with dH2O. Pararosaniline (4 g) was added and the 
solution was stirred for 2 hours, before adding 1 g G-60 Grade charcoal and filtering the 
solution through Whatman No. 1 filter paper. Schiff reagent is light sensitive and so was 
stored in a dark bottle, at 4°C. 
 
• IPG gel strip rehydration stock 
 
Urea    7 M 
Thiourea   2 M 
CHAPS   2% (w/v) 
IPG buffer 3-10  0.5% (v/v) 
Bromophenol blue  0.002% (w/v) 
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The solution was prepared in dH2O, warmed slightly to dissolve the urea and then 
stored in 500 µl aliquots at -20°C. When required for use, an aliquot was thawed and to 
it DL-Dithiothreitol (DTT) was added to a final concentration of 20 mM before use. 
 
• IPG gel strip SDS equilibration buffer 
 
Tris    50 mM 
Urea    6 M 
Glycerol   30% (w/v) 
SDS    2% (w/v) 
Bromophenol blue  0.002% (w/v) 
pH    8.8 
The buffer was prepared in dH2O, warmed slightly to dissolve the urea and then 10 ml 
aliquots were stored at -20°C. When required for use, an aliquot was thawed and to it 
100 mg of DTT was added immediately before use for a final concentration of 10 
mg/ml. 
 
• Tris buffered saline (TBS) 
  
Tris-HCl  20 mM 
 NaCl   150 mM 
 CaCl2   1 mM (from 1 M stock) 
 MgCl2   1 mM (from 1 M stock) 
 MnCl2   1 mM (from 1 M stock) 
 pH   7.6 
For TBST, the detergent Triton X-100 was added to a final concentration of 0.1% (v/v). 
 
• Phosphate buffered saline (PBS) 
  
NaCl   137 mM 
 NaH2PO4  4.3 mM 
 KCl   2.7 mM 
 K2HPO4  1.5 mM 
 pH   7.4 
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• Western blot transfer buffer 
  
Tris   60 mM 
 Glycine  149 mM 
 SDS   0.055% (w/v) 
Directly before use, Methanol was added to the buffer in the ratio of 1:4. 
 
• Lectin affinity chromatography (LAC) equilibration buffer 
  
Tris-HCl  20 mM 
 NaCl   150 mM 
 CaCl2   1 mM (from 1 M stock) 
 MgCl2   1 mM (from 1 M stock) 
 MnCl2   1 mM (from 1 M stock) 
 pH   5.5 
 
• LAC elution buffer 
  
Tris-HCl  20 mM 
 NaCl   500 mM 
 pH   7.5 
For the lectin WGA, N-acetylglucosamine was also added to a final concentration of 
500 mM before pH adjustment. For the lectin Con A, 200 mM α-methyl mannoside and 
200 mM α-methyl glucoside were added to the above list. Finally for agarose bound 
Griffonia simplicifolia lectin I (GSL I) the elution buffer also contained 200 mM 
galactose and 200 mM N-acetylgalactosamine. 
 
• Trypsin buffer for the in-gel trypsin digestion of proteins (Shevchenko et al. 
2007) 
 
Trypsin   13 ng/µl 
Ammonium bicarbonate 10 mM 
Acetonitrile   10% (v/v) 
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2.4 Antibiotics 
 
Table 2.4 Antibiotics 
Antibiotic Stock conc. Prepared in Working conc. 
(solid media) 
Working conc. 
(liquid media) 
     
Ampicillin 100 mg/ml dH2O 100 µg/ml 100 µg/ml 
Rifampicin 20 mg/ml Methanol 100 µg/ml 50 µg/ml 
Tetracycline 10 mg/ml 50% Ethanol 10 µg/ml 10 µg/ml 
Chloramphenicol 20 mg/nl 100% Ethanol 20 µg/ml 20 µg/ml 
Gentamicin 100 mg/ml dH2O 20 µg/ml 20 µg/ml 
Kanamycin 100 mg/ml dH2O 30 µg/ml 30 µg/ml 
 
Note: The working concentrations stated in table 2.4 were used for both E. coli and P. 
luminescens strains. 
 
2.5 Storing and culturing of bacteria 
 
2.5.1 E. coli and P. luminescens strains 
 
Glycerol stocks were prepared for each strain. Multiple stocks of the same P. 
luminescens strain were prepared at a time as the bacteria lose viability very quickly if 
they are repeatedly frozen and thawed. A 0.5 ml aliquot of an exponentially growing 
culture was added to 0.5 ml of sterile 80% (v/v) glycerol in a cryogenic tube. Stocks 
were stored at -80°C.  
 
In order to culture E. coli and P. luminescens an inoculating loop was used to transfer 
culture from a glycerol stock to an LB or nutrient agar plate (section 2.2). E. coli plates 
were incubated at 37°C overnight and P. luminescens plates were incubated at 30°C for 
24-48 hours. Working stocks were stored on agar plates at 4°C for up to one week for E. 
coli and up to three days for P. luminescens. 
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For liquid cultures one single colony from a plate was transferred to 5 ml of LB or 
nutrient broth in a 25 ml tube and tubes were incubated at 37°C for E. coli and 30°C for 
P. luminescens in a shaker incubator at 200 rpm overnight. For larger cultures, 1 ml of a 
5 ml overnight culture was added to 100 ml of broth in a 250 ml flask or 5 ml of 
overnight culture was added to 500ml of broth in a 1 L flask and incubated in the same 
way as 5 ml cultures. Where hosts were harbouring plasmids, the appropriate antibiotic 
was added to the growth medium (section 2.4). 
 
2.5.2 C. jejuni NCTC 11168 
 
Glycerol stocks were prepared by adding a 0.5 ml aliquot of stationary phase culture to 
0.5 ml of sterile 40% (v/v) glycerol in a cryogenic tube. Stocks were stored at -80°C.  
 
In order to culture C. jejuni, sterile cotton tipped swabs were used to transfer bacteria 
from a glycerol stock to Campylobacter selective agar plates (section 2.2). Plates were 
immediately transferred to an anaerobic jar, lid side down. An Oxoid gas generating kit 
was added to the jar. This consisted of a foil sachet with tablets of sodium borohydride, 
sodium bicarbonate and tartaric acid in a porous membrane container. A 10 ml aliquot 
of sterilised dH2O was added to the sachet, activating the system, causing hydrogen and 
carbon dioxide to be produced. The gas generating kit created an atmosphere of 5-6% 
oxygen, 10% carbon dioxide and 84-85% nitrogen. The anaerobic jar was quickly 
sealed and the plates were incubated at 37°C for 48 hours. Working stocks of C. jejuni 
were stored on agar plates at 4°C for no more than two days. 
 
In order to prepare liquid cultures, sterile cotton tipped swabs were used to transfer a 
large amount of culture from an agar plate to 5 ml of BBL brucella broth (section 2.2) in 
a 5 ml tube (very little headspace was left at the top of the tube to keep the oxygen 
content low). The lid of the tube was tightly secured and the cultures were grown at 
44°C for 24-48 hours with no shaking. For larger scale cultures, 1 ml of the stationary 
phase 5 ml culture was added to a 100 ml flask containing 100 ml of BBL brucella broth 
and grown the same way as the 5 ml cultures. 
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Because C. jejuni grows at very low densities, the cultures are very susceptible to 
contamination. New glycerol stocks were prepared regularly. C. jejuni has a very 
distinctive colour, smell and morphology so cultures were continually checked to ensure 
contamination was not present. 
 
2.6 Preparation of total genomic DNA using the Wizard® genomic 
DNA kit 
 
The kit was used according to the manufacturer’s instructions (Promega) with some 
modifications. An overnight culture of the appropriate organism was prepared and a 1 
ml aliquot of this culture was pelleted by centrifugation at 13,000 rpm for 2 minutes. 
The supernatant was removed and the pellet was resuspended in 600 µl of nuclei lysis 
solution. The suspension was incubated at 80°C for 5 minutes to lyse the cells and then 
cooled to room temperature. To the cell lysate 3 µl of RNase solution was added. The 
tube was inverted several times to mix and incubated at 37°C for 15-60 minutes. To 
remove the protein in the sample, 200 µl of protein precipitation solution was added and 
vortexed vigorously for 20 seconds. The sample was incubated on ice for 5 minutes then 
the precipitated protein was pelleted by centrifugation at 13,000 rpm for 3 minutes. The 
supernatant was transferred to a fresh tube and 600 µl of 
phenol/chloroform/isoamylalcohol (25:24:1) was added. The suspension was mixed 
slowly by inversion. The aqueous and organic layers were separated by centrifugation at 
13,000 rpm for 5 minutes. The aqueous (top) layer was transferred to a fresh tube and 
the phenol/chloroform/isoamylalcohol (25:24:1) purification step was repeated. The 
aqueous layer was removed and added to a fresh tube containing 600 µl of room 
temperature isopropanol. The sample was mixed gently by inversion until thread-like 
strands of DNA formed a visible mass. The genomic DNA was pelleted by 
centrifugation at 13,000 rpm for 2 minutes. The pellet was washed twice with 100 µl of 
70% ethanol, and air dried for 10-15 minutes. The dried pellet was resuspended in 100 
µl of DNA rehydration solution overnight at 4°C and stored at 4°C. 
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2.7 Plasmid preparation by the 1, 2, 3 method 
 
The method described is adapted from the procedure described by Birnboim and Doly 
(1979). In this method the high molecular weight chromosomal DNA undergoes 
selective alkaline denaturation, while the covalently closed circular plasmid DNA 
remains double stranded. A 1.5 ml volume of overnight bacterial culture was 
centrifuged at 13,000 rpm to pellet the cells. The supernatant was discarded and the 
pellet thoroughly resuspended in 200 µl of solution 1 (section 2.3). The tube was left at 
room temperature for 5 minutes. A 200 µl aliquot of solution 2 (section 2.3) was added 
and mixed by inversion several times. The tube was left on ice for 5 minutes. A 200 µl 
aliquot of solution 3 (section 2.3) was added to the tube and inverted several times. The 
tube was left on ice for 10 minutes. A clot of chromosomal DNA was formed and this 
was pelleted by centrifugation at 13,000 rpm for 10 minutes. The supernatant was 
transferred to a fresh tube containing 450 µl of phenol/chloroform/isoamylalcohol 
(25:24:1), mixed by vigorous vortexing and centrifuged for 10 minutes at 13,000 rpm to 
separate the aqueous and organic layers. The aqueous layer was transferred to a fresh 
tube and an equal volume of isopropanol was added. The contents of the tube were 
mixed by inversion and left on ice for 10 minutes and then centrifuged for 10 minutes at 
13,000 rpm to pellet the plasmid DNA. The pellet was washed with 100 µl of 70% 
ethanol and centrifuged at 13,000 rpm for 5 minutes. The ethanol was removed and the 
pellet was dried in a vacuum dryer for 5 minutes. The dried pellet of plasmid DNA was 
resuspended in 50 µl of TE buffer and stored at 4°C. 
 
2.8 Plasmid DNA isolation using the GenElute HP plasmid miniprep 
kit 
 
The kit was used according to the manufacturer’s instructions (Sigma-Aldrich). A 1.5 
ml aliquot of an overnight bacterial culture was pelleted by centrifugation at 13,000 rpm 
for 5 minutes. The cell pellet was resuspended in 200 µl of resuspension solution. 200 
µl of cell lysis solution was added to the suspension to lyse the cells. This was allowed 
to stand at room temperature for 5 minutes. A 350 µl aliquot of neutralisation/binding 
buffer was added to the tube and mixed by inversion to precipitate the cell debris and 
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chromosomal DNA. The precipitate was pelleted by centrifugation at 13,000 rpm for 10 
minutes. In the meantime a spin column in a tube was prepared for use by the addition 
of 500 µl of column preparation solution and centrifugation at 13,000 rpm for 1 minute. 
The flow-through was discarded. The supernatant was transferred to the column and 
centrifuged at 13,000 rpm for 1 minute to bind the plasmid DNA to the column. The 
flow through was discarded. A 750 µl aliquot of wash solution was added to the column 
and centrifuged at 13,000 rpm for 1 minute. The flow through was discarded and the 
column was dried by centrifugation at 13,000 rpm for 2 minutes. The column was 
transferred to a fresh tube and 100 µl TE buffer was added. This was allowed to stand 
for 2 minutes before elution of the plasmid DNA by centrifugation at 13,000 rpm for 1 
minute. Plasmid DNA was stored at 4°C. 
 
2.9 Agarose gel electrophoresis 
 
DNA was analysed by agarose gel electrophoresis. Typically 0.7% agarose gels 
prepared in 1X TAE buffer (section 2.3) were used. The agarose was dissolved in the 
buffer by boiling and poured into plastic trays with a plastic comb fitted to create 
sample wells and allowed to set. The gels were run in a BioRad horizontal gel apparatus 
using 1X TAE as the running buffer. The DNA samples were mixed with loading dye 
(section 2.3) and loaded into the wells. The loading dye aided loading and visualisation 
of the migration process during electrophoresis. Gels were run at 120 V for 20-40 
minutes depending on the gel length. Staining was achieved by immersion in ethidium 
bromide staining solution (section 2.3) for 15 minutes. DNA was visualised on a UV 
transilluminator. 1 kb DNA ladder (Invitrogen) was run as a molecular size marker in 
every gel. 
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Figure 2.4 1 kb DNA ladder, Invitrogen.  
A representative image of the DNA ladder used for agarose gel electrophoresis in this study. 
 
2.10 Isolation of DNA from agarose gels 
 
DNA that had been separated and visualised by agarose gel electrophoresis could be 
excised and purified. To purify DNA from agarose gels the HiYield Gel/PCR DNA 
extraction kit (Real Biotech Corporation) was used according to the manufacturer’s 
instructions. The DNA to be purified was run as normal on an agarose gel that 
contained 1 ng/ml SYBR® Safe DNA gel stain (Invitrogen). The DNA was visualised 
using a blue light transilluminator (Invitrogen) and the bands were excised using a clean 
scalpel. The gel slice was placed in a microfuge tube and 500 µl of DF buffer was 
added. The gel slice was dissolved in the buffer by incubating at 55°C for 10-15 
minutes. The solution was added to a DF column in a collection tube and centrifuged at 
13,000 rpm for 30 seconds. The flow through was discarded and 750 µl of wash buffer 
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was added to the column. The column was centrifuged as before. The flow through was 
discarded and the column was centrifuged at 13,000 rpm for 2 minutes to dry the 
column. The dried column was transferred to a new tube and 30 µl of elution buffer was 
added to the centre of the column matrix allowed to stand for 2 minutes to absorb into 
the matrix. The purified DNA was eluted by centrifugation for 2 minutes at 13,000 rpm. 
Purified DNA was stored at 4°C. 
 
2.11 Competent cells 
 
2.11.1 Preparation of electrocompetent cells 
 
A glycerol stock of an E. coli strain was streaked on LB agar and incubated at 37°C 
overnight. A 5 ml aliquot of SB broth (section 2.2) was inoculated with a single colony 
from this plate and incubated at 37°C overnight. A 1 ml inoculum of this overnight 
culture was added to two 200 ml flasks of pre-warmed SB broth. These cultures were 
grown at 37°C and 220 rpm until an O.D.600 nm of 0.7 – 0.8 was reached. The flasks 
were cooled on ice for 15 minutes. From this point on, all steps were preformed on ice 
or in a 4°C cold room. The cultures were transferred to two cooled, sterile 250 ml 
centrifuge tubes. The cells were pelleted in a Beckman JA-21 centrifuge at 4,000 rpm at 
4°C for 15 minutes. The cell pellets were resuspended in 200 ml of pre-cooled, 
sterilised 10% glycerol and centrifuged as before. The cell pellets were then 
resuspended in 100 ml of pre-cooled, sterilised 10% glycerol. The two suspensions were 
transferred to one centrifuge tube and the suspension was centrifuged as before. The cell 
pellet was then resuspended in 25 ml of pre-cooled, sterilised 10% glycerol, transferred 
to a smaller centrifuge tube and centrifuged at 3,000 rpm at 4°C for 15 minutes. Finally 
the cell pellet was resuspended in 0.5 ml of pre-cooled, sterilised 10% glycerol. The cell 
suspension was dispensed into 50 µl aliquots in sterile cooled microfuge tubes. These 
were flash frozen in -80°C ethanol and stored at -80°C. The electrocompetent cells were 
then ready for electroporation. Cells prepared using this method frequently gave 
transformation efficiencies of 109 transformants/µg DNA. 
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2.11.2 Electroporation of electrocompetent cells 
 
To 50 µl of electrocompetent cells that had been thawed on ice, 1 µl of plasmid DNA or 
a ligation mixture was added. An electroporation cuvette was also cooled on ice. The 
BioRad Gene Pulser electroporator was set to 2,500 volts, 200 ohms and 25 µFaraday 
when transforming E. coli cells. The cells were transferred to the cooled electroporation 
cuvette and any air pockets between the two metal plates in the cuvette were removed 
by tapping the cuvette on a hard surface. The cuvette was placed in the electroporator 
and the cells were shocked for approximately 5 seconds. Immediately after 
electroporation, 800 µl of SOC broth (section 2.2) was added to the cuvette. This 
suspension was then transferred to a sterile microfuge tube and then incubated in a 37°C 
water bath for 60 minutes. A 100 µl aliquot of the resulting transformation mixture was 
then plated on the appropriate selective media and incubated at 37°C overnight. 
 
2.11.3 Preparation of chemical competent cells by the TB method 
 
This method was performed as described by Inoue et al. (1990). A glycerol stock of an 
E. coli strain was streaked on LB agar and incubated at 37°C overnight. A 5 ml aliquot 
of LB broth was inoculated with a single colony from this fresh plate and incubated at 
37°C overnight while shaking at 200 rpm. 1 ml of this overnight culture was used to 
inoculate 250 ml of SOB medium (Section 2.2) in a 1 L flask. The culture was grown at 
37°C, shaking at 200 rpm until an O.D.600 nm of 0.6 was reached. The flask was then 
placed on ice for 10 minutes. All subsequent steps were carried out at 4°C. The culture 
was transferred to a sterile 250 ml centrifuge tube and centrifuged in a Beckman JA-21 
centrifuge at 3,000 rpm for 5 minutes. The supernatant was discarded and the pellet was 
resuspended in 80 ml of ice-cold TB buffer (Section 2.3). The suspension was placed on 
ice for 10 minutes and centrifuged as before. The resulting cell pellet was gently 
resuspended in 20 ml of ice-cold TB buffer and DMSO was added to a final 
concentration of 7%. After incubation in an ice bath for 10 minutes the cell suspension 
was dispensed into 200 µl aliquots in microfuge tubes. The cells were then flash frozen 
in -80°C ethanol and stored at -80°C. The competent cells were then ready for 
transformation. Cells prepared using this method frequently gave transformation 
efficiencies of 108 transformants/µg DNA. 
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2.11.4 Transformation of chemical competent cells 
 
A 2 µl aliquot of plasmid DNA or a ligation mixture was mixed gently with 200 µl of 
competent cells that had been thawed on ice. The mixture was kept on ice for 30 
minutes. The cells were heat shocked at 42°C for 30 seconds and then quickly placed 
back on ice for 2 minutes. An 800 µl aliquot of LB broth was added to the cells and the 
mixture incubated in a 37°C water bath for 1 hour. A 100 µl aliquot of the resulting 
transformation mixture was then plated on the appropriate selective media and 
incubated at 37°C overnight. 
 
2.11.5 Determination of competent cell efficiency 
 
Competent cell efficiency is defined in terms of the number of colony forming units 
obtained per µg of transformed plasmid DNA. A 25 ng/µl stock of pBR322 plasmid 
DNA (section 2.1) was diluted to 250 pg/µl, 25pg/µl and 2.5 pg/µl. Each dilution was 
transformed as described in sections 2.11.2 and 2.11.4. The cell efficiency was 
calculated from the number of colonies obtained, taking into account the dilution factor 
and the fraction of culture transferred to the spread plate. 
 
2.12 In silico analysis of DNA and protein sequences 
 
• The P. luminescens genome sequence was obtained from the sequencing study, 
Photorhabdus luminescens subsp. laumondii TTO1 (NC_005126) and is accessible 
at http://cmr.tigr.org/tigr-scripts/CMR/GenomePage.cgi?org=ntpl01 
• The C. jejuni subsp. jejuni 81-176 genome sequence was obtained from the study 
Campylobacter jejuni subsp. jejuni 81-176 (NC_008787) and is accessible at 
http://cmr.jcvi.org/tigr-scripts/CMR/GenomePage.cgi?org=gcj81176 
• BLAST programs at NCBI, www.ncbi.nlm.nih.gov were used to identify 
homologous sequences in GenBank. 
• DNA and protein sequences were aligned using the MultAlin programme 
http://prodes.toulouse.inra.fr/multalin/multalin.html and the Genedoc program, 
available to download from http://www.nrbsc.org/ 
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• DNA sequences were analysed for restriction enzyme sites using the Webcutter 2.0 
tool at http://rna.lundberg.gu.se/cutter2/ 
• DNA sequences analysed using the pDRAW32 program downloaded at 
http://www.acaclone.com/ 
• Protein sequences were analysed online at ExPASy Molecular Biology Server 
http://us.expasy.org/ 
• The MASCOT search engine available at http://www.matrixscience.com/ was used 
to identify proteins using peptide mass fingerprinting 
 
2.13 Bacterial conjugation by tri-parental mating 
 
Two E. coli cultures, one containing the donor plasmid and another carrying the 
mobilising plasmid, pRK600 (section 2.1), were grown to stationary phase in 5 ml of 
LB broth containing appropriate antibiotics. A 0.75 ml aliquot of each of the cultures 
was taken, mixed together and pelleted by centrifugation at 13,000 rpm for 1 minute. 
The cell pellet was resuspended in 100 µl of fresh LB broth and then spotted onto the 
centre of an LB agar plate with no antibiotics and incubated overnight at 37°C. The 
following day the bacteria were removed from the plate and resuspended in 3 ml of 
fresh LB broth. This mixture of E. coli was known as the intermediate. Meanwhile a 5 
ml culture of P. luminescens (the recipient) had been grown to stationary phase in LB 
broth. A 0.75 ml aliquot of the intermediate was added to 0.75 ml of the recipient 
culture and pelleted as before. The cells were resuspended in 100 µl of fresh LB broth, 
spotted onto the centre of an LB agar plate and incubated at 30°C overnight. As 
negative controls, the intermediate and recipient strains were also spotted on agar plates 
separately and carried through the procedure. The bacteria from each plate were 
resuspended in 2 ml of LB broth, dilutions of the suspensions were made and 100 µl of 
each dilution was spread on selective media (section 2.4). Plates were incubated at the 
appropriate temperatures and transconjugates were visible within two days. 
 
 75 
2.14 Protein expression 
 
Sterile 250 ml conical flasks containing 50 ml of LB or nutrient broth were inoculated 
with 1 ml of a 5 ml overnight saturated stationary phase culture harbouring the 
expression plasmid. Selective antibiotics and sterile glycerol to a final concentration of 
20 mM were added to the flask. The culture was incubated at 200 rpm and 37°C for E. 
coli or 30°C for P. luminescens until an O.D.600 nm of 0.4-0.6 was reached. At this point 
expression was induced with the addition of 1 mM IPTG. Cultures were then incubated 
overnight. 
 
2.15 Extracellular, periplasmic, cytoplasmic and membrane protein 
isolation using the water lysis method 
 
The water lysis method was preformed as described by Ward et al. (2000). The method 
uses osmotic pressure to lyse the cells. A 50 ml culture of the desired bacteria was 
prepared as described in section 2.5 or section 2.14. The culture was centrifuged in a 
Beckman JA-21 centrifuge at 6,500 rpm for 8 minutes at 10°C. The supernatant 
(extracellular fraction) was decanted and stored at -20°C. The pellet was resuspended in 
10 ml of 0.2 M Tris-HCl, pH 8.0 and left stirring for 20 minutes at room temperature. 
At this point 9.6 ml of dH2O was aliquoted in anticipation of the water lysis step. At 
time zero, 4.85 ml of 1 M sucrose/ 0.2 M Tris, pH 8.0/ 1 mM EDTA was added. At time 
1.5 minutes, 65 µl of 10 mg/ml lysozyme solution prepared in 1 M sucrose/ 0.2 M Tris, 
pH 8.0/ 1 mM EDTA buffer was added. At time 2 minutes, the prepared 9.6 ml aliquot 
of dH2O was added. The suspension was left to stir for 20 minutes. Spheroplasts were 
formed and sedimented by centrifugation at 18,000 rpm for 20 minutes at 4°C. The 
supernatant was retained and stored at -20°C (periplasmic fraction) and the spheroplasts 
were completely resuspended in 15 ml of dH2O using a 15 ml homogeniser. This was 
left stirring for 30 minutes at room temperature. The suspension was sedimented at 
18,000 rpm for 20 minutes at 4°C. The supernatant was retained (cytoplasmic fraction) 
and stored at -20°C. The preparation was then washed by resuspending the pellet in 30 
ml of sodium phosphate resuspension buffer (section 2.3) using a homogeniser followed 
by centrifugation at 18,000 rpm for 20 minutes at 4°C. The wash step was repeated. The 
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final pellet was completely resuspended in 500 µl ice cold resuspension buffer using a 1 
ml homogeniser. These samples were kept on ice and stored at -80°C (membrane 
fraction). The protein concentration in each fraction was determined using the BCA 
Assay (section 2.17). 
 
2.16 Immobilised metal affinity chromatography (IMAC) 
 
2.16.1 Protein purification using IMAC with Ni-NTA resin 
 
A 1 ml aliquot of nickel-nitrilotriacetic acid resin (Ni-NTA, Invitrogen) was mixed with 
5 ml of periplasmic protein sample (section 2.15) at 4°C overnight. The mixture was 
then poured into a 0.7 x 10 cm column and the resin was allowed to settle. The resin 
was drained and the flow through collected. The column was then washed with 10 ml of 
Ni-NTA wash buffer (section 2.3) and the wash was collected. The resin was 
subsequently washed with wash buffer supplemented with 20, 40, 60, 80 and 100 mM 
imidazole using 5 ml of buffer each time. Each wash was collected. Finally the bound 
protein was eluted using 10 ml of Ni-NTA elution buffer (section 2.3). Imidazole was 
then removed and the proteins were concentrated using vivaspin 15 centrifugal 
ultrafiltration devices (Sartorius Stedim Biotech). The sample was transferred to the unit 
and centrifuged in a Hettich Rotanta 460R centrifuge fitted with a swing-out rotor 
(model number 5624) at 3,800 rpm for 20 minutes. The protein was washed twice in 
PBS, and concentrated to a final volume of 500 µl. Concentrated protein samples were 
stored at -20°C. 
 
2.16.2 Recharging of Ni-NTA resin 
 
The Ni-NTA resin was routinely recharged prior to re-use. The used resin was poured 
into a column and washed with 2 column volumes of dH2O, followed by 2 column 
volumes of 50% (v/v) ethanol. The resin was then stripped with 2 column volumes of 
100 mM EDTA, pH 8.0. Remaining impurities were removed with 2 column volumes 
of 200 mM NaCl, followed by 2 column volumes of dH2O. Hydrophobically bound 
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proteins and lipoproteins were removed by washing with 10 column volumes of 30% 
isopropanol for 30 minutes, followed by 10 column volumes of water. The resin was 
then recharged by adding 2 column volumes of 100 mM NiSO4. The resin was washed 
again with 10 column volumes of dH2O. 
 
2.17 Protein quantification by the BCA assay 
 
The bicinchoninic acid (BCA) assay was preformed to determine total protein content in 
a sample using the QuantiPro BCA Assay Kit (Sigma). The assay gives a linear 
response from 0.5 to 30 µg/ml. A range of protein standards from 0 to 30 µg/ml were 
prepared by diluting the protein standard solution provided (bovine serum albumin 
(BSA)) in PBS (section 2.3). A range of dilutions for the unknown samples were also 
prepared in PBS. A 150 µl aliquot of each standard/sample was added to a 96 well plate 
in triplicate. BCA reagent was prepared by mixing QuantiPro Buffer QA, QuantiPro 
Buffer QB and 4% Copper (II) Sulphate pentahydrate solution QC in the ratio of 
25:25:1. To each sample 150 µl BCA reagent was added. The samples were incubated 
at 37°C for 2 hours. The absorbance of each sample was read at 570 nm. A standard 
curve was constructed using the BSA standards and the protein concentrations of the 
unknown samples were determined from this. 
 
2.18 SDS-PAGE 
 
Protein samples were analysed by SDS-PAGE.  
 
2.18.1 Gel preparation 
 
Table 2.5 outlines the recipe used to prepare a 15% acrylamide resolving gel and 4% 
acrylamide stacking gel. 
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Table 2.5 SDS-PAGE gel recipes 
Solution 15% Resolving gel 4% Stacking gel 
   
dH2O 1.56 ml 1.538 ml 
1.5 M Tris-HCl, pH 8.8 1.625 ml - 
0.5 M Tris-HCl, pH 6.8 - 625 µl 
20% (w/v) SDS 32.5 µl 12.5 µl 
Acrylamide/bis-acrylamide 30%/0.8% (w/v) 3.25 µl 335 µl 
10% Ammonium persulphate (APS) 32.5 µl 12.5 µl 
TEMED 3.25 µl 2.5 µl 
 
The reagents were added in the order listed in the table. For use in 2-D electrophoresis, 
0.002% bromophenol blue was also added to the stacking gel after the addition of 
dH2O. APS and TEMED were always added last to the mix as they polymerise the 
acrylamide. Gels were cast using the ATTO vertical mini electrophoresis system. The 
resolving gel was poured immediately after the addition of APS and TEMED, leaving 
about 1.5 cm of space at the top and overlayed with a layer of room temperature 
isopropanol. Once the gel was polymerised, the isopropanol was removed and the 
interface was rinsed with dH2O. The stacking gel was poured on top of the resolving 
gel. A comb was immediately inserted into the top of the gel to create wells. The 
stacking gel was allowed to set. 
 
2.18.2 Sample preparation and application 
 
In a microfuge tube 8 µl of sample was added to 2 µl of 5X sample buffer (section 2.3). 
For each gel that was run, one lane was used for a relative molecular weight marker. A 
10 µl aliquot of broad range protein marker (2-212 kDa) from NEB was used for 
coomassie or silver stained gels and 12 µl broad range prestained protein marker (7-175 
kDa) from NEB was used for Schiff stained gels and gels to be used for western 
blotting. A representative image of the protein markers used in this study is shown in 
figure 2.5. 
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Figure 2.5 (a) Broad range protein marker (2-212 kDa), (b) Prestained protein marker, broad 
range (7-175 kDa), (c) ColorPlus prestained protein marker, broad range (7-175 kDa), New 
England Biolabs. 
Representative images of protein markers used in this study for SDS-PAGE. (a) 10 µl of broad range 
marker on a 15% SDS-PAGE gel stained with coomassie blue. The bands at 66.4 kDa and 27.0 kDa have 
double the intensity to serve as reference bands. (b) 12 µl of prestained protein marker on a 15% SDS-
PAGE gel. (c) 12 µl of ColorPlus prestained protein marker on a 15% SDS-PAGE gel. There is one 
orange band at 80 kDa and a green band at 23 kDa to serve as reference bands. 
 
Before loading on a gel, samples were heated at 100°C in a heating block for 5 minutes. 
The gel was positioned in the electrophoresis chamber with 1X SDS-PAGE running 
buffer, the comb was removed and the wells were flushed with buffer to remove any 
unpolymerised acrylamide. Once cooled to room temperature the samples were loaded 
into the wells and the gel was run at 30 mA for 80 minutes at room temperature. 
 
2.19 2-Dimensional gel electrophoresis 
 
For a more comprehensive separation of proteins, 2-D gel electrophoresis was carried 
out. For the first step in 2-D gel electrophoresis, the isoelectric focusing (IEF) step, 
immobilised pH gradient (IPG) dehydrated gel strips were used. ImmobilineTM DryStrip 
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IPG strips, 7 cm in length with a linear pH gradient of 3-10 were purchased from GE 
Healthcare. IPG strips were stored at -20°C. Rehydration of IPG strips was carried out 
using the IPGbox kit and IEF was performed using the Ettan IPGphor 3 instrument, 
both manufactured by GE Healthcare. 
 
2.19.1 Rehydration of IPG strips and addition of sample 
 
The protein sample to be separated was prepared by adjusting the concentration to 1-3 
µg/µl in dH2O. Protein sample was loaded onto the IPG strip using the rehydration 
loading technique. A 10 µl aliquot of the prepared protein sample was added to 115 µl 
of IPG gel strip rehydration stock (section 2.3) for a total volume of 125 µl. The IPGbox 
was placed on a level surface and a reswell tray was positioned in the IPGbox. The 
solution was pipetted into a channel of the reswell tray and spread out over 
approximately 7 cm. Holding the IPG strip with a forceps, the protective plastic backing 
was removed and the strip was placed gel-side down in the solution. The strip was 
gently slid back and forth a few times to distribute the solution evenly over its surface 
also ensuring that no air bubbles were trapped under the strip. The lid of the IPGbox 
was closed and the strips were allowed to rehydrate at room temperature for 10-24 
hours. 
 
2.19.2 Preparation of manifold 
 
A ceramic manifold was used to hold the IPG strips during the IEF run. The manifold 
contained 12 channels for the simultaneous separation of 12 different samples. The 
manifold was cleaned using manifold cleaning detergent and non-abrasive cloths, rinsed 
with dH2O and allowed to air dry. The Ettan IPGphor platform was cleaned and the 
manifold was positioned on it. A spirit level was used to ensure the manifold was level. 
Exactly 108 ml of ImmobilineTM DryStrip cover fluid was measured out and distributed 
evenly over the 12 manifold channels (9 ml per channel). 
 
A rehydrated IPG strip was positioned gel side up under the cover fluid in a manifold 
channel so that the anodic (+) end of the strip was directly above the anode of the 
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instrument and vice versa. Two electrode wicks were moistened with 150 µl of dH2O 
each and were placed on the strip so that each wick overlapped the end of the gel on the 
IPG strip. With the electrode cams in the open position, the electrode assembly was 
placed on top of the wicks, ensuring that electrodes were touching the part of the wicks 
that were in contact with the gel. The cams were swivelled into the closed position 
under the external lip of the manifold and the lid of the Ettan IPGphor unit was closed. 
 
2.19.3 1st dimension IEF 
 
The Ettan IPGphor unit was controlled by the Ettan IPGphor 3 control software. The PC 
and IPGphor unit were powered on and communication between them was established. 
A protocol detailing the run conditions was created and the number of strips in use was 
entered. The protocol was transferred to the instrument and initiated. The typical run 
conditions used for 7 cm, pH 3-10 strips are outlined in table 2.7. 
 
Table 2.6 Run conditions for isoelectric focusing of 7 cm, pH 3-10 IPG strips 
 Step voltage mode Voltage (V) Time (h:min) kVh 
     
1 Step and Hold 300 2:30 750 
2 Gradient 1000 0:30 325 
3 Gradient 5000 1:20 4000 
4 Step and Hold 5000 0:25 2083 
Total   4:45 7158 
 
Following IEF, the strips were removed from the manifold and if the 2nd dimension was 
not to be carried out immediately they were stored in separate tubes at -80°C. 
 
2.19.4 2nd dimension SDS-PAGE 
 
A 15% SDS-PAGE resolving gel was prepared as outlined in section 2.18.1. An IPG 
strip was removed from the freezer and 10 ml of IPG gel strip SDS equilibration buffer 
(section 2.3) was added to the tube. The strip was equilibrated for 30 minutes at room 
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temperature on a rocker. The isopropanol was washed from the surface of the 
polymerised resolving gel and, using a forceps, the IPG strip was removed from the 
equilibration buffer and placed carefully on top of the separating gel so that it was in 
contact with the gel surface and no air bubbles were present. The gel strip was pushed 
over to one side to leave space for a molecular weight marker on the other. A 4% 
stacking gel was prepared (section 2.18.1) and poured on top of the IPG strip. A 12 well 
comb was inserted and the gel was allowed to polymerise. A molecular weight marker 
sample was prepared and applied to the gel and the gel was run as outlined in section 
2.18.2. Staining was performed using the silver stain method (section 2.20). 
 
2.20 SDS-PAGE and 2-D gel staining 
 
SDS-PAGE and 2-D gels were removed from the electrophoresis apparatus and washed 
with dH2O.  
 
• Coomassie blue staining 
 
Gels were immersed in coomassie blue staining solution (section 2.3) and left stirring 
overnight at room temperature. The staining solution was removed and gels were 
destained overnight in destain solution (section 2.3). Destained gels were rinsed in 
dH2O. 
 
• Silver staining 
 
When a higher degree of sensitivity was required the silver staining method was used. 
This method is outlined in table 2.6. 
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Table 2.7 Silver staining of SDS-PAGE gels 
Step Reagent (50 ml per gel) Duration 
   
Fix 30% (v/v) ethanol, 10% (v/v) acetic acid 1 hour to overnight 
Rinse 20% (v/v) ethanol 15 minutes 
Rinse dH2O 3 x 5 minutes 
Sensitise 0.01% (w/v) Na2S2O3 1 minute 
Rinse dH2O 2 x 20 seconds 
Silver stain 0.1% (w/v) AgSO4, 0.026% (v/v) formaldehyde 30 minutes 
Rinse dH2O 2 x 20 seconds 
Develop 3% (w/v) Na2CO3, 0.019% (v/v) formaldehyde, 
0.002% (w/v) Na2S2O3 
Until bands appear 
Stop 5% (w/v) Tris, 2.5% (v/v) acetic acid 1 minute 
 
• Periodic acid-Schiff stain for glycoproteins 
 
If required, gels were first stained with coomassie blue to stain all proteins. Destained 
gels were completely immersed in methanol/acetic acid/dH2O (40:5:55) containing 1% 
(w/v) periodic acid for 1 hour, followed by overnight incubation in methanol/acetic 
acid/dH2O (40:5:55) solution. The gel was subsequently immersed in Schiff solution 
(section 2.3) and incubated with gentle agitation for 50 minutes in the dark at 4°C. The 
gel was washed three times for 30 minutes each time with 0.5% (w/v) potassium 
metabisulphite solution, using fresh solution for each wash. Excess stain was removed 
by washing with dH2O. Glycoproteins were evident as dark pink bands against a pale 
pink background. Non-glycoprotein bands remained blue. 
 
2.21 Preparation of polyclonal antibody against P. luminescens whole 
cells 
 
P. luminescens whole cell antigen was prepared by growing a 500 ml culture of 
wildtype P. luminescens in LB broth as described in section 2.5.1. This culture was 
grown at 30°C overnight. The following day the culture was separated into two sterile 
250 ml centrifuge tubes and the cells were pelleted in a Beckman JA-21 centrifuge at 
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6,500 rpm for 10 minutes. The cells in each tube were resuspended in 25 ml of PBS and 
then mixed together in a 50 ml centrifuge tube and pelleted using the Hettich Rotanta 
460R centrifuge fitted with a swing-out rotor (model number 5624). The cell pellet was 
washed 3 more times using 25 ml of PBS to remove any traces of broth remaining. The 
final cell pellet was resuspended in 10 ml of PBS. The cells were heat killed by heating 
them in an autoclave to 70°C and holding at this temperature for 20 minutes. The 
antigen sample was sent to GenScript Corporation (New Jersey) where a polyclonal 
antibody was raised to it. The antibody was produced in a rabbit and was purified using 
Protein A affinity chromatography. The antibody was shipped in lyophilised form and 
resuspended to a final concentration of 5.5 mg/ml in PBS with 0.02% sodium azide and 
stored in 20 µl aliquots at -20°C. 
 
2.22 Western blotting 
 
A 1-D or 2-D gel was run as outlined in sections 2.18 and 2.19. Four pieces of blotting 
paper and a piece of nitrocellulose with a pore size of 0.45 µm were cut to exactly the 
same dimensions as the gel. The gel, blotting paper and nitrocellulose were soaked in 
western blot transfer buffer (section 2.3) for 15 minutes and assembled on a semi-dry 
electroblotter. Two pieces of blotting paper were placed first, overlaid by the 
nitrocellulose membrane, then the gel and finally the last two sheets of blotting paper. 
Any air bubbles were removed. Transfer occurred at 10 V for 30 minutes. 
 
To detect glycoproteins the membrane was blocked with Carbo-Free blocking solution 
(Vector Laboratories), diluted to the correct concentration in PBS (section 2.3). The 
membrane was washed four times for 5 minutes in TBST then incubated for 1 hour with 
a 1 µg/ml solution of a biotin labelled lectin of choice in TBST. The membrane was 
washed again then incubated with 1:10,000 horseradish peroxidase (HRP) labelled 
murine anti-biotin antibody in TBS. After a final washing the membrane was developed 
using 15 ml of dH2O containing a SIGMAFAST 3,3′-diaminobenzidine 
tetrahydrochloride tablet. The developed blot was washed with dH2O. 
 
To detect P. luminescens proteins, the membrane was blocked and washed as above and 
then incubated with rabbit anti-P.l. antibody (section 2.21), diluted 1:5000 in TBS. The 
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membrane was washed again and then incubated with a secondary antibody, HRP 
labelled goat anti-rabbit IgG, diluted 1:10000 in TBS. After a final washing, the blot 
was developed as outlined above. 
 
2.23 Enzyme linked lectin assay (ELLA) 
 
Solutions containing 10 µg/ml of glycoproteins were prepared in PBS (section 2.3). A 
50 µl aliquot of each glycoprotein was added in triplicate to a 96 well Nunc MaxiSorp 
ELISA plate. The plate was incubated overnight at 4°C to immobilise the glycoproteins. 
Any unbound glycoprotein was removed by inverting the plate. The wells were blocked 
with 150 µl of 2.5% BSA in TBS for one hour. Excess blocking solution was removed 
and the wells were washed three times with TBST. A 50 µl aliquot of 5 µg/ml biotin 
labelled lectin in TBST was added to each well and left to incubate at room temperature 
for one hour. Unbound lectin was removed by inversion and the plate washed as before. 
50 µl of 1:10,000 HRP labelled murine anti-biotin antibody diluted in 1% BSA-TBS 
was added to each well and incubated for one hour at room temperature. Unbound 
antibody was removed by inversion and washed as before.  
 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate was prepared by dissolving 2 mg of 
TMB in 200 µl of dimethyl sulphoxide (DMSO). This was added to 9.8 ml of citrate 
buffer, pH 5.5 which had been prepared by mixing 5 ml of dH2O with 1.37 ml of 0.1 M 
citric acid and 3.63 ml of 0.1 M sodium citrate. Directly before use 3 µl of 30% (v/v) 
H2O2 was added to the TMB solution. A 100 µl aliquot of TMB substrate was added to 
each well. After 5-10 minutes the reaction was stopped by the addition of 50 µl of dilute 
H2SO4. The absorbance was read at 450 nm. 
 
2.24 Lectin affinity chromatography (LAC) 
 
A 0.5 ml aliquot of agarose bound lectin resin (Vector Laboratories) was poured into a 
column and washed with 10 ml of LAC equilibration buffer (section 2.3).  Proteins 
prepared by the water lysis method (section 2.15) or a solution of a commercial 
glycoprotein was added to the column and allowed to bind to the resin. Unbound 
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material was collected as flow though followed by a 20 ml wash using equilibration 
buffer collected in 1 ml fractions. Glycoprotein elution was facilitated by the addition of 
10 x 1 ml of LAC elution buffer (section 2.3) specific for the lectin being used. All flow 
through, wash and elution fractions were analysed for the presence of protein by reading 
their absorbance at 280 nm in a quartz cuvette and comparing the values to a blank run. 
 
2.25 Enzymatic reactions 
 
2.25.1 Enzymes and buffers 
 
All enzymes and their relevant buffers were obtained from Promega Corporation, 
Invitrogen Life Technologies, New England BioLabs or Sigma-Aldrich Corporation 
and were used according to the manufacturer’s instructions. 
 
2.25.2 Standard Phusion PCR reaction mixture 
 
 Sterile dH2O     32 µl 
5X Buffer     10 µl 
dNTPs (10 mM each)    3 µl 
Template DNA    2 µl 
 Primers (10 mM each)   1 µl of each 
 Phusion DNA polymerase (1:3 dilution) 1 µl 
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2.25.3 Standard PCR program cycle 
 
 Stage 1 Step 1: 98°C for 5 minutes 
 
 Stage 2 Step 1: 98°C for 30 seconds 
   Step 2: Annealing temperature for 30 seconds 
   Step 3: 72°C for 30 seconds for every kb to be 
synthesised 
 
 Stage 3 Step 1: 72°C for 10 minutes 
 
2.25.4 T4 DNA ligase reaction 
 
 PCR product  5 µl 
 Plasmid DNA  3 µl 
 10X ligase buffer 1 µl 
 T4 DNA ligase 1 µl 
 
2.25.5 In-gel trypsin digestion of proteins 
 
The in-gel trypsin digestion of proteins was performed as described by (Shevchenko et 
al. 2007). All reagents used in this procedure were of mass spectrometry (MS) grade 
and supplied by Sigma-Aldrich Chemical Co. A protein from a band from an SDS-
PAGE gel was digested using trypsin and the tryptic peptides analysed by MS in order 
to identify the protein in a technique known as peptide mass fingerprinting. 
 
An SDS-PAGE gel was run as described in section 2.18.2 and stained using silver 
staining (section 2.20). The entire gel was rinsed with dH2O for at least two hours. 
Using a clean scalpel the protein band of interest was excised, cut into 1 x 1 mm cubes 
and placed in a microfuge tube. A 500 µl aliquot of acetonitrile was added to the tube 
and the gel pieces were incubated for 10 minutes until they shrank, became opaque and 
30 cycles 
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stuck together. The gel pieces were spun down and all liquid was removed. A 50 µl 
aliquot of 10 mM DTT/100 mM ammonium bicarbonate was added to completely cover 
the gel pieces. The gel pieces were incubated for 30 minutes at 56°C in an air 
circulation incubator. The gel pieces were cooled to room temperature, 500 µl of 
acetonitrile was added and the gel pieces shrunk as before. All liquid was removed. A 
50 µl aliquot of 55 mM iodoacetamide/100 mM ammonium bicarbonate was added to 
cover the gel pieces and they were incubated at room temperature in the dark for 20 
minutes. The gel pieces were shrunk as before and all liquid was removed. 
 
A 50 µl aliquot of trypsin buffer (section 2.3) was added to cover the gel pieces and the 
tube was placed on ice. If after 30 minutes the buffer had been completely absorbed 
more trypsin buffer was added and the tube was left on ice for a further 90 minutes. A 
10 µl aliquot of 100 mM ammonium bicarbonate was added to the tube and the 
digestion reaction was left to proceed overnight at 37°C in an air circulation incubator. 
Extraction buffer was prepared by mixing one part 5% (v/v) formic acid with two parts 
acetonitrile. Extraction buffer was added to the digest such that the approximate digest 
to extraction buffer ratio was 1:2. The tube was incubated in a shaker at 37°C for 15 
minutes. The mixture was briefly spun down in a centrifuge and the supernatant was 
withdrawn into a new microfuge tube. The liquid was dried down completely in a 
vacuum dryer and then reconstituted in 10 µl of 0.1% trifluoroacetic acid (TFA). 
 
The sample was desalted using Supel-Tips C18 Micropipette Tips (Sigma-Aldrich). The 
tip was first prepared by attaching it to a 10 µl pipette. Trapped air was displaced and 
the sorbent bed was conditioned by aspirating and dispensing 10 µl of methanol, 
followed by 10 µl of 50% methanol and finally 2 x 10 µl of dH2O. The sample was 
allowed to bind to the medium by aspirating and dispensing it 10-20 times. Salts and 
detergents were removed by washing twice with 10 µl dH2O. Finally the bound peptides 
were eluted in 3 x 5 µl aliquots of 70% methanol containing 0.1% TFA. The three 
aliquots were combined and the peptides were then ready for analysis using the mass 
spectrometer (section 2.27). 
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2.25.6 Glycosidase treatment of glycoproteins 
 
• Endo Hf /PNGaseF 
 
Denaturation reaction 
 
Glycoprotein     20-100 µg 
10X glycoprotein denaturing buffer  1 µl 
dH2O      to 10 µl 
Glycoproteins were denatured by heating the reaction mixture at 100°C for 10 minutes 
followed by cooling to room temperature. 
 
Glycosidase reaction 
 
Denaturation reaction mixture  10 µl 
10X reaction buffer    2 µl 
(10% NP40 (PNGaseF only)   2 µl 
Enzyme     2 µl 
dH2O      to 20 µl 
Reaction was incubated in a 37°C water bath overnight. 
 
 
• Neuraminidase/β-N-Acetyl-Hexosaminidasef 
 
Glycoprotein     20-100 µg 
10X reaction buffer    1 µl 
Enzyme     2 µl 
dH2O      to 10 µl 
Reaction was incubated in a 37°C water bath overnight. 
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• α1-3, 6 Galactosidase/α-N-Acetyl-Galactosaminidase 
 
Glycoprotein     20-100 µg 
10X reaction buffer    1 µl 
10X BSA     1 µl 
Enzyme     2 µl 
dH2O      to 10 µl 
Reaction was incubated in a 37°C water bath overnight. 
 
2.26 β-Elimination reaction to remove O-linked glycans from 
glycoproteins 
 
The β-elimination reaction was performed using the GlycoprofileTM β-Elimination Kit 
from Sigma-Aldrich. The glycoprotein was dissolved in dH2O to a concentration of 1-
10 µg/µl. The glycoprotein solution was heated at 100°C for 30 minutes to completely 
denature the protein and then allowed to cool to room temperature. β-elimination 
reagent mixture was prepared just before use by mixing β-elimination reagent with 5 M 
NaOH in the ratio 94:6. To the denatured protein sample, β-elimination reagent mixture 
was added equal to 20% of the protein sample volume i.e. to 100 µl of protein sample, 
20 µl of β-elimination reagent mixture was added. The mixture was incubated at 4°C 
overnight and was then neutralised by adjusting the pH to 6-8 with 1 M HCl. 
 
A centrifugal filter unit was assembled and the filter was washed using 500 µl of dH2O 
by centrifugation at 14,000 g for 30 minutes. The water wash was discarded and the 
wash step was repeated. The neutralised protein sample was transferred to the sample 
reservoir and centrifuged as before until most of the protein sample had passed through 
(about 30 minutes per 500 µl), being careful not to let the filter dry out. The protein 
solution was washed 2-3 times with 200 µl of dH2O by centrifugation for 10 minutes. 
The protein sample was recovered by inverting the filter unit in a new collection tube 
and centrifuging for 3 minutes at 1,000 g. The sample reservoir was washed twice with 
200 µl of dH2O by pipetting up and down and the washes were combined with the rest 
of the deglycosylated protein sample. 
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2.27 Matrix assisted laser desorption ionization mass spectrometry 
(MALDI-MS) 
 
The matrix used for MALDI analysis was a 1:1 (w/w) mixture of α-cyano-4-
hydroxycinnamic acid and 2,5-dihydroxy benzoic acid (CHCA:DHB). The matrix was 
prepared by dissolving it in 70% acetonitrile (mass spec grade) to a concentration of 20 
mg/ml. TFA was then added to a final concentration of 0.1%. Samples prepared as 
described in section 2.25.5 were mixed 1:1 with the prepared matrix and spotted on a 
stainless steel MALDI target plate and air dried. 
 
MALDI analysis was carried out using a quadrupole orthogonal acceleration time of 
flight (Q-TOF) mass spectrometer. Two models were available for use, the Q-TOF 
Ultima Global and the Q-TOF Premier (Micromass MS Techologies, Manchester, 
UK). The Q-TOF Premier is an upgraded version of the Q-TOF Ultima Global. Both 
instruments used a nitrogen laser, operating at 337 nm but the laser had a hit frequency 
of 10 Hz for the Q-TOF Ultima Global and 200 Hz for the Q-TOF Premier. All other 
parameters used were identical. The laser was fired at the dried matrix/analyte mixture 
on the MALDI target plate. Ions were generated and focused into a beam by a radio 
frequency (RF) lens. The ions were transmitted through a hexapole collision cell, with a 
collision energy of 10 V then pulsed into the TOF analyser. Samples were analysed in 
positive ion mode with the TOF analyser set at 9.10 kV. The instrument was operated in 
V reflectron mode and the reflectron was set to 35.6 V. The pusher was set to 974 µs. 
Data was acquired using a time-to-digital converter (TDC) operating at 4 GHz. Mass 
spectra were recorded using a microchannel plate (MCP) detector. A mass range (m/z) 
of 500 – 5000 was scanned over 2.4 seconds with an inter scan delay time of 0.1 
second.  
 
The instrument was calibrated using a range of standard peptides with molecular 
weights ranging from 756.4 Da to 3493.7 Da, the range that most tryptic digestion 
fragments will lie between. Data was analysed using the software MassLynx version 4.1 
(Waters, Manchester, UK). 
Chapter 3 
Detection & isolation of glycoproteins from P. 
luminescens
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3.1 Introduction 
 
As previously stated, the primary objective of this research is to investigate the 
possibility that P. luminescens produces glycoproteins and thus contains a protein 
glycosylation system. In order to do this, glycoproteins have to be isolated from the 
large mix of proteins normally found in the cell and characterised. The use of lectins is 
one of the most effective means of detecting, purifying and isolating glycoproteins. 
Lectins are carbohydrate binding proteins that bind to mono or oligosaccharides. The 
affinity of lectins is relatively weak but the specificity of the binding is very high. 
Lectins can be used in enzyme linked lectin assays (ELLAs), in western blots and bound 
to affinity matrices to detect, characterise and isolate glycoproteins. 
 
In order to further characterise the isolated glycoproteins, glycosidase enzymes can be 
used to cleave sugar units from the linked glycan of a glycoprotein. The resulting 
glycoprotein may be retested with the same lectin in order to investigate how the 
interactions between the carbohydrate and the lectin have changed. In this way more 
knowledge can be gained about the types of sugar moieties that are present on a 
glycoprotein and the way that they are linked together. 
 
Lectins and glycosidases have been utilised previously to successfully detect 
glycoproteins in C. jejuni (Linton et al. 2002), which has an N-linked protein 
glycosylation system that is already well characterised. In this chapter certain lectins 
and glycosidases were employed to detect, isolate and characterise glycoproteins from 
the various cell fractions of P. luminescens. Comparable experiments were carried out 
using C. jejuni proteins to act as a control for the P. luminescens study. 
 
3.2 P. luminescens growth curve 
 
In order to examine the growth pattern of P. luminescens, a growth curve was 
constructed. A 500 ml culture of P. luminescens was grown at 30°C (section 2.5.1) for 
30 hours and samples were taken at regular time intervals. The absorbance readings of 
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the samples were read at 600 nm and a growth curve was constructed as shown in figure 
3.1. 
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Figure 3.1 P. luminescens growth curve 
A 500 ml culture P. luminescens culture was grown at 30°C over 30 hours. Samples were taken 
approximately every two hours and their absorbance readings at 600 nm were plotted against time. 
 
The result is the characteristic S-shape growth curve. The lag phase lasts ~4 hours, 
followed by the exponential phase for ~8 hours after which the growth of the culture 
enters the stationary phase. 
 
3.3 Extracellular, periplasmic, cytoplasmic and membrane protein 
isolation from P. luminescens using the water lysis method 
 
In order to get maximum protein yield two 100 ml cultures of P. luminescens were 
grown for 24 and 48 hours as described in section 2.5.1. Using the water lysis method 
described in section 2.15, extracellular proteins and proteins from the periplasm, 
cytoplasm and membrane were isolated. The protein concentration in each fraction was 
determined using a BCA assay (section 2.17). The results are shown in figure 3.2 and 
table 3.1. 
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Figure 3.2 BCA assay standard curve used to quantify protein concentration in P. luminescens 
water lysis samples 
The equation of the standard curve y = 0.0159 x – 0.0113 was used to calculate x, the concentration of the 
unknown samples. The calculated concentration values are shown in table 3.1. 
 
Table 3.1 Concentrations of water lysis samples from P. luminescens 
Sample Concentration Total protein 
Extracellular (24 h) 1.62 mg/ml 81 mg 
Extracellular (48 h) 1.56 mg/ml 78 mg 
Periplasmic (24 h) 236 µg/ml 6.1 mg 
Periplasmic (48 h) 173 µg/ml 4.5 mg 
Cytoplasmic (24 h) 1.11 mg/ml 17.8 mg 
Cytoplasmic (48 h) 1.54 mg/ml 24.6 mg 
Membrane (24 h) 9.68 mg/ml 14.5 mg 
Membrane (48 h) 6.34 mg/ml 9.5 mg 
 
Using the calculated concentration values, 30 µg of each sample was loaded on a 15% 
SDS-PAGE gel and proteins were separated (section 2.18) followed by staining with 
coomassie blue (section 2.20). Figure 3.3 shows a scanned image of this gel. 
 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Isolated protein samples from P. luminescens released by the water lysis method  
30 µl of each protein sample was separated on a 15% SDS-PAGE gel which was then stained with 
coomassie blue. Lane 1 = NEB broad range protein marker, lane 2 = extracellular (24 h), lane 3 = 
extracellular (48 h), lane 4 = periplasmic (24 h), lane 5 = periplasmic (48 h), lane 6 = cytoplasmic (24 h), 
lane 7 = cytoplasmic (48 h), lane 8 = membrane (24 h), lane 9 = membrane (48 h) and lane 10 = NEB 
broad range protein marker.  
 
A distinct protein pattern is visible in each fraction suggesting that the protein fractions 
have been well separated. There appears to be very little difference in protein expression 
between the two samples. Both cultures would have been in stationary phase of the 
growth cycle (figure 3.1). 
 
Figure 3.4 shows the same SDS-PAGE gel which has been stained using the periodic 
acid-Schiff stain for carbohydrate (section 2.20) following the coomassie blue staining. 
Coomassie blue stains all proteins a blue colour while the Schiff stain can distinguish 
between glycosylated and non-glycosylated proteins. The carbohydrate part of the 
glycoprotein is stained pink with the Schiff stain while non-glycosylated proteins 
remain blue from the coomassie blue stain. 
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Figure 3.4 Isolated protein samples from P. luminescens released by the water lysis method  
Following coomassie staining of the water lysis protein samples shown in figure 3.3, the gel was 
subsequently stained with periodic acid-Schiff stain for the presence of carbohydrate. Lane 1 = NEB 
broad range protein marker, lane 2 = extracellular (24 h), lane 3 = extracellular (48 h), lane 4 = 
periplasmic (24 h), lane 5 = periplasmic (48 h), lane 6 = cytoplasmic (24 h), lane 7 = cytoplasmic (48 h), 
lane 8 = membrane (24 h), lane 9 = membrane (48 h) and lane 10 = NEB broad range protein marker.  
 
Figure 3.4 demonstrates that glycoproteins could possibly be present in each fraction. 
There is some very high molecular weight carbohydrate present in the extracellular 
fraction, however, it is difficult to see distinct bands. This was not seen with the 
coomassie stain (figure 3.3) so this suggests that it is not glycoproteins but is probably 
some very high molecular weight carbohydrates that were present in the media. Some 
bands are present in the periplasmic fractions at ~200 kDa and ~10 kDa, in the 
cytoplasmic fraction at ~200 kDa and membrane proteins at ~100 kDa. There is also 
distinct pink area visible in the low molecular weight region of the extracellular 
fractions which could be low molecular weight sugars that were present in the media. 
There is also a pink area in the low molecular weight region of the membrane proteins 
between about 5 and 15 kDa which could be lipopolysaccharide. Figure 3.4 shows that 
it is probable that the glycoproteins are present in the periplasmic, cytoplasmic and 
membrane protein fractions. 
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3.4 Analysis of isolated protein fractions using ELLAs and western 
blots 
 
A number of ELLAs were carried out on the four different protein fractions using a 
variety of commercially available plant lectins. Table 3.2 outlines the lectins used in this 
analysis, the concentration used in the assays and the glycans they have affinity for. 
 
Table 3.2 Commercial plant lectins used in this study and their corresponding 
affinities 
Lectin Working Conc. Affinity 
AAL 1 µg/ml α-1,6-Fucose 
UEA I 5 µg/ml α-1,2-Fucose 
Con A 1 µg/ml core mannose of biantennary complex glycan 
LCA 5 µg/ml fucosylated core mannose of complex glycan 
NPL 5 µg/ml terminal mannose / high mannose 
GNL 5 µg/ml terminal mannose / high mannose 
RCA 5 µg/ml terminal β-gal / lactosamine 
ECL 5 µg/ml terminal β-gal / lactosamine 
PNA 5 µg/ml terminal β-gal / T-antigen 
GSL I 5 µg/ml terminal α-gal 
Jacalin 5 µg/ml β-gal / T-antigen 
SBA 5 µg/ml terminal GalNAc 
DBA 5 µg/ml terminal GalNAc 
DSL 5 µg/ml GlcNAc / lactosamine 
GSL II 5 µg/ml terminal GlcNAc 
WGA 5 µg/ml GlcNAc, NeuNAc 
MAL I 5 µg/ml Lactosamine / tolerates α-2,3 NeuNAc 
MAL II 10 µg/ml α-2,3 NeuNAc 
SNA 10 µg/ml α-2,6 NeuNAc 
 
ELLAs were performed as per the procedure in section 2.23. The protein samples were 
cleaned up using vivaspin 500 µl centrifugal ultrafiltration devices (Sartorius Stedim 
Biotech) to remove any interfering sugars. Vivaspin columns with a molecular weight 
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cut off of 10,000 Da were used. The protein samples were added to the columns which 
were then centrifuged at 13,000 rpm for 10 minutes. The flow through was removed and 
PBS was added to the concentrated sample and the centrifugation step was repeated. 
The protein concentration of each sample was found using a BCA assay and the 
samples were diluted down to 10 µg/ml for the ELLA analysis. Figure 3.5 shows the 
results of the ELLA analysis. 
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Figure 3.5 ELLAs profiling the interactions between P. luminescens extracellular, periplasmic, cytoplasmic and membrane proteins with various commercial lectins 
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Figure 3.5 continued... ELLAs profiling the interactions between P. luminescens extracellular, periplasmic, cytoplasmic and membrane proteins with various 
commercial lectins 
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Because of the specificity of the linkage between a glycan and lectin, as outlined in 
section 1.4.2, ELLAs enable us to get some insight into the nature of the carbohydrate 
moieties of glycoproteins that might be present. The results in figure 3.5 show that there 
is a huge diversity between the four fractions in terms of the glycoproteins that are 
possibly present. More than one lectin reacted quite strongly with each fraction. The 
extracellular proteins are binding quite strongly to the mannose binding lectins and 
WGA and so the results indicate that they may contain high mannose and GlcNAc. The 
cytoplasmic proteins are binding strongly to galactose, GalNAc and GlcNAc binding. 
Finally the periplasmic and membrane proteins are both binding GSL I, SBA, DBA and 
WGA most strongly and so they may also contain terminal galactose, GalNAc or 
GlcNAc in their glycan moieties. 
 
It is probable that the interactions shown in figure 3.5 are not all due to lectin / 
glycoprotein binding. The lectins may also be binding to proteins that are not 
glycosylated but are involved in the transport or biosynthesis of glycans. Whether any 
of the proteins that are binding to the lectins in the ELLAs are definitely glycosylated 
needs to be further investigated. 
 
Some of the lectins that produced very strong ELLA responses with the different 
fractions were chosen for western blot analysis. Western blots were performed using the 
periplasmic, cytoplasmic and membrane proteins and probing them with various lectins. 
Western blot analysis was carried out according to section 2.22 and the results are 
shown in figure 3.6 
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Figure 3.6 Western blot analysis showing interactions between P. luminescens periplasmic, 
cytoplasmic and membrane proteins with the lectins Con A (a), DBA (b) and GSL I (c) 
Lane 1 = NEB ColorPlus prestained protein marker (7-175 kDa), lane 2 = periplasmic proteins, lane 3 = 
cytoplasmic proteins and lane 4 = membrane proteins. 
 
The protein pattern visible in the Con A, DBA and GSL I blots for each of the three 
fractions are very similar. Strong bands are showing up at ~55, 50, 46, 34, 29 and 13 
kDa for the periplasmic proteins. Bands are visible at ~55, 38, 34 29, 25, 23 and 15 kDa 
for the cytoplasmic proteins. For the membrane proteins bands can be seen at ~55, 36, 
29 and 26 kDa in the blots. 
 
From the result in figure 3.6 it can be deduced that the putative glycoproteins from the 
three fractions contain mannose, terminal galactose and terminal GalNAc. As discussed 
in chapter 1, N-linked glycans from C. jejuni contain terminal GalNAc. Typical O-
linked glycans found in Neisseria spp. contain terminal galactose. Proteins from Gram-
positive Actinomycetes have been shown to be O-mannosylated. Therefore, the types of 
glycans being recognised in figure 3.6 are consistent with glycans that have already 
been discovered in other bacteria. 
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3.5 Isolation/purification of glycoproteins from P. luminescens protein 
fractions using lectin affinity chromatography (LAC) 
 
The next step in the analysis of glycoproteins from P. luminescens was to isolate them 
from the large mix of other proteins in the cell using LAC. If glycoproteins are present 
they were likely to be in very low concentrations. LAC was used to concentrate any 
glycoproteins present to make further analysis of them easier. Agarose bound lectin 
resins are commercially available for this purpose. In this study agarose bound WGA, 
Con A and GSL I were the resins used. They were chosen because they produced a 
strong signal in the ELLAs and/or western blots with all four protein fractions (figure 
3.5 and figure 3.6). 
 
LAC was carried out according to the procedure described in section 2.24. LAC was 
preformed with either the periplasmic fractions or the cytoplasmic fractions. A column 
containing 500 µl of resin was used and 2-5 ml of protein sample prepared using the 
water lysis method was passed over the resin. The absorbance readings (at 280 nm) of 
the various protein fractions were plotted. Readings were compared to a blank run 
containing no protein. A positive control was also used where a commercial 
glycoprotein that is known to bind the lectin in question was passed over the resin.  
 
3.5.1 LAC using Wheat Germ Agglutinin (WGA) agarose 
 
Figures 3.7 and 3.8 show the results of the LAC using WGA resin and periplasmic and 
cytoplasmic proteins. 
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Figure 3.7 Periplasmic proteins from P. luminescens fractionated using LAC with WGA bound 
agarose 
A 3 ml sample of periplasmic proteins prepared using the water lysis method was passed over the column 
and any unbound proteins were washed from the column (fractions 1-8). Any proteins that bound to the 
resin were eluted with 500 mM GlcNAc (fractions 9-16). Fetuin was used as a positive control. (b) 
Enlarged area of the graph where the proteins were eluted. 
 
It can be seen that a big majority of protein from the periplasmic extract did not bind to 
the column and was washed off in the unbound fractions. The column was washed with 
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buffer until the absorbance readings reached baseline levels to completely remove any 
unbound proteins prior to elution of bound protein. A small amount of protein from the 
periplasmic extract did bind and was eluted in fractions 9 to 10. 
 
Figure 3.8 Cytoplasmic proteins from P. luminescens fractionated using LAC with WGA bound 
agarose 
(a) A 2 ml sample of cytoplasmic proteins prepared using the water lysis method was passed over the 
column. Unbound proteins were washed from the column in fractions 1-12. Any proteins that bound to 
the resin were eluted and collected in fractions 13-20. Fetuin was again used as a positive control. (b) 
Enlarged area of the graph where the proteins were eluted. 
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The cytoplasmic protein extract contained a majority of protein that did not bind to the 
WGA resin and was washed off in the unbound fractions. A bigger percentage of 
protein bound to the column for the cytoplasmic protein run compared to the 
periplasmic protein run in figure 3.7. Fractions 13 to 18 contained eluted proteins. The 
absorbance readings for the eluted cytoplasmic proteins were even higher than those 
seen for the fetuin control which contained 300 µg of fetuin. This indicates that the 
cytoplasmic fraction could contain a significant quantity of glycoprotein. Fractions from 
the LAC of the periplasmic and cytoplasmic proteins were run on a 15% SDS-PAGE 
gel and stained with silver stain (section 2.20) as shown in figure 3.9. 
 
Figure 3.9 WGA LAC periplasmic protein fractions (a) and cytoplasmic protein fractions (b) 
Proteins were separated on a 15% SDS-PAGE gel and stained with silver stain. (a) Lane 1 = NEB broad 
range protein marker, lane 2 = crude periplasmic fraction from water lysis method, lanes 3, 4 = unbound 
periplasmic proteins from LAC, lanes 5, 6 = eluted periplasmic proteins from LAC. (b) Lane 1 = NEB 
broad range protein marker, lane 2 = crude cytoplasmic fraction from water lysis method, lane 3 = 
unbound cytoplasmic proteins from LAC, lanes 4, 5 = eluted cytoplasmic proteins from LAC. Red ovals 
indicate some proteins that have been enriched. 
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Lanes 3 and 4 in figure 3.9 (a) contain many proteins that did not bind to the resin. 
Lanes 5 and 6 contain the proteins that were eluted from the resin of which the three at 
~40 kDa, ~27 kDa and ~17kDa are the most abundant (circled in red). The eluted 
periplasmic proteins visible in lanes 5 and 6 of figure 3.9 (a) are also visible in the crude 
sample (lane 2) but they have been concentrated. This is especially evident with the 27 
kDa protein. 
 
For the cytoplasmic proteins (figure 3.9 (b)) again many proteins did not bind to the 
resin and these are visible in lane 3. Some of the eluted cytoplasmic proteins visible in 
lanes 4 and 5 in figure 3.9 (b) have also been substantially enriched (circled in red) 
compared to the crude sample in lane 2. Lanes 4 and 5 contain the eluted proteins. Many 
more cytoplasmic proteins bound to the resin compared to the periplasmic proteins. 
 
Some of the eluted periplasmic and cytoplasmic proteins are also visible in the unbound 
protein fraction. This could be explained by the fact that lectins, although they have a 
very high specificity, have a low affinity for glycoproteins. Therefore the lectin may not 
bind all of the available glycoprotein and even some that it does bind may dissociate 
from the lectin again during washing.  
 
It is very likely that the proteins that have bound to the lectin are binding through 
glycan-protein interactions and not through protein-protein interactions because binding 
was inhibited with the addition of GlcNAc in the elution buffer which is the inhibiting 
sugar for WGA. The results shown in figure 3.9 were reproducible over several runs. 
 
In order to confirm that the proteins that were eluted from the LAC column (figure 3.9) 
were actually binding to WGA and not just binding non-specifically to the column a 
western blot was carried out using the samples from figure 3.9. The samples on the blot 
were probed with biotinylated WGA lectin, followed by an anti-biotin lectin and were 
then developed. The results of this western blot are shown in figure 3.10. 
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Figure 3.10 Western blot showing WGA LAC periplasmic protein fractions and cytoplasmic 
protein fractions 
The western blot was probed with 1 µg/ml WGA. Lane 1 = crude periplasmic fraction from water lysis 
method, lane 2 = unbound periplasmic proteins from LAC, lane 3 = eluted periplasmic proteins from 
LAC, lane 4 = NEB prestained protein marker, lane 5 = ovalbumin, lane 6 = crude cytoplasmic fraction 
from water lysis method, lane 7 = unbound cytoplasmic proteins from LAC, lanes 8, 9 = eluted 
cytoplasmic proteins from LAC. 
 
Ovalbumin, a protein known to bind to the lectin WGA was used as a control in this 
blot. In lane 3, which contains the periplasmic proteins that were eluted from the WGA 
column, there are some distinct bands showing up at approximately 50, 40, 25 and 17 
kDa. The prestained protein marker is not as accurate as the broad range protein marker 
and so taking this into account these sizes correspond quite well to the strong bands that 
showed up in the eluted protein sample in figure 3.9 (a). There is a strong band showing 
up in the crude and unbound periplasmic protein samples (lanes 1 and 2) at ~55 kDa 
that does not appear to be present in the eluted sample. This may be because this protein 
bound very weakly to WGA in the column and dissociated from the column in the 
washing step. For the eluted cytoplasmic proteins (lanes 8 and 9) there are quite a few 
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bands showing up and again the pattern of bands corresponds quite well with what was 
seen in figure 3.9 (b). Strong bands are showing up at approximately 55, 35, 29, 25, 15 
and 12 kDa. Again, the slight variation in sizes can be accounted for by the fact that the 
prestained protein marker is not extremely accurate. The fact that many of the same 
bands that showed up on the protein gels in figure 3.9 are showing up on the western 
blot provides strong evidence that these proteins are in fact binding to WGA through 
protein-sugar interactions. 
 
ELLAs were also carried out to show the interactions between these glycoproteins and 
the lectin WGA as well as Con A and GNL (mannose binding lectins) and DSL (another 
GlcNAc binding lectin). A BCA assay was first performed using the crude periplasmic 
and cytoplasmic proteins and unbound and eluted LAC proteins. The concentration of 
each sample was adjusted to 10 µg/ml for the ELLAs so that results could be easily 
compared. The results of the ELLA analysis are shown in figures 3.11 and 3.12. 
 
Figure 3.11 ELLA profiling the interactions of mannose and GlcNAc binding lectins with 
periplasmic protein samples fractionated using WGA LAC 
Crude periplasmic proteins and unbound and eluted proteins from WGA LAC were analysed. 
 
The results of this experiment indicate that the glycoproteins that are eluted from the 
WGA resin contain more GlcNAc than those in the unbound fraction. This result was 
expected as this resin should have bound glycoproteins containing GlcNAc. The 
unbound proteins do still contain some GlcNAc however because of the low affinity of 
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the lectin carbohydrate binding. The periplasmic proteins that bound to WGA contain 
less mannose than those that did not bind but the eluted proteins are still producing a 
significant signal with the mannose binding lectins. It is possible that those proteins that 
did not bind to WGA contain terminal mannose and those that did contain some core 
mannose.  
 
Figure 3.12 ELLA profiling the interactions of mannose and GlcNAc binding lectins with 
cytoplasmic protein samples fractionated using WGA LAC 
Crude cytoplasmic proteins and unbound and eluted proteins from WGA LAC were analysed. 
 
The results in figure 3.12 show that the signals for the GlcNAc binding lectins, WGA 
and DSL have gone up for the eluted proteins compared to the unbound proteins and the 
signals for the mannose binding lectins have also increased. This suggests that the 
glycoproteins that were isolated from the cytoplasm using WGA contain mannose as 
well as GlcNAc. 
 
3.5.2 LAC using Concanavalin A (Con A) agarose 
 
LAC was also carried out with cytoplasmic proteins using Con A agarose. A 2 ml 
protein sample prepared using the water lysis method was passed over the column and 
collected, the column was washed and bound proteins were eluted using 200 mM α-
methyl mannoside and 200 mM α-methyl glucoside. As a control a run using 500 µg of 
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invertase (a high mannose glycoprotein) was also carried out. The O.D. 280 nm readings 
were plotted and the results are shown in figure 3.13. 
 
Figure 3.13 Cytoplasmic proteins from P. luminescens fractionated using LAC with Con A bound 
agarose 
(a) A 2 ml sample of cytoplasmic proteins prepared using the water lysis method was passed over the 
column. Unbound proteins were washed from the column in fractions 1-15. Any proteins that bound to 
the resin were eluted and collected in fractions 16-23. Invertase was used as a positive control. (b) 
Enlarged area of the graph where the proteins were eluted 
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For the Con A LAC a significant amount of protein bound to the resin and was eluted.  
The proteins were eluted in two peaks, one major peak from fractions 15 to 20 and 
another smaller peak from fractions 20 to 23 which likely contains glycoproteins that 
bound more tightly to the resin and so required a larger volume of inhibiting sugar to 
elute them. The peak containing the eluted invertase appears very insignificant next to 
the eluted cytoplasmic proteins. Some of the protein fractions were run on a 15% SDS-
PAGE gel and stained with silver stain as shown in figure 3.14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Con A LAC cytoplasmic protein fractions 
Proteins were separated on a 15% SDS-PAGE gel and stained with silver stain. Lane 1 = NEB broad 
range protein marker, lane 2 = crude cytoplasmic proteins, lane 3 = unbound cytoplasmic proteins, lanes 
4-8 eluted cytoplasmic proteins. The two most abundant proteins to be eluted from the column had 
molecular weights of ~60 kDa and ~17 kDa and these proteins are circled in red. 
 
The two proteins that are circled in red in figure 3.14 were relatively abundant and had 
molecular weights of approximately 60 and 17 kDa. For the LAC using WGA resin 
with cytoplasmic proteins (figure 3.9 (b)) there were also two very strong eluted bands 
at ~60 and 17 kDa. It is possible that these are the same proteins because from figure 
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3.12 it was seen that eluted proteins from the WGA LAC also gave a very strong 
response with Con A in an ELLA. 
 
3.5.3 LAC using Griffonia Simplicifolia Lectin I (GSL I) agarose 
 
The final lectin that was used in LAC was GSL I. This lectin was used to purify 
glycoproteins from P. luminescens periplasmic proteins. A 5 ml sample of protein 
prepared by the water lysis method was passed over the column and bound proteins 
were eluted with buffer containing 200 mM galactose and 200 mM N-
acetylgalactosamine. For this lectin 100 µg of the commercial glycoprotein asialofetuin 
(from foetal calf serum) was used as a control. Asialofetuin contains terminal β-
galactose. GSL I binds most strongly to α-galactose but will also tolerate some β-
galactose. Therefore it is not expected that a large amount of asialofetuin will bind to 
the GSL I resin however this was the best commercial glycoprotein that was available at 
the time to act as a control. 
 
Figure 3.15 shows a plot of the O.D. 280 nm readings. 
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Figure 3.15 Periplasmic proteins from P. luminescens fractionated using LAC with GSL I bound 
agarose 
(a) A 5 ml sample of periplasmic proteins prepared using the water lysis method was passed over the 
column. Unbound proteins were washed from the column in fractions 1-11. Any proteins that bound to 
the resin were eluted and collected in fractions 13-16. Asialofetuin was used as a positive control. (b) 
Enlarged area of the graph where the proteins were eluted. 
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It can be seen from this graph that the majority of the protein sample did not bind to the 
column and was washed away but a small amount of protein from the periplasm did 
bind to the column and was eluted in fractions 13-16. Again the fractions were run on a 
15% SDS-PAGE gel which was stained with silver stain and the results are shown in 
figure 3.16. 
 
Figure 3.16 GLS I LAC periplasmic protein fractions 
Proteins were separated on a 15% SDS-PAGE gel and stained with silver stain. Lane 1 = NEB broad 
range protein marker, lane 2 = crude asialofetuin, lane 3 = unbound asialofetuin, lanes 4-6 = eluted 
asialofetuin, lane 7 = crude periplasmic proteins, lane 8 = unbound periplasmic proteins, lanes 9-12 = 
eluted periplasmic proteins. The two most abundant proteins to be eluted from the column had molecular 
weights of ~60 kDa and ~17 kDa and these proteins are circled in red. 
 
For the control glycoprotein, as expected the majority of the asialofetuin did not bind to 
the resin, however, a proportion of it did and it was eluted (lanes 4 and 5). Some of the 
proteins that were eluted from the GSL I column are similar in molecular weight to the 
periplasmic proteins that were eluted from the WGA column and could possibly be the 
same glycoproteins that could contain both galactose and GlcNAc residues. An 
interesting observation can be made about the proteins eluted from this column. Lane 12 
contains proteins that were eluted last after the addition of 4 ml of elution buffer. The 
      1    2    3     4     5     6     7    8    9    10  11   12 
 
212 kDa 
 
97.2 kDa 
 
66.4 kDa 
55.6 kDa 
 
42.7 kDa 
 
34.6 kDa 
 
 
27.0 kDa 
 
 
 
 
20.0 kDa 
 
 
14.3 kDa 
 117 
two proteins highlighted by blue arrows are not visible in the other elution samples and 
must be glycoproteins that were very tightly bound to the resin and needed a large 
volume of elution buffer to inhibit their binding. This provides further evidence that the 
interaction between the lectin and the protein is carbohydrate based. 
 
3.6 Extracellular, periplasmic, cytoplasmic and membrane protein 
isolation from C. jejuni using the water lysis method 
 
In order to validate the study carried out using P. luminescens proteins, a control study 
was carried out using an organism that had previously been shown conclusively to 
contain a protein glycosylation system. The organism chosen was C. jejuni NCTC 
11168. Many glycoproteins have been discovered in this organism and their glycan 
structures have been determined. Research carried out by Linton et al. (2002) 
discovered two glycoproteins produced by C. jejuni NCTC 11168 by using the lectin 
soybean agglutinin (SBA) to isolate them. They found that the glycoproteins contained 
N-acetylgalactosamine residues on their glycans. 
 
In order to compare glycoproteins from the two organisms, proteins were prepared from 
C. jejuni cells in the same way as they were for P. luminescens i.e. using the water lysis 
method (section 2.15). The total concentration of protein in each fraction was 
determined using a BCA assay (section 2.17) and the results are shown in figure 3.17 
and table 3.3. 
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Figure 3.17 BCA assay standard curve to quantify protein concentration in C. jejuni water lysis 
samples 
The equation of the standard curve y = 0.0085 x + 0.0138 was used to calculate x, the concentration of the 
unknown samples. The calculated concentration values are shown in table 3.3. 
 
Table 3.3 Concentrations of C. jejuni water lysis samples 
Sample Concentration Total protein 
Extracellular 144 µg/ml 7.2 mg 
Periplasmic 77 µg/ml 2.0 mg 
Cytoplasmic 120 µg/ml 1.9 mg 
Membrane 340 µg/ml 0.5 mg 
 
It can be seen from table 3.3 that the protein concentrations were extremely low for each 
sample compared to those obtained for P. luminescens in table 3.1. This is because the 
cell density of C. jejuni in liquid cultures is very low, only reaching an O.D.600 nm of 
approximately 0.1 at most. In order to run these samples on an SDS-PAGE gel they 
were first concentrated in vivaspin 500 µl centrifugal ultrafiltration devices (Sartorius 
Stedim Biotech). Vivaspin columns with a molecular weight cut off of 10,000 Da were 
used. The protein samples were added to the columns which were then centrifuged at 
13,000 rpm for 10 minutes. The flow through was removed and PBS was added to the 
concentrated sample and the centrifugation step was repeated. Once concentrated to 
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~10% of their original volume the proteins were run on a 15% SDS-PAGE gel and 
stained with coomassie blue as shown in figure 3.18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Isolated protein samples from C. jejuni released by the water lysis method  
Protein samples were separated on a 15% SDS-PAGE gel which was then stained with coomassie blue. 
Lane 1 =  broad range protein marker, lane 2 = extracellular proteins, lane 3 = periplasmic proteins, lane 4 
= cytoplasmic proteins, lane 5 = membrane proteins. 
 
3.7 Analysis of isolated C. jejuni protein fractions using western blots 
and ELLAs 
 
According to the paper by Linton, et al. (2002), SBA gave the best response of all of the 
lectins that they tested against C. jejuni proteins and so a western blot that was probed 
with SBA using the same samples as in figure 3.18 was carried out and this is shown in 
figure 3.19. 
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Figure 3.19 Western blot analysis showing interactions between C. jejuni extracellular, periplasmic, 
cytoplasmic and membrane proteins with the lectin SBA 
Lane 1 = prestained protein marker, lane 2 = asialofetuin control, lane 3 = extracellular proteins, lane 4 = 
periplasmic proteins, lane 5 = cytoplasmic proteins, lane 6 = membrane proteins.  
 
As expected, strong binding was demonstrated by the SBA blot. In order to test other 
lectins for which C. jejuni glycoproteins had affinity for an ELLA was carried out. The 
concentration of each sample was adjusted to 10 µg/ml with PBS and ELLAs were 
carried out using a range of lectins with different binding specificities. The results are 
shown in figure 3.20. 
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Figure 3.20 ELLA profiling interactions between C. jejuni protein fractions and various 
commercial lectins 
 
The periplasmic and cytoplasmic proteins are producing strong signals with mannose 
binding lectins Con A and GNL. All proteins, especially the membrane proteins are 
binding strongly to GSL I, SBA and WGA. RCA, a lectin that binds β-linked galactose 
is not binding to the proteins in any fraction. These results correspond quite well to 
what was seen by Linton et al. (2002). In their analysis SBA and WGA gave the best 
response against whole-cell proteins and RCA gave very little response. They did not 
test the lectin GSL I in their analysis. 
 
It can be seen from the ELLA analysis that the periplasmic proteins are producing a 
greater response with the mannose binding lectins than with the membrane proteins. On 
the other hand the membrane proteins are producing a stronger signal with GalNAc and 
α-galactose binding lectins than the periplasmic proteins. Many of the proteins found in 
the periplasm of a bacterial cell will ultimately end up in the membrane of the cell. The 
ELLA results are providing some evidence that further processing of the glycans linked 
to some glycoproteins may be occurring in the periplasm before they are transported to 
the membrane. Perhaps some of the glycans that are found on glycoproteins in the 
periplasm contain mannose structures initially which are then cleaved off and replaced 
with GalNAc or galactose residues. 
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A western blot of a 2-D gel was also carried out to get better separation of the proteins 
and a better view of what proteins are actually binding to SBA. A western blot of 
periplasmic proteins on a 1-D gel was compared to proteins visualised on a 2-D gel. 
Periplasmic proteins were chosen because they produced a strong signal with SBA on 
the blot in figure 3.19. The results of the 1-D analysis versus the 2-D analysis are shown 
in figure 3.21. 
 
Figure 3.21 Comparison of 1-D vs. 2-D separation of C. jejuni periplasmic proteins 
a) C. jejuni periplasmic proteins separated on a 15% 1-D SDS-PAGE gel and stained with silver stain. 
Lane 1 = NEB broad range marker, lane 2 = C. jejuni periplasmic proteins. b) C. jejuni periplasmic 
proteins separated on a western blot and probed with SBA lectin. Lane 1 = NEB prestained protein 
marker, lane 2 = periplasmic proteins. c) 2-D gel containing C. jejuni periplasmic proteins stained with 
silver stain. d) 2-D western blot containing C. jejuni periplasmic proteins probed with SBA. 
 
From the 1-D analysis ((a) and (b)) it appears that almost all of the periplasmic proteins 
are reacting with SBA. This is because each band contains multiple proteins. However, 
it may be seen from (c) and (d) that in fact a lot of the periplasmic proteins are not 
interacting with SBA. It is mainly high molecular weight proteins with a broad range of 
c) 
d) 
a) b) 
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pI values and lower molecular weigh proteins with high pI values that are interacting 
with SBA. It appears that as the glycoproteins containing GalNAc decrease in molecular 
weight their pI increases. This can be explained by the fact that the smaller the protein, 
the more of an effect any modification will have on its pI. GalNAc is a negatively 
charged molecule and so this modification could be altering the properties of the low 
molecular weight glycoproteins and giving them higher pI values. It can be seen from 
figure 3.21 that 2-D gel electrophoresis is a much more powerful method for use in the 
analysis of protein glycosylation than 1-D electrophoresis. 
 
3.8 Susceptibility of P. luminescens and C. jejuni proteins to 
glycosidases and β-elimination 
 
Glycoside hydrolases or glycosidases are enzymes that catalyse the hydrolysis of 
glycosidic linkages. They are extremely useful molecules with which to investigate the 
types of glycan moieties that are present in glycoproteins. In this study P. luminescens 
and C. jejuni proteins were treated with various glycosidases and then the binding of 
treated and untreated samples to lectins were compared using ELLAs. The glycosidases 
used in this study and their targets are listed in table 3.4. The lectins that were used to 
analyse the deglycosylated proteins are also listed in table 3.4. 
 
Table 3.4 Glycosidase enzymes used in this study and their corresponding 
targets 
Glycosidase Target Lectin 
Endoglycosidase Hf 
(Endo Hf) 
The chitobiose core (GlcNAc-GlcNAc) of high 
mannose and hybrid N-linked glycoproteins 
Con A 
α-(1,3/6) 
galactosidase 
α-(1,3/6) linked D-galactose GSL I 
β-N-acetyl-
hexosaminidasef 
Terminal β-(1,3/4/6) linked D-N-acetyl-galactosamine 
Terminal β-(1,4) linked D-N-acetyl-glucosamine 
SBA 
α-N-acetyl-
galactosaminidase 
α-linked D-N-acetyl-galactosamine SBA 
Neuraminidase α-(2,3/6/8) linked N-acetyl-neuraminic acid WGA 
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The β-elimination reaction, a chemical means of completely removing O-linked glycans 
was also utilised in this study. This reaction will remove any O-linked glycan regardless 
of its linkage. 
 
In order to carry out the glycosidase or β-elimination treatment of protein samples, the 
protein sample was concentrated to ~10 µg/µl. Glycosidase reactions were carried out as 
described in section 2.25.6. The β-elimination reaction was carried out as described in 
section 2.26. A non-treated sample was also prepared in the same way except that 
instead of enzyme or β-elimination reagent mixture, dH2O was used. All other 
constituents of the reaction were identical. The same protein sample was used in treated 
and non-treated samples so that the signals seen in the ELLA analysis could be directly 
compared. 
 
Following treatment the samples were adjusted to 10 µg/ml with the addition of PBS 
and ELLA analysis was carried out to see if the signal was reduced in the treated 
samples compared to untreated samples. In the ELLAs, lectins were used that bind to 
the glycan moiety for which the glycosidase is specific. So for Endo Hf treatment, the 
lectin Con A was used. For α1-3,6 galactosidase treatment, GSL I was used. For β-N-
acetyl-hexosaminidasef and α-N-acetyl-galactosaminidase, SBA was used. Finally for 
neuraminidase, WGA was used. WGA was also used to examine the effect of the β-
elimination treatment. The results of the ELLA analysis are shown in figure 3.22. 
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Figure 3.22 ELLA analysis of glycosidase and β-elimination treated P. luminescens and C. jejuni proteins 
Untreated samples are represented by the blue bars and treated samples are represented by the green bars. 
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Figure 3.22 continued... ELLA analysis of glycosidase and β-elimination treated P. luminescens and C. jejuni proteins 
Untreated samples are represented by the blue bars and treated samples are represented by the green bars. 
0.0
0.2
0.4
0.6
0.8
1.0
P. luminescens PP P. luminescens CP P. luminescens MP
A
b
s
.
 
@
 
4
5
0
 
n
m
α-N-Acetyl galactosaminidase - α-N-Acetyl galactosaminidase +
Lectin used = SBA
0.0
0.2
0.4
0.6
0.8
1.0
C. jejuni PP C. jejuni CP C. jejuni MP
A
b
s
.
 
@
 
4
5
0
 
n
m
α-N-Acetyl galactosaminidase - α-N-Acetyl galactosaminidase +
Lectin used = SBA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
P. luminescens PP P. luminescens CP P. luminescens MP
A
b
s
.
 
@
 
4
5
0
 
n
m
Neuraminidase - Neuraminidase +
Lectin used = WGA
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
C. jejuni PP C. jejuni CP C. jejuni MP
A
b
s
.
 
@
 
4
5
0
 
n
m
Neuraminidase - Neuraminidase +
Lectin used = WGA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
P. luminescens PP P. luminescens CP P. luminescens MP
A
b
s
.
 
@
 
4
5
0
 
n
m
β-Elimination - β-Elimination +
Lectin used = WGA
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
C. jejuni PP C. jejuni CP C. jejuni MP
A
b
s
.
 
@
 
4
5
0
 
n
m
β-Elimination - β-Elimination +
Lectin used = WGA
 127 
In many cases the ELLA signal observed was reduced in the untreated samples 
compared to the treated samples. Endo Hf treatment reduced the binding of all protein 
samples to the lectin Con A. Upon researching published literature no incidences have 
been found where this enzyme has previously been used to cleave bacterial 
glycoproteins. In eukaryotic glycoproteins the enzyme cleaves the chitobiose core of an 
N-linked glycoprotein. Bacterial glycoproteins that have been discovered to date are not 
known to contain this chitobiose core so it is possible that this enzyme has a slightly 
different target in prokaryotic glycoproteins. 
 
The galactosidase enzyme does not appear to be having any effect on P. luminescens 
proteins but treatment with this enzyme has significantly reduced the signal obtained for 
C. jejuni membrane proteins. β-N-acetyl-hexosaminidasef treatment does not seem to be 
affecting P. luminescens proteins or C. jejuni proteins to any great extent. Linton et al. 
(2002) also found this to be the case. However, α-N-acetyl-galactosaminidase treatment 
is having a big effect on the signal obtained for SBA binding to C. jejuni proteins. 
Again this result was seen by Linton et al. (2002). However, this enzyme is not causing 
a decrease in signal for the P. luminescens proteins. Neuraminidase treatment of C. 
jejuni membrane proteins produced a large reduction in signal. Neuraminidase targets 
the glycan moiety sialic acid and C. jejuni flagellin proteins are known to be modified 
with pseudaminic acid, a glycan that is very similar to sialic acid ((Thibault et al. 2001). 
Finally the β-elimination treatment is seen to have a significant effect on the binding of 
all P. luminescens proteins fractions and C. jejuni membrane proteins to WGA. Once 
again, it has been previously reported that C. jejuni flagellin proteins contain O-linked 
glycans (Szymanski et al. 2003) therefore, the fact that the signal for the membrane 
proteins is reduced is not surprising. These results indicate that many of the 
glycoproteins produced by P. luminescens are O-linked. 
 
The fact that galactosidase and N-acetyl-galactosaminidase did not produce any effect 
on P. luminescens proteins is disappointing as the lectins GSL I and DBA gave the best 
responses in the initial western blots that were carried out (figure 3.6). This suggested 
that the glycoproteins that are produced by P. luminescens contain galactose and/or 
GalNAc. However the enzyme may not be able to cleave the glycans for a number of 
reasons including stearic hindrance and aberrant linkages between glycan moieties that 
the enzyme cannot recognise. 
Chapter 4 
Identification of a glycosylated outer membrane protein 
from P. luminescens 
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4.1 Introduction 
 
Peptide mass fingerprinting (PMF) is a technique widely used to identify unknown 
proteins. It involves digesting the protein with a protease enzyme such as trypsin, 
producing many peptides. The masses of the peptides are then accurately determined by 
mass spectrometry (MS) (Pappin et al. 1993). Trypsin cleaves proteins at the carboxyl 
side of lysine and arginine only so that these cleavages are specific. Various online tools 
exist that theoretically cleave all proteins from a database of interest into peptides using 
the protease of choice and calculates the masses of these peptides. These tools then 
compare the masses of the peptides generated from the digestion of the unknown 
protein to those of known proteins in the database. The protein with the best match is 
chosen. This method of protein identification is very advantageous because no 
information needs to be known about the protein except for the masses of the peptides. 
However, in order for the identification to be successful the protein must be present in 
the chosen database. This technique does not work well for complex protein mixtures so 
proteins must first be separated using SDS-PAGE or 2-D gel electrophoresis. 
 
The gel is stained with silver stain and the protein band or spot of interest is excised 
from the gel. The protein in the band is then treated with dithiothreitol (DTT) to reduce 
any disulphide bonds. Next the protein is treated with iodoacetamide to modify cysteine 
residues in the reduced protein to produce carbamidomethyl cysteine which helps to 
increase the strength of the signal produced during mass spectrometric analysis. The 
protein is digested into peptides using trypsin and the resultant peptides are extracted 
from the gel with acetonitrile, dried under vacuum and then resuspended in the 
appropriate solvent before analysis by MS. The procedure used in this study for the in-
gel trypsin digestion of proteins is described in section 2.25.5.  
 
Matrix assisted laser desorption ionization MS (MALDI-MS) was used in this study to 
analyse digested peptides. The analyte (the peptides) must be ionised in order to be 
analysed by the mass spectrometer. Ionization is triggered by a laser beam. The solvent 
chosen to resuspend the analyte is important for facilitating ionization. For positive 
ionization an acidic solvent such as trifluoroacetic acid (TFA) or formic acid is used to 
resuspend the analyte. In MALDI-MS the solvent donates one proton (H+) to each 
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peptide to give the peptides a positive charge. The observed mass of each peptide is 
therefore the molecular weight of the peptide plus the molecular weight of one proton 
(Mr+H)+. In order to calculate the actual molecular weight of each peptide, 1.008 Da 
(the molecular weight of H+) must be subtracted from the observed mass. Ionization by 
the laser is a very harsh process so the peptides are mixed with a matrix to protect them 
from being destroyed by being directly hit by the laser. The matrix absorbs the energy 
from the laser and passes it on to the analyte. 
 
Once the sample is ionised, the ions are extracted to the analyser where they are 
separated based on their mass (m) to charge (z) ratio (m/z). The separated ions are 
detected and a spectrum is generated by the operating software indicating the m/z ratios 
of the components of the mixture and their relative abundance. 
 
4.2 Identification of proteins isolated by lectin affinity chromatography 
using peptide mass fingerprinting 
 
Chapter 3 described the isolation of many putative glycoproteins from the periplasm 
and cytoplasm of P. luminescens using LAC. Putative glycoproteins from the periplasm 
were chosen to attempt to identify them using PMF as described in section 4.1. Figure 
4.1 shows the proteins isolated from the periplasm using LAC and those that were 
chosen to be identified using PMF. This gel was also shown previously in figure 3.9. 
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Figure 4.1 P. luminescens periplasmic proteins isolated by WGA lectin affinity chromatography 
Proteins were separated on a 15% SDS-PAGE gel which was subsequently stained with silver stain. Lane 
1 = NEB Broad Range Protein Marker, lane 2 = crude periplasmic fraction from water lysis method, lanes 
3, 4 = unbound periplasmic proteins from LAC, lanes 5, 6 = eluted periplasmic proteins from LAC. The 
proteins circled in red at ~40 kDa and ~17 kDa were chosen for identification by PMF. 
 
4.2.1 Identification of the isolated 40 kDa putative glycoprotein from the periplasm 
of P. luminescens 
 
The 40 kDa band from figure 4.1 was excised from the gel and digested into peptides 
using the in-gel trypsin digestion method described in section 2.25.5. Generated 
peptides were analysed using MALDI-MS according to the procedure outlined in 
section 2.27. Two mass spectrometers were used to analyse the sample, the Q-TOF 
Ultima Global and the Q-TOF Premier. The Q-TOF Premier is an upgraded version 
of the Q-TOF Ultima Global with the main difference between the two instruments 
being the hit frequency of the laser. For the Q-TOF Ultima Global the maximum hit 
frequency obtainable is 10 Hz and for the Q-TOF Premier the maximum hit frequency 
is 200 Hz. Therefore the Q-TOF Premier can generate a much stronger signal compared 
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to the Q-TOF Ultima Global as the amount of times the laser is hitting the sample is 
increased twenty-fold. Some analytes do not ionise as well as others and so may create 
very low intensity peaks. This is true for glycopeptides. They do not tend to take on the 
positive charge as readily as a non-glycosylated peptide due to their low hydrophobicity 
(Zhang and Reilly 2009). Using an instrument with a higher hit frequency should 
increase the sensitivity of the instrument and allow more of the lower intensity peaks to 
be seen. This means that better protein coverage may be obtained and any glycopeptides 
that are present may be detected. Mass spectra were generated for the 40 kDa protein 
using both instruments and the results are shown in figure 4.2. 
 
Figure 4.2 Mass spectra generated from the trypsin digestion of the 40 kDa protein isolated from 
the periplasm of P. luminescens by LAC 
(a) Peptides were analysed using the Q-TOF Ultima Global mass spectrometer. (b) Peptides were 
analysed using the Q-TOF Premier mass spectrometer. 
(a) Non-treated Digest, no clean up
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The total ion count (LD+) was higher for the Q-TOF Premier (3.48 x 103, figure 4.2 (b)) 
than for the Q-TOF Ultima Global (1.28 x 103, figure 4.2 (a)). Most of the peaks that 
are showing up are common to both spectra however there is a relatively large 
difference in intensity for some of the peaks between the two spectra. 
 
As previously stated, the pattern of molecular weights of peptides generated from the 
proteolytic digestion of a protein may be used to identify that protein. MASCOT 
(section 2.12) is a search engine that uses mass data to identify proteins from primary 
sequence databases. MASCOT lets the user select different parameters to use in the 
search, for example, the enzyme used for digestion, any fixed or variable modifications 
of the peptides (e.g. carbamidomethylation of cysteine, oxidation of methionine, etc.), 
the primary sequence database which you would like to search (MSDB, NCBI or 
SwissProt), the number of missed cleavages allowable, the error allowed etc. A report is 
generated showing the closest protein match and the percentage sequence coverage. A 
MASCOT score is also calculated with any score over 78 being regarded as a 
significant match. 
 
MASCOT was used to identify the protein from the masses of the peptides in figure 4.2 
(b). The database searched was NCBI, one missed cleavage was allowed, and a 
tolerance of ±0.05 Da was used. The protein identified was an outer membrane protein 
N precursor (porin OmpN) from P. luminescens subsp. laumondii TTO1. 
 
The MASCOT score obtained for the matched protein, OmpN, was 313 and the 
percentage sequence coverage was 44%. Table 4.1 shows the matched peptides, their 
position in the sequence, the difference between the expected molecular weight and the 
calculated molecular weight and the number of missed cleavages. Figure 4.3 shows the 
sequence of OmpN precursor. 
 
 134 
Table 4.1 Peptides generated from the digestion of the 40 kDa protein (from 
figure 4.2 (b)) that matched to the sequence of OmpN 
Residue 
Observed 
mass (Da) 
Expected 
Mr (Da) 
Calculated 
Mr (Da) 
Delta Miss Sequence 
       
29 – 38 1122.56 1121.5527 1121.5717 -0.0189 1 K.DGNKLDLYGK.V 
50 – 60 1154.48 1153.4727 1153.4636 0.0091 0 K.SGEDGDNSFAR.L 
61 – 78 1967.01 1966.0027 1956.9909 0.0119 1 R.LGFKGETQVNDQLTGFGR.W 
65 – 78 1521.72 1520.7127 1520.7220 -0.0092 0 K.GETQVNDQLTGFGR.W 
85 – 96 1306.57 1305.5627 1305.5797 -0.0169 1 K.GNRAEGTDEETK.T 
88 – 96 979.42 978.4127 978.4142 -0.0014 0 R.AEGTDEETK.T 
88 – 98 1236.54 1235.5327 1235.5630 -0.0302 1 R.AEGTDEETKTR.L 
150 – 157 910.49 909.4827 909.4620 -0.0092 0 R.STGLLTYR.N 
190 – 219 3048.34 3047.3327 3047.3533 -0.0206 1 
R.KDNGDGYGFSATYDVGYGI
SVGGAYSNSAR.T 
191 – 219 2920.27 2919.2627 2919.2584 0.0043 0 
K.DNGDGYGFSATYDVGYGIS
VGGAYSNSAR.T 
249 – 257 975.44 974.4327 974.4818 -0.0494 0 R.AESWNIGAK.Y 
258 – 273 1864.88 1863.8727 1863.8461 0.0266 0 K.YDANNIYLAAMYGETR.N 
294 – 319 3017.51 3016.5027 3016.5294 -0.0267 0 
K.TQNIELTAQYQFDFGLRPSL
AYVQSK.G 
339 – 350 1503.71 1502.7027 1502.7082 -0.0054 0 K.YISVGSYYYFNK.N 
351 – 359 1116.54 1115.5327 1115.5499 -0.0172 0 K.NLTTYVDYK.I 
360 – 370 1293.66 1292.6527 1292.6612 -0.0085 0 K.INLLDSNEFTK.A 
 
 
     1 MMKRNVLAVV IPALLAAGAA NAAEVYNKDG NKLDLYGKVE VQHKFANNKS  
    51 GEDGDNSFAR LGFKGETQVN DQLTGFGRWE YNIKGNRAEG TDEETKTRLA  
   101 FAGLKLSNYG SLNYGRNYGV VYDVNAWTDV LPVFGGDSMA QTDNFMTGRS  
   151 TGLLTYRNTD FFGLVDGLNF ALQYQGENSE NTANSRINRK DNGDGYGFSA  
   201 TYDVGYGISV GGAYSNSART SAQKTAFSVV EEKGKKDKPT GSTALGDRAE  
   251 SWNIGAKYDA NNIYLAAMYG ETRNMTRFGG NVDGVNWENI ANKTQNIELT  
   301 AQYQFDFGLR PSLAYVQSKG KNLLGDDGKE SSSRDLVKYI SVGSYYYFNK  
   351 NLTTYVDYKI NLLDSNEFTK ATGTSTDNVV GVGMIYQF 
 
Figure 4.3 The sequence of the outer membrane porin protein N precursor, OmpN 
The peptides that were generated from the digestion of the 40 kDa protein that matched to the sequence of 
OmpN are shown in bold red. 44% of the sequence was covered.  
 
44% is a relatively high percentage sequence coverage. It is never possible to get 100% 
coverage as many of the peptides generated after digestion will be only one or two 
amino acids in length and so will be too small. Some of the peptides may not be capable 
of accepting a proton and so will not ionise. Sometimes the trypsin cannot completely 
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cleave a protein because some of the cleavage sites will be buried within the 3D 
structure of the protein and will not be accessible. 
 
The data from figure 4.2 (a) was also inserted into MASCOT to confirm the 
identification of the protein. This data also matched to OmpN from P. luminescens (data 
not shown) however the sequence coverage was a lot lower at 22% and the MASCOT 
score was 80, just above the threshold level for a significant match. The reason for the 
lower coverage is that some of the lower intensity peptides were not being detected by 
the Q-TOF Ultima Global. For example peptides 29 – 38 (1121.5717 Da), 88 – 96 
(974.4818 Da) and 294 – 319 (3016.5294 Da) were not detected by the Q-TOF 
Ultima Global. The potential error was also about ten times greater for the Q-TOF 
Ultima Global. The peptide tolerance used for the Q-TOF Ultima Global data was 
±0.5 Da whereas for the Q-TOF Premier it was only ±0.05 Da. A much tighter 
calibration could be achieved using the Q-TOF Premier making the MASCOT score 
much higher. 
 
To unambiguously confirm that the protein was indeed OmpN, a gel slice containing the 
protein of interest was sent to the company, Alphalyse. They carry out specialised 
protein identification using similar techniques as those used in this study. Alphalyse 
confirmed that the protein was indeed OmpN. They achieved a sequence coverage of 
20% and a MASCOT score of 347. They also chose four of the matching peptides and 
carried out peptide sequencing using MS/MS (section 1.4.3). The sequences obtained 
for the four peptides using this technique matched exactly to the expected peptide 
sequences. 
 
Porins are a family of proteins found in the outer membrane of Gram-negative bacteria. 
They are synthesised at the inner side of the cytoplasmic membrane as precursor 
proteins. The precursor protein contains a signal peptide at its N-terminus that functions 
in directing the transport of the protein across the cytoplasmic membrane into the 
periplasm. Once in the periplasm, the signal peptide is cleaved by a signal peptidase and 
the mature protein is integrated into the outer membrane (Lengeler et al. 1999). Porins 
are transport proteins that form aqueous channels in the outer membrane to facilitate 
passive diffusion of hydrophilic molecules in and out of the bacterial cell.  
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The OmpN porin precursor is a 388 amino acid protein with a molecular weight of 
42,542 Da. OmpN and its orthologues contain a signal peptide at the beginning of the 
protein at the amino terminus (Inokuchi et al. 1982, Duchene et al. 1988). In OmpN 
from P. luminescens this signal peptide is 22 amino acids in length. This peptide is 
cleaved in the periplasm and the mature protein contains 366 amino acids and has a 
molecular weight of 40.4 kDa. This is the molecular weight of the peptide backbone 
only. It is expected that if the protein is glycosylated the molecular weight of the 
modified protein would be higher than this. On an SDS-PAGE gel it is difficult to 
determine an accurate molecular weight but it appears in figure 4.1 that OmpN is 
migrating at an apparent molecular weight of ~40 kDa. This means that the modifying 
glycan is not very large, perhaps only several glycan units in length. 
 
Many of the peaks that were seen in figure 4.2 (b) did not match to the P. luminescens 
protein OmpN. There are several reasons for this. Some of the non-matching peaks 
could be contaminants. One of the most common contaminants in this type of analysis is 
keratin. Keratin is very abundant in the air and comes from the shedding of skin and 
hair. The unmatched peaks in figure 4.2 were compared against a list of the most 
common contaminant keratin peaks but none of them appeared as if they were coming 
from keratin contamination. However these were only the common contaminants and 
there are thousands of other possible peptides that could be contaminating the sample. 
Sometimes the matrix can form ions giving rise to contaminant peaks. Some of the 
unmatched peaks could be peptides that were cleaved at some point other than at lysine 
or arginine residues. Peptides may get fragmented during the preparation process or in 
the mass spectrometer itself if the conditions are harsh (Hillenkamp and Peter-Katalinić 
2007).  
 
Another possible reason that peptides may not match is that they could be glycosylated. 
It has already been discussed in section 1.3 that outer membrane proteins such as pili 
and flagella are glycosylated in some pathogenic organisms (C. jejuni, Neisseria spp. 
and P. aeruginosa). Apart from surface appendages, other structural outer membrane 
proteins have been discovered. The glycosylation of the outer membrane nitrate 
reductase, AniA in Neisseria spp. has already been discussed in section 1.3.4. Other 
glycosylated structural outer membrane proteins that have shown to be glycosylated 
include the major surface lipoproteins OspA and OspB from the Gram-negative 
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spirochete Borrelia burgdorferi, the causative agent of Lyme disease (Schwan and 
Piesman 2002). These proteins are differentially expressed during infection by this 
organism and have been shown to be directly implicated in pathogenesis. Chlamydia 
trachomatis, which causes sexually transmitted disease and the eye infection, trachoma, 
produces a 40 kDa major outer membrane protein that is the main structural protein of a 
complex called the infectious extracellular elementary body (Swanson and Kuo 1991). 
In the strain serovar L2/434/bu this 40 kDa protein has been shown to be glycosylated 
with an N-linked glycan containing 8 to 9 mannose residues. When this modification is 
absent the bacteria are no longer capable of attaching and infecting HeLa cells. 
Therefore, this glycosylation has a direct affect on the pathogenicity of this organism 
(Swanson and Kuo 1991, Kuo et al. 1996). The above examples are all instances of 
protein glycosylation of structural outer membrane proteins. Following extensive 
examination of the literature no instances could be found where outer membrane porins 
have been shown to be glycosylated. 
 
The evidence provided so far in this study shows that there is a strong possibility that 
OmpN is glycosylated. Any of the unmatched peptides in figure 4.2 could be 
glycopeptides. Some of the larger peaks visible in figure 4.2 (b), for example 2183.03 
Da, 2919.26 Da or 3018.50 Da, are likely to be glycopeptides because of their size and 
because their intensity is very low (as discussed earlier, glycopeptides do not ionise 
very well). In order to investigate if these peptides are glycopeptides the glycan would 
have to be removed by chemical or enzymatic means (see next section 4.2.2). The 
OmpN protein could also be purified and its exact molecular weight could be 
determined by MS analysis. By comparing the molecular weight of the peptide 
backbone to the measured mass of the purified protein, it could be determined if there 
are any modifications present (section 4.3.4). 
 
4.2.2 PNGaseF treatment of OmpN to investigate N-linked glycosylation 
 
Many previous studies have been done to identify sites of N-linked glycosylation using 
the enzyme PNGaseF in eukaryotic glycoproteins (Fan et al. 2004, Zhang et al. 2008). 
PNGaseF (also known as N-glycosidase F) is an endoglycosidase enzyme that cleaves 
the entire N-linked glycan from a protein. It cleaves between the innermost GlcNAc of 
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an N-linked glycan and the asparagine residue. In order to use PNGaseF to identify sites 
of N-linked glycosylation, a trypsin digested protein is treated with the enzyme to 
remove any N-linked glycans, then the spectrum obtained for the untreated protein 
digest and the PNGaseF treated protein digest are compared. If a glycopeptide is 
modified with an N-linked glycan, cleaving it will decrease the molecular weight of the 
peptide. The spectrum of the PNGaseF treated protein will contain a new peak that was 
not seen in the original spectrum. The sequence of the peptide may be determined by 
MS/MS peptide sequencing and the site of the modification found by analysing the 
peptide sequence for the consensus sequence Asn-X-Ser/Thr. 
 
OmpN contains three possible N-linked glycosylation sites. These are at residue 274 
(sequence = NMT), residue 292 (sequence = NKT) and residue 351 (sequence = NLT). 
The consensus sequence at residue 351 is likely not to be glycosylated because a 
peptide containing this residue (residues 351 – 359 (table 4.1)) was identified in the 
initial MS analysis. Therefore, this residue is unlikely to contain a modification. 
Peptides containing residues 274 and 292 were not identified and therefore they are 
possible sites of N-linked protein glycosylation. To investigate if OmpN contained any 
N-linked glycans the trypsin digested protein was treated with PNGaseF according to 
the procedure described in section 2.25.6. The treated peptides were analysed using 
MALDI-MS. The results are shown in figure 4.4. 
 
Figure 4.4 Mass spectrum generated from the analysis of the PNGaseF treated OmpN digest 
Peptides were analysed using the Q-TOF Ultima Global mass spectrometer. 
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The peaks obtained for the PNGaseF treated OmpN digest were compared to the 
untreated digest in figure 4.2 (a). If N-linked glycans were present on either residue 274 
or 292, removing them would yield peptides with molecular weights of 520.61 Da 
(NMTR) and 1733.83 Da (FGGNVDGVNWENIANK) or 2236.43 Da if there was one 
missed cleavage (NMTRFGGNVDGVNWENIANK). However, the spectra before and 
after PNGaseF treatment are almost identical. There are no new peaks showing up that 
were not seen before. This suggests that if this protein is glycosylated then the glycan is 
not N-linked but is perhaps O-linked. 
 
Unfortunately there is no enzyme available commercially that removes an entire O-
linked glycan like PNGaseF does for N-linked glycans. A sequential enzymatic 
deglycosylation may be performed using a range of exoglycosidases to remove 
monosaccharides one by one from the glycan but it is not possible to know what 
enzyme to use since it is not known which monosaccharide is at the terminus of the 
glycan. Glycosidases can be quite expensive and so this type of analysis may not be 
possible. An alternative is to use chemical deglycosylation to remove O-linked glycans. 
Alkaline β-elimination is the most common O-deglycosylation strategy. It uses a 
mixture of sodium hydroxide and sodium borohydride to release the O-glycans (Carlson 
1968). However, alkaline β-elimination can sometimes damage the protein structure 
leading to difficult determination of the results. 
 
4.2.3 Identification of the isolated 17 kDa putative glycoprotein from the periplasm 
of P. luminescens 
 
A second protein isolated from the periplasm by LAC with the lectin WGA was also 
excised and identified using PMF. This protein came from the 17 kDa band circled in 
figure 4.1. The protein was digested with trypsin as before and the peptides were 
analysed using MALDI-MS. The spectrum can be seen in figure 4.5. 
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Figure 4.5 Mass spectrum generated from the trypsin digestion of the 17 kDa protein isolated from 
the periplasm of P. luminescens by LAC 
Peptides were analysed using the Q-TOF Ultima Global mass spectrometer. 
 
The signal obtained for this sample was quite strong with a total ion count of 2.07 x 103. 
MASCOT was again used to identify the digested 17 kDa protein from the masses of 
the peptides in figure 4.5. The database searched was NCBI, one missed cleavage was 
allowed, and a tolerance of ±0.5 Da was used. The protein identified was hypothetical 
protein, plu3795 from P. luminescens subsp. laumondii TTO1. The MASCOT score 
was 180 and the percentage sequence coverage was 67%. Table 4.2 shows the matched 
peptides as before and figure 4.6 shows the sequence of plu3795. 
 
Table 4.2 Peptides generated from the digestion of the 17 kDa protein (from 
figure 4.5) that matched to the sequence of plu3795 
Residue 
Observed 
mass (Da) 
Expected 
Mr (Da) 
Calculated 
Mr (Da) 
Delta Miss Sequence 
       
14 – 30 1832.87 1831.8627 1832.0077 -0.1450 1 K.LESMLDASVRTVITAVK.N 
35 – 59 2206.6200 2205.6127 2205.1641 0.4486 0 K.VTVGPLPQTPELIPSASEQSR.Y 
60 – 74 1692.86 1691.8527 1691.8770 -0.0243 0 R.YTIIPPVGPTTYQDK.V 
60 – 77 2033.58 2032.5727 2032.1245 0.4482 1 R.YTIIPPVGPTTYQDKVLK.F 
78 – 89 1334.84 1333.8327 1333.7606 0.0722 0 K.FTTVVQSQALLK.K 
90 – 98 1178.6900 1177.6827 1177.6244 0.0583 1 K.KIWVFQDSR.D 
91 – 98 1050.57 1049.5627 1049.5294 0.0333 0 K.IWVFQDSR.D 
91 – 105 1830.87 1829.8627 1830.0040 -0.1412 1 K.IWVFQDSRDPLLTIK.Y 
106 – 121 1972.62 1971.6127 1971.8751 -0.2624 0 K.YWVGEQFNYDDANPVR.V 
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     1 MSEMNEMKVK IEKLESMLDA SVRTVITAVK NDLSSSLKVT VGPLPQTPEL  
    51 IPSASEQSRY TIIPPVGPTT YQDKVLKFTT VVQSQALLKK IWVFQDSRDP  
   101 LLTIKYWVGE QFNYDDANPV RVSAEGGGNK FMIINEDSDG IAGIAVTMY 
 
 
Figure 4.6 The sequence of plu3795, a hypothetical protein from P. luminescens 
The peptides that were generated from the digestion of the 17 kDa protein that matched to the sequence of 
plu3795 are shown in bold red. 67% of the protein sequence was matched. 
 
plu3795 is a hypothetical protein. This means that the existence of the protein has been 
predicted usually through identification of open reading frames during analysis of the 
genome, but no experimental evidence exists that the protein is expressed in vivo 
(Zarembinski et al. 1998). BlastP searches using the sequence of plu3795 against all 
organisms revealed an orthologue in Photorhabdus asymbiotica which was also a 
hypothetical protein but no significant orthologues were found in any other organisms. 
A search of the sequence for conserved domains also yielded no results. Because so 
little is known about this protein no further work was carried out on it. 
 
4.3 The cloning of ompN, and expression and purification of the 
encoded protein 
 
PMF is a powerful tool for identifying protein samples (Henzel et al. 1993). Only µg 
quantities of sample are required and the protein does not have to be in pure form as the 
protein mixture is first separated using gel electrophoresis. However, in order to carry 
out other analyses, for example molecular weight determination of the intact protein, 
enzymatic/chemical removal of glycans and ELLA/western blot analysis of 
deglycosylated protein, a larger quantity of pure protein sample is required. 
 
For this reason a recombinant OmpN protein was produced. The ompN gene was 
amplified using PCR then ligated to a broad host range cloning vector pBBR1MCS-5 
(figure 2.1). The construct was transformed into E. coli then delivered to P. luminescens 
by conjugation in order to express OmpN in its natural environment so that the protein 
would be correctly glycosylated. 
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4.3.1 The cloning of ompN 
 
P. luminescens genomic DNA was prepared as outlined in section 2.6. A 1176 kb region 
of DNA was amplified that included the ompN gene with its signal peptide and also its 
ribosome binding site, a five base sequence which lies upstream from the start codon, to 
ensure correct translation of the gene. Primers were designed to incorporate a HindIII 
restriction site at the beginning of the PCR product and a 6 x histidine tag followed by a 
BamHI restriction site at the end of the PCR product. The PCR reaction was carried out 
as outlined in sections 2.25.2 and 2.25.3. The region of DNA to be amplified and the 
primers used are shown in figures 4.7 and 4.8. 
 
2089282 5′ ATGAGGGTAATAATAATGATGAAACGCAATGTTCTTGCAGTAGTAATCCCAGCTCTGT 
TAGCTGCTGGGGCAGCAAATGCAGCTGAAGTTTATAATAAAGACGGCAACAAACTGGACCTATACGGTAA
AGTTGAAGTCCAGCACAAATTCGCTAACAACAAAAGTGGCGAAGATGGCGATAACTCCTTCGCCCGTCTG
GGTTTCAAAGGTGAAACTCAAGTTAATGACCAACTGACCGGTTTTGGCCGTTGGGAATACAATATCAAAG
GTAACCGTGCAGAAGGTACTGACGAAGAAACCAAAACGCGTTTAGCTTTCGCTGGTTTGAAACTTTCTAA
CTACGGTTCACTGAACTACGGCCGTAACTACGGTGTGGTTTATGATGTCAACGCTTGGACCGATGTGTTG
CCAGTATTTGGTGGCGACTCAATGGCGCAGACTGACAACTTCATGACCGGCCGTTCTACTGGTCTGTTGA
CTTACCGCAATACCGATTTCTTCGGTTTAGTTGATGGCCTGAATTTTGCCCTGCAATATCAGGGTGAAAA
TAGTGAAAACACGGCTAATAGCCGTATCAACCGTAAAGACAACGGTGATGGTTACGGTTTCTCTGCAACT
TATGACGTAGGTTATGGTATTAGCGTCGGTGGTGCATACTCTAACTCTGCCCGTACTTCTGCGCAAAAAA
CTGCTTTTAGCGTTGTTGAGGAAAAAGGGAAAAAAGACAAACCTACTGGCTCTACTGCCTTGGGTGATCG
CGCTGAATCATGGAACATTGGCGCCAAATACGATGCCAACAACATCTACCTGGCTGCCATGTACGGTGAA
ACCCGTAATATGACTCGTTTCGGTGGAAATGTTGACGGTGTAAACTGGGAAAATATCGCTAACAAAACCC
AGAACATCGAATTGACCGCCCAATATCAGTTCGACTTCGGTTTACGTCCATCTCTGGCATACGTTCAGTC
CAAAGGTAAAAATCTGCTCGGTGACGATGGGAAAGAATCCAGCAGCCGCGATCTCGTAAAATATATTTCT
GTTGGTAGTTACTACTACTTCAACAAAAACTTGACTACCTATGTTGATTACAAAATCAACCTGCTGGATA
GCAATGAATTCACCAAAGCAACGGGTACCAGCACTGACAACGTTGTTGGCGTAGGTATGATTTACCAATT
CTAA 3′ 2088101 
 
Figure 4.7 The region of P. luminescens DNA to be amplified by PCR in order to clone the ompN 
gene 
The top strand of DNA is written in the 5′ → 3′ direction. The coordinates of the DNA are shown. The 
ribosome binding site is shown in red. The signal peptide is shown in blue font. The start codon, ATG is 
underlined. The stop codon, TAA is represented by green font and is underlined. 
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ompN_F1: 5′  GTCAGTAAGCTTATGAGGGTAATAATAATGATGAAA  3′ 
ompN_F2: 5′  GTCAGTGGATCCTTAGTGATGGTGATGGTGATGGAATT 
     GGTAAATCATACCTACG  3′ 
 
Figure 4.8 PCR primers used for the amplification of the region of P. luminescens DNA shown in 
figure 4.7, encoding OmpN 
Non-binding regions of DNA are shown in bold type. Restriction sites are in red font. Six additional bases 
were added at the 5′ of the primers to enable efficient binding of the restriction enzymes to their 
restriction sites. The start codon, ATG is underlined in ompN_F1 and the stop codon is in green font in 
ompN_F2. A 6 x histidine tag has been incorporated into the reverse primer before the stop codon and is 
shown in blue. 
 
The complete strategy for the cloning of ompN with a C-terminal histidine tag is shown 
in figure 4.9. 
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Figure 4.9 Strategy used for the cloning of ompN with a C-terminal histidine tag 
pMF1.2 C B/H was constructed by restricting the ompN PCR product and the vector pBBR1MCS-5 with 
BamHI and HindIII restriction enzymes. The restricted pieces of DNA were then ligated together and 
transformed into E. coli. pMF1.2 C B/H was delivered from E. coli to P. luminescens by conjugation. 
P. luminescens genomic DNA 
PCR amplifying ompN 
gene incorporating C-
terminal 6 x His Tag 
and restriction sites at 
ends of product 
Cut with restriction 
enzymes and ligate 
GmR 
mob 
rep 
ompN 
GmR 
mob 
rep 
Transform into E. coli then deliver 
to P. luminescens by conjugation 
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The ompN PCR product was purified as outlined in section 2.10. Plasmid DNA from 
pBBR1MCS-5 was prepared (section 2.8). Prepared pBBR1MCS-5 DNA and the 
purified ompN PCR product were restricted with BamHI and HindIII enzymes to 
generate cohesive ends and allow ompN to be ligated to pBBR1MCS-5. Prior to ligation 
the restriction digest products were purified by gel extraction (section 2.10) to remove 
the restriction reaction components. The ligation reaction was carried out as outlined in 
section 2.25.4 and the construct pMF1.2 C B/H was formed. 
 
Chemically competent E. coli XL10-Gold cells were prepared (section 2.11.3) and 
transformed with the construct pMF1.2 C B/H (section 2.11.4) then grown on LB agar 
containing the selective antibiotic, gentamicin. Transformants were visible on the plates 
following overnight incubation. Plasmid DNA was prepared from five transformants 
using the 1, 2, 3 method (section 2.7) to confirm if the plasmids contained the ompN 
gene insert. The results are shown in figure 4.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Plasmid DNA prepared from E. coli XL10-Gold cells transformed with pMF1.2C B/H 
Plasmid DNA was prepared using the 1, 2, 3 method described in section 2.7. The DNA samples were 
separated on a 0.7 % agarose and stained with ethidium bromide. Lane 1 = Invitrogen 1 kb DNA ladder, 
lane 2 = pBBRMCS-5, lanes 3 – 7 = pMF1.2C B/H transformants 1-5.  
 
In figure 4.10 two forms of plasmid DNA are visible in some lanes. The two forms are 
covalently closed circular (CCC) DNA and open circular (OC) DNA. The CCC form 
migrates further down the gel than the OC form as it is more compact. The CCC form is 
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also usually more concentrated that the OC form. Lane 2 contains pBBR1MCS-5 empty 
vector plasmid DNA. By comparing the sizes of the DNA bands obtained for the 
transformants to the empty vector it may be deduced that transformants 3 and 5 (lanes 5 
and 7) do not contain the ompN gene, as their DNA is migrating to the same region of 
the gel as pBBR1MCS-5. Transformants 1, 2 and 4 do contain the insert (lanes 3, 4 and 
6). Their plasmid DNA is larger than the empty vector. 
 
Three of the five transformants chosen appeared to have the correct ompN insert. This 
was confirmed by restriction analysis. One of the transformants, number 1 (shown in 
lane 3), was chosen and digested with BamHI and HindIII in one reaction and with 
KpnI in a separate reaction. The results are shown in figure 4.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 BamHI / HindIII and KpnI restriction digests of the plasmid pMF1.2C B/H to confirm 
that it contained the ompN insert 
Restriction analysis was carried out and DNA fragments were separated on an agarose gel and stained 
with ethidium bromide. Lane 1 = Invitrogen 1 kb DNA ladder, lane 2 = pBBRMCS-5 uncut, lane 3 = 
pBBRMCS-5 cut with BamHI/Hind III, lane 4 = pBBRMCS-5 cut with KpnI, lane 5 = pMF1.2C B/H 
uncut, lane 6 = pMF1.2C B/H 5 cut with BamHI/Hind III, lane 7 = pMF1.2C B/H cut with KpnI.  
 
Because the BamHI and HindIII restriction sites are only 30 bp apart in pBBR1MCS-5, 
cutting pBBR1MCS-5 with both of these enzymes yields only one visible linear 
fragment of 4.7 kb in size (lane 3). pBBR1MCS-5 contains one KpnI site so cutting 
with this enzyme linearises the DNA (lane 4). Lane 5 shows uncut pMF1.2 C B/H, with 
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the OC and CCC forms visible. Cutting with BamHI and HindIII removes the ompN 
insert yielding two linear fragments of ~4.7 kb and ~1.2 kb. pMF1.2 C B/H contains 
two KpnI sites, one of which lies within the ompN insert. Cutting with KpnI yields two 
fragments of ~4.7 and ~1.2 kb. This also shows that the insert is in the correct 
orientation. The restriction analysis shown in figure 4.11 confirms that the ompN insert 
is present in pMF1.2 C B/H. 
 
In order to express OmpN in its natural environment, to ensure correct glycosylation, 
the construct was delivered to P. luminescens from E. coli by conjugation. Tri-parental 
mating was used for conjugation to occur. The method used for bacterial conjugation by 
tri-parental mating is described in section 2.13. The principles of how this method 
works is shown in figure 4.12. 
 
 
Figure 4.12 The principles of tri-parental mating 
Transfer genes (tra) are highlighted in purple, mobilisation genes (mob) are highlighted in pink and 
antibiotic resistance genes are highlighted in yellow for chloramphenicol (Cm), red for gentamicin (Gm) 
and grey for rifampicin (Rif). 
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The helper strain contains the plasmid pRK600 that provides transfer functions (tra 
genes). The plasmid in the donor strain contains the gene of interest. The helper plasmid 
is transferred to the donor strain to create an intermediate strain that contains all the 
elements to transfer the plasmid of interest to the recipient strain, P. luminescens (tra 
and mob). The pBBR1MCS-5 construct is transferred to the recipient by conjugation to 
create a transconjugate. Correct intermediates and transconjugates may be selected for 
by culturing on media containing antibiotics, chloramphenicol and gentamicin for 
intermediates and gentamicin and rifampicin for transconjugates. 
 
Both empty vector, pBBR1MCS-5 and the construct pMF1.2 C B/H were transferred 
separately to P. luminescens by conjugation. A number of transconjugates from each 
mating were chosen and plasmid preparations were carried out. Plasmid DNA isolated 
from P. luminescens transconjugates was run on an agarose gel and compared to 
plasmid DNA from E. coli. The results are shown in figure 4.13. 
 
Figure 4.13 Plasmid DNA prepared from P. luminescens transconjugates 
The pBBR1MCS-5 and pMF1.2C B/H plasmids were transferred from E. coli XL10-Gold to P. 
luminescens by tri-parental mating. Plasmid DNA was prepared from P. luminescens transconjugates and 
visualised on an ethidium bromide stained agarose gel. Lane 1 = Invitrogen 1 kb DNA ladder, lane 2 = 
pBBR1MCS-5 plasmid prep from E. coli, lanes 3 – 5 = pBBR1MCS-5 plasmid prep from P. luminescens 
(transconjugates), lane 6 = pMF1.2C B/H plasmid prep from E. coli, lanes 7 – 11 = pMF1.2C B/H 
plasmid prep from P. luminescens (transconjugates).  
 
Plasmid DNA prepared from P. luminescens was much less concentrated than that from 
E. coli, however it can be seen that the plasmid is present in all transconjugates and is 
the correct size. 
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4.3.2 The expression of OmpN in E. coli and P. luminescens 
 
Following the cloning of ompN, the gene was expressed in both E. coli XL10-Gold and 
P. luminescens. Because multiple copies of this plasmid exist in each bacterial cell, in 
theory a higher level of expression of ompN should be obtained in P. luminescens 
pMF1.2 C B/H than in the normal wildtype. 
 
Protein expression was carried out as indicated in section 2.14. Following OmpN 
expression in P. luminescens, periplasmic proteins were isolated from the cells using the 
water lysis method (section 2.15). A wildtype P. luminescens culture was grown 
simultaneously and periplasmic proteins were also isolated from it as a comparison. The 
concentrations of the protein samples were measured using the BCA assay (section 
2.17) and 20 µg of each protein sample was run on a 2-D gel as described in section 
2.19. The gels were subsequently visualised by staining with silver stain (section 2.20). 
The images of both 2-D gels are shown in figure 4.14. 
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Figure 4.14 2-Dimensional gel electrophoresis comparing periplasmic proteins isolated from P. 
luminescens wildtype (a) and P. luminescens pMF1.2 C B/H (b) 
Protein samples were separated using 2-D electrophoresis and stained with silver stain. The OmpN 
protein is indicated in both gels by a red arrow.  
 
It can be seen from figure 4.14 that the level of expression of OmpN in P. luminescens 
pMF1.2 C B/H is much higher that the expression in the wildtype. OmpN is migrating 
at a molecular weight of ~40 kDa and a pI of ~5.3. Figure 4.14 indicates that 
recombinant OmpN is being produced by P. luminescens pMF1.2 C B/H. In order to 
carry out further analysis of the recombinant protein it was first purified from the mix of 
other proteins in the periplasm using its 6 x histidine affinity tag for purification using 
IMAC. 
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4.3.3 Purification of OmpN from E. coli and P. luminescens using IMAC 
 
Recombinant OmpN was purified from periplasmic proteins prepared from E. coli 
XL10-Gold and P. luminescens pMF1.2 C B/H strains using the procedure described in 
section 2.16. A protein sample from before the purification (crude sample) and samples 
from throughout the purification were analysed on a 15% SDS-PAGE gel (section 2.18) 
and stained with silver stain (section 2.20). The results of the purification from E. coli 
are shown in figure 4.15 and from P. luminescens in figure 4.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 IMAC purification of OmpN from the periplasm of E. coli XL10-Gold pMF1.2C B/H 
Periplasmic proteins were isolated from E. coli XL10-Gold pMF1.2C B/H using the water lysis method 
and were applied to an IMAC column. Proteins were eluted from the column with an increasing gradient 
of imidazole. Lane 1 = NEB broad range protein marker, lane 2 = crude E. coli XL10-Gold pMF1.2C B/H 
periplasmic proteins, lane 3 = flow through from IMAC resin, lane 4 = 10 mM imidazole wash, lane 5 = 
20 mM wash, lane 6 = 40 mM wash, lane 7= 80 mM wash, lane 8 = 100 mM wash, lane 9 = 300 mM 
imidazole elution.  
 
Figure 4.15 shows that a small amount of pure OmpN was isolated from the periplasm 
and can be seen in lane 9. 
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Figure 4.16 IMAC purification of OmpN from the periplasm of P. luminescens pMF1.2C B/H 
Periplasmic proteins were isolated from P. luminescens pMF1.2C B/H using the water lysis method and 
were applied to an IMAC column. Proteins were eluted from the column with an increasing gradient of 
imidazole. Lane 1 = NEB broad range protein marker, lane 2 = crude P. luminescens pMF1.2C B/H 
periplasmic proteins, lane 3 = flow through from IMAC resin, lane 4 = 10 mM imidazole wash, lane 5 = 
20 mM wash, lane 6 = 40 mM wash, lane 7= 60 mM wash, lane 8 = 80 mM wash, lane 9 = 100 mM 
wash, lane 10 = 300 mM imidazole elution. 
 
The level of OmpN expression in both E. coli and P. luminescens is relatively low. This 
is because OmpN is a membrane protein and so forcing high levels of expression is 
usually not possible. However, more importantly, the samples are pure, which is vital 
for ELLA analysis where only small amounts of protein are needed for analysis. 
 
4.3.4 Analysis of recombinant OmpN purified from E. coli and P. luminescens 
 
After attaining a pure sample of OmpN from P. luminescens pMF1.2 C B/H, it was 
dried down in a vacuum drier to completely evaporate it and the sample was sent to the 
company Alphalyse for accurate relative molecular mass determination. It was hoped 
that the measured molecular mass would be higher than the calculated mass of the 
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protein backbone and so the size of the glycan(s) modifying the protein could be 
calculated. Unfortunately, the company were unable to determine the molecular weight 
because the spectrum obtained for the sample was too weak. This was probably due to 
insufficient sample amount. Due to limitations in funding another sample could not be 
sent for analysis and so lectins were employed to analyse the OmpN protein further. 
 
OmpN purified from P. luminescens pMF1.2 C B/H was analysed using LAC. The 
lectin WGA was initially used to isolate OmpN from wildtype P. luminescens so this 
lectin was used again to see if the recombinant protein was still properly glycosylated 
and could still bind to WGA. The procedure used for LAC is described in section 2.24. 
The eluted protein sample was concentrated down in a vivaspin 15 centrifugal filter 
device. Purified OmpN, before application to the column, unbound protein from the 
WGA column and concentrated eluted protein were run on a 15% SDS-PAGE gel 
stained with silver stain. The results are shown in figure 4.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Investigation into whether OmpN purified from P. luminescens pMF1.2C B/H is 
capable of binding WGA in a lectin affinity chromatography column  
OmpN purified from P. luminescens pMF1.2C B/H using IMAC was applied to a WGA LAC column. 
Unbound proteins were washed away and bound proteins were eluted using 0.5 M GlcNAc. Samples were 
run on a 15% SDS-PAGE gel and stained with silver stain. Lane 1 = Broad range protein marker, lane 2 = 
OmpN Purified from P. luminescens pMF1.2C B/H before addition to the column, lane 3 = unbound 
OmpN, lane 4 = OmpN eluted from WGA column. 
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Figure 4.17 shows that recombinant OmpN from P. luminescens still has the ability to 
bind to the WGA lectin and has been eluted from the column with the addition of 0.5 M 
GlcNAc (lane 4). The recombinant OmpN is binding quite strongly since little or no 
protein was visible in the unbound fraction (lane 3). In order to confirm that the 
interactions between WGA and OmpN were protein-glycan based and not protein-
protein, OmpN purified from E. coli was used as a control. E. coli does not contain the 
same glycosylation machinery as P. luminescens and so OmpN from E. coli would not 
be glycosylated. An ELLA was carried out to investigate the interactions been OmpN 
(from both sources) and the lectins WGA and GSL I. Crude periplasmic proteins before 
IMAC purification and proteins from the first wash using 10 mM imidazole were also 
analysed. The results are shown in figure 4.18. 
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Figure 4.18 ELLA comparing interactions of OmpN purified from P. luminescens and E. coli with 
the lectins WGA and GSL I 
P. l. = P. luminescens pMF1.2 C B/H, E. c. = E. coli pMF1.2 C B/H, Crude = Periplasmic proteins before 
IMAC purification, 300 mM elution = purified OmpN. Fetuin and Thyroglobulin are commercial 
glycoproteins that were used as assay control. Fetuin (black bars) is known to bind WGA and 
Thyroglobulin (grey bars) is known to bind GSL I. 
 
It can be seen from figure 4.18 that proteins from the P. luminescens crude periplasmic 
sample (green) and 10 mM wash sample (yellow) bound very strongly to both lectins. 
No proteins from E. coli crude periplasmic sample (purple) and 10 mM wash sample 
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(dark green) bound to WGA but a signal was seen for both of these samples with the 
lectin GSL I. OmpN purified from P. luminescens (light blue) produced a significant 
signal with both lectins. However, in contrast the signal obtained for OmpN purified 
from E. coli (pink) was at baseline levels for both lectins. These results strongly indicate 
that OmpN from P. luminescens is glycosylated as it binds to the lectins WGA and GSL 
I, while the exact same protein produced in E. coli without glycosylation does not. The 
interaction between OmpN and the lectins is therefore concluded to be a glycan-protein 
binding and not a protein-protein interaction. 
Chapter 5 
Mutagenesis of wbl genes in P. luminescens and analysis 
of altered glycosylation patterns
 157 
5.1 In silico analysis of the P. luminescens genome in search of 
glycosylation genes 
 
The genome of P. luminescens subsp. laumondii TTO1 has been sequenced (Duchaud et 
al. 2003) and is accessible online. The P. luminescens genome was examined to identify 
encoded proteins with homology to the general protein glycosylation system in C. jejuni 
subsp. jejuni 81-176 using the BlastP program (NCBI). Figure 5.1 shows the genes 
encoding the general protein glycosylation system in C. jejuni. This cluster of genes is 
called the pgl gene cluster. 
 
 
 
Figure 5.1 The pgl gene cluster in C. jejuni 
Schematic representation of the pgl gene cluster that produces N-linked glycoproteins. ORFs are indicated 
by arrows. Glycosyltransferases are shown in green, enzymes involved in sugar biosynthesis are shown in 
blue, the oligosaccharyltransferase, pglB is shown in red and the predicted ABC transporter, pglK is 
shown in yellow. The function of pglG is unknown (Linton et al. 2005). 
 
Almost all of the proteins encoded in this cluster were found to have orthologues in P. 
luminescens. Some of these orthologues were very similar to the C. jejuni proteins over 
the entire sequence, others had only part homology to the C. jejuni proteins. Table 5.1 
summarises the results of the homology searches carried out between C. jejuni Pgl 
proteins and P. luminescens proteins. 
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Table 5.1 Proteins encoded by genes in the pgl gene cluster in C. jejuni and their orthologues in P. luminescens 
C jejuni 
protein 
Locus Identification 
JCVI  role 
category1 
Protein 
length 
P. luminescens 
orthologue 
Locus Identification 
JCVI role 
category 
Protein 
length 
Sequence 
similarity2 
GalE 
CJJ81176 
_1148 
UDP-glucose 4-
epimerase 
1, 2 328 aa GalE plu4831 
UDP-glucose 4-epimerase 
(galactowaldenase) 
2 340 aa 
38% (59%) 
(overall) 
PglK 
CJJ81176 
_1147 
ABC transporter, 
permease/ATP-
binding protein 
1, 3 564 aa plu3125 plu3125 unnamed protein product 4, 5 706 aa 
43% (62%) 
(part) 
PglH 
CJJ81176 
_1146 
General 
glycosylation 
pathway (GGP) 
protein 
1 359 aa plu3361 plu3361 unnamed protein product 1 404 aa 
31% (51%) 
(part) 
PglI 
CJJ81176 
_1145 
GGP protein 1 309 aa plu4290 plu4290 unnamed protein product 1 329 aa 
22% (45%) 
(overall) 
PglJ 
CJJ81176 
_1144 
GGP protein 1 365 aa WalW plu4851 WalW protein 1 367 aa 
27% (46%) 
(overall) 
PglB 
CJJ81176 
_1143 
GGP protein 1 713 aa 
no significant 
orthologue 
N.A. N.A. N.A. N.A. N.A. 
PglA 
CJJ81176 
_1142 
GGP protein 1 376 aa WalR plu4862 WalR protein 1 373 
28% (51%) 
(part) 
PglC 
CJJ81176 
_1141 
GGP protein 1 200 aa WblF plu4808 WblF protein 6, 7, 8 203 aa 
34% (55%) 
(overall) 
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Table 5.1 Continued… 
C jejuni 
protein 
Locus Identification 
JCVI  role 
category13 
Protein 
length 
P. luminescens 
orthologue 
Locus Identification 
JCVI role 
category 
Protein 
length 
Sequence 
similarity24 
PglD 
CJJ8117 
_1140 
GGP protein 1 203 aa LpxD plu0682 
UDP-3-O-[3-
hydroxymyristoyl] 
glucosamine N-acyltransferase 
1 342 aa 
29% (49%) 
(part) 
PglE 
CJJ81176 
_1139 
GGP protein 1 386 aa WblK plu4807 WblK protein Not assigned 385 aa 
27% (48%) 
(overall) 
PglF 
CJJ81176 
_1138 
GGP protein 1 590 aa WblM plu4809 WblM protein 6, 7, 8 624 aa 
36% (51%) 
(overall) 
PglG 
CJJ81176 
_1137 
GGP protein 1 297 aa 
no significant 
orthologue 
N.A. N.A. N.A. N.A. N.A. 
                                               
1
 J. Craig Venter Institute (JCVI) Cellular Role Category:  
1 = Cell envelope: Biosynthesis and degradation of surface polysaccharides and lipopolysaccharides 
2 = Energy metabolism: Sugars 
3 = Transport and binding proteins: Other 
4 = Transport and binding proteins: Unknown substrate 
5 = Transport and binding proteins: Amino acids, peptides and amines 
6 = Energy metabolism: Electron transport 
7 = Regulatory functions: Other 
8 = Protein synthesis: Ribosomal proteins: synthesis and modification 
 
2
 Sequence Similarity: First value = % identities (exact match), second value = % positives (similar match) 
 160 
It can be seen from the table that the orthologues found in P. luminescens are not all 
encoded adjacent to each other as the pgl genes in C. jejuni are. Apart from GalE, the 
three proteins in P. luminescens that showed the closest similarity overall to Pgl 
proteins in C. jejuni were WblK (PglE orthologue), WblF (PglC orthologue) and WblM 
(PglF orthologue). Section 1.3.2.3 described how PglC, PglE and PglF from C. jejuni 
are homologous to PglB, PglC and PglD from N. meningitidis respectively. 
Consequently PglB, PglC and PglD from N. meningitidis are homologous to WblF, 
WblK and WblM respectively from P. luminescens. PglB from N. meningitidis shows 
54% similarity with WblF covering 42% of the protein sequence. PglC from N. 
meningitidis shows 58% similarity with WblK covering 69% of the protein sequence.  
Finally PglD from N. meningitidis shows 70% similarity with WblM covering almost all 
of the protein sequence (98%). The Pgl proteins from N. meningitidis are involved in 
the OT mediated O-linked glycosylation of pili and other proteins. In the case of the OT 
enzymes, PglB from C. jejuni and PglL from N. meningitidis, no significant orthologues 
have been found in P. luminescens. 
 
The MultAlin and Genedoc programs (section 2.12) were used to perform global 
sequence alignments of the three Pgl proteins from C. jejuni that showed high similarity 
to Wbl proteins from P. luminescens and these alignments are shown in figures 5.2 to 
5.4. 
 
 
Figure 5.2 Sequence alignment of C. jejuni PglE with P. luminescens WblK 
Black indicates conserved amino acids 
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Figure 5.3 Sequence alignment of C. jejuni PglC with P. luminescens WblF 
Black indicates conserved amino acids 
 
 
 
Figure 5.4 Sequence alignment of C. jejuni PglF with P. luminescens WblM 
Black indicates conserved amino acids 
 
The three proteins are very similar to their orthologues in sequence and size. However, 
the three Wbl proteins have not been assigned the same cellular role by the JCVI as 
their orthologues. According to the JCVI, PglC, E and F are involved in biosynthesis 
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and degradation of surface polysaccharides and LPS, while WblK has not been assigned 
to a role category and WblF and WblM are described as being involved in electron 
transport, the synthesis of ribosomal proteins and to have regulatory functions.  
 
In the NCBI database WblF is listed as being similar to putative glycosyltransferases. It 
contains a similar conserved domain as proteins found in the Bac_transf (bacterial sugar 
transferase) superfamily. WblK is listed as being highly similar to putative hydro-lyases 
(enzymes that catalyze the removal of water from a substrate by breakage of a carbon-
oxygen bond). WblK contains a conserved domain found in WecE proteins. These 
proteins are predicted to be pyridoxal phosphate-dependent enzymes involved in the 
regulation of cell wall biogenesis. WblK also contains a conserved domain from the 
AHBA_syn (3-amino-5-hydrozybenzoic acid synthase) family. The members of this 
family are involved in various biosynthetic pathways for secondary metabolites. Some 
members of this family are involved in the synthesis of an amine containing sugar 
called perosamine. Perosamine is an important element in the glycosylation of several 
cell products such as LPS. Another well studied protein in this family is PglA, a 
galactosyltransferase involved in pilin glycosylation in N. meningitidis. In the NCBI 
database WblM is listed as being similar to proteins involved in galactose modification. 
It contains conserved domains from proteins in two superfamilies, LbetaH and NADB-
Rossmann. The LbetaH (left-handed parallel beta-helix) superfamily contains 
acetyltransferases and proteins involved in ion transport or translation initiation. The 
NADB-Rossmann (Rossmann-fold NAD(P)(+))-binding proteins are involved in many 
metabolic pathways. WblM also contains a conserved domain from nucleoside-
diphosphate sugar epimerase proteins involved in cell envelope biogenesis and 
carbohydrate transport and metabolism. All three proteins contain conserved domains 
that suggest that they are involved in glycosylation in some way. They could be 
involved in LPS production or protein glycosylation or these enzymes could be 
common to both pathways. 
 
Finally, the amino acid sequences of WblK, WblF and WblM were compared against 
the NCBI database of protein sequences using the BlastP program to find other 
orthologues to these proteins to gain a better insight into the possible functions of these 
proteins. The results of these BlastP searches are shown in figures 5.5 to 5.7. The three 
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closest orthologues to WblK, WblF and WblM were aligned using the MultAlin and 
Genedoc programs. 
 
 
Figure 5.5 Multiple sequence alignments of WblK from P. luminescens with its three closest 
orthologues 
P.l._WblK = WblK from P. luminescens, P.a._WblK= WblK from P. asymbiotica, H.p._WbgX = WbgX 
from Haemophilus parasuis SH0165 and H.p._SCPBP = spore coat polysaccharide biosynthesis protein 
from H. parasuis 29755.  Sequence highlighted in black = 100% conservation, dark grey = 75% 
conservation and light grey = 50% conservation. 
 
Figure 5.5 shows that WblK from P. luminescens has 92% (96%) homology with WblK 
from P. asymbiotica, 71% (87%) homology with WbgX and 71% (87%) homology with 
SCPBP. WblK from P. asymbiotica is reported as being an aminotransferase, WbgX is 
also an aminotransferase involved in LPS and spore coat polysaccharide biosynthesis 
and SCPBP is involved in spore coat polysaccharide biosynthesis. 
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Figure 5.6 Multiple sequence alignments of WblF from P. luminescens with its three closest 
orthologues 
P.l._WblF = WblF from P. luminescens, P.a._WblF = WblF from P. asymbiotica, S.p._1414 = Spea_1444 
from Shewanella pealeana ATCC 700345 and Sh.s._WbgY = WbgY from Shigella sonnei Ss046.   
 
WblF from P. luminescens has 90% (95%) homology with WblF from P. asymbiotica, 
60% (75%) homology with Spea_1444 and 59% (79%) homology with WbgY. All three 
orthologues are reported as being glycosyltransferases. 
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Figure 5.7 Multiple sequence alignments of WblM from P. luminescens with its three closest 
orthologues 
P.l._WblM = WblM from P. luminescens, P.a._WblM= WblM from P. asymbiotica, Y.r._TrsG = TrsG 
like protein from Yersinia rohdei ATCC 43380 and Pl.s._WbgZ = WbgZ from Plesiomonas shigelloides. 
 
WblM from P. luminescens has 93% (97%) homology with WblM from P. asymbiotica, 
58% (77%) homology with TrsG and 57% (74%) homology with WbgZ. WblM from P. 
asymbiotica is reported as being a polysaccharide biosynthesis protein, TrsG and WbgZ 
are both reported as being nucleoside-diphosphate epimerases. 
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The results of the BlastP searches on WblK, WblF and WblM suggest that WblK is an 
aminotransferase, WblF is a glycosyltransferase and WblM is an epimerase. In order to 
confirm the function of the three proteins they can be mutated by insertional 
inactivation using a kanamycin resistance (KanR) cassette (as described in section 5.2). 
The mutated gene may be introduced into the P. luminescens genome by triparental 
mating and recombination mediated reciprocal exchange (as described in section 5.2). It 
is anticipated that if these genes are involved in protein glycosylation in P. luminescens, 
mutating them will lead to changes in the glycan patterns of the glycoproteins isolated 
from the organism. Figure 5.8 shows the location of the genes wblK, wblF and wblM in 
the genome of P. luminescens. 
 
 
Figure 5.8 The location of wblK, wblF and wblM in the genome of P. luminescens 
The coordinates of wblK are 5581963→5583120, the coordinates of wblF are 5583121→5583732 and the 
coordinates of wblM are 5583742→5585616. wblK is 1158 bp, wblF  is 612 bp and wblM is 1875 bp in 
length. All three genes are found in the positive orientation in the genome. 
 
The three genes wblK, wblF and wblM lie adjacent to each other in the genome. There is 
no gap between wblK and wblF and only ten base pairs separate wblF and wblM. This 
suggests that all three genes are controlled by the same promoter so mutation of wblK 
will likely lead to mutation of wblF and wblM also.  
 
5.2 The principles of mutagenesis by insertional inactivation, tri-
parental mating and recombination mediated reciprocal exchange 
 
With the availability of so many sequenced microbial genomes and rapid advances in 
PCR it has become possible to target a specific gene in a microorganism for 
mutagenesis. Antibiotic resistance cassettes are widely used to mutate targeted genes by 
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insertional inactivation. Suicide vectors such as pJQ200sk+ (figure 2.2) (Quandt and 
Hynes 1993) have been developed to introduce the mutated gene into the organism. 
 
In order to mutate the gene of interest using insertional inactivation, a 2 – 4 kb region of 
P. luminescens DNA carrying the target gene of interest is ligated to the pJQ200sk+ 
vector. An antibiotic resistance cassette is inserted into the recombinant target gene to 
cause the mutation. The orientation of the resistance cassette should be opposite to that 
of the target gene to ensure that transcriptional read-through cannot occur. For the 
mutagenesis of a P. luminescens gene, pJQ200sk+ vector constructs are prepared in E. 
coli (the donor strain) and delivered by conjugation into P. luminescens (the recipient 
strain) using tri-parental mating with the help of a plasmid such as pRK600 (Finan et al. 
1986) in a helper strain. The principles of tri-parental mating are illustrated and 
discussed in figure 4.12. 
 
The vector pJQ200sk+ is a narrow host range plasmid. Once the plasmid has been 
delivered to the recipient, P. luminescens, it cannot replicate in this host and so it 
secures and maintains itself by integrating into the chromosome by homologous 
recombination (figure 5.9). 
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Figure 5.9 Homologous recombination 
The circular suicide vector, pJQ200sk+ is shown, containing the gentamicin (Gm) resistance gene (red) 
and sacB gene (blue) and the recombinant DNA from P. luminescens (upper case letters) that has been 
mutated (light blue triangle). The straight black lines indicate a section of chromosomal DNA. The wild 
type gene is indicated by lower case letters. Double ended arrows indicate homologous regions of DNA. 
After the 2nd recombination event the mutation is incorporated into the chromosomal DNA. 
 
About 1 – 2 kb of homologous sequence is required on either side of the insertion to 
facilitate successful recombination.  The first recombination event integrates the entire 
pJQ200sk+ construct into the chromosomal DNA. The pJQ200sk+ vector encodes 
gentamicin resistance which allows for selection in P. luminescens. In order to excise 
the vector from the chromosomal DNA, leaving behind only the mutated gene a second 
recombination event must occur. Second recombination events occur randomly and at 
low frequency. pJQ200sk+ also encodes the sacB gene that results in a suicide effect in 
the presence of 5% sucrose. This facilitates the selection of second recombinant events 
at a detectable level. Any cells that have undergone the second recombination event 
will not contain the sacB gene and so will survive in the presence of 5% sucrose. 
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5.3 Antibiotic resistance cassette mutagenesis of wblK 
 
wblK was selected for mutagenesis based on the results obtained from the in silico 
analysis in section 5.2. However, because wblK, wblF and wblM are adjacent to each 
other and appear to be part of the same operon, mutating wblK will likely prevent 
transcription of wblF and wblM also. Mutagenesis of wblK was achieved by insertional 
inactivation of the gene using a KanR cassette. Genomic DNA from P. luminescens was 
prepared (section 2.6) and used as a template to amplify two adjacent 2040 bp regions 
of the genome containing the wblK gene using PCR. Primers were designed to 
incorporate a BamHI site at the beginning and a PstI site at the end of the first region 
(wblK1) and the primers for the second region (wblK2) incorporated a PstI site at the 
beginning and an XhoI site at the end of the region. This is indicated by figure 5.10. The 
PstI site would be used later to insert the KanR cassette into the gene. 
 
Figure 5.10 PCR amplifying two regions of P. luminescens DNA incorporating the wblK gene 
The wblK gene is split over the two regions. The KanR cassette may be inserted at the PstI site in the 
opposite orientation to interrupt the gene. 
 
The primers also contained nine additional bases at the beginning to enable efficient 
recognition of the restriction site by the restriction enzyme. The primers used for wblK 
mutagenesis are shown in figure 5.11. The PCR reaction components used are shown in 
section 2.25.2 and the PCR program cycle used is shown in section 2.25.3. 
wblK wblK 
PCR amplifying 2 x 2040 bp 
adjacent regions of the genome 
containing the wblK gene  
 
Primers designed to incorporate 
restriction sites at the start and end 
of both regions. 
P. luminescens genomic DNA 
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wblK_F1: 5′  ACGTGACATGGATCCTTCCATGCTTCCTAAAGTAC  3′ 
wblK_R1 5′  ACGTGACATCTGCAGATATTGCGCAAAATCTTGTTC  3′ 
wblK_F2 5′  ACGTGACATCTGCAGTTAGGTTCCGATGTTGAAGC  3′ 
wblK_R2 5′  ACGTGACATCTCGAGTAGCGTTCTATAGATAAATCTTG  3′ 
 
Figure 5.11 PCR primers used for the amplification of the region of P. luminescens DNA encoding 
wblK 
Non-binding regions of DNA are shown in bold type. Restriction sites are shown in red. wblK_F1 and 
wblK_R1 were used to amplify wblK1 and wblK_F2 and wblK_R2 were used to amplify wblK2. 
 
The suicide vector pJQ200sk+ (figure 2.2) was employed to introduce the wblK 
fragment containing the KanR cassette into the genome of P. luminescens. Plasmid 
DNA from pJQ200sk+ was prepared (section 2.8). Prepared pJQ200sk+ DNA and the 
PCR product, wblK1, which had been purified (section 2.10), were restricted with 
BamHI and PstI to generate cohesive ends to allow wblK1 to be ligated to pJQ200sk+. 
pJQ200sk+ and wblK1 digests were purified by gel extraction (section 2.10) to remove 
the restriction reaction components prior to ligation. The ligation reaction is described 
in section 2.25.4. This created the first construct in the mutagenesis strategy called 
pMF2.0 B/P which is shown in figure 5.12.  
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Figure 5.12 The construction of pMF2.0 B/P 
pMF2.0 B/P was constructed by ligation of BamHI/PstI restricted wblK1 and pJQ200sk+. wblK1 
contains the 5′ region of the wblK gene. 
 
Electrocompetent E. coli XL1-Blue cells were prepared (section 2.11.1) and 
transformed using electroporation (section 2.11.2) with the clone pMF2.0 B/P then 
grown on agar containing gentamicin to select for transformants. Plasmid DNA from 
twelve transformants was prepared using the 1, 2, 3 method (section 2.7) to confirm that 
they contained the wblK1 insert. The results are shown in figure 5.13. 
 
Ori T 
Ori V 
traJ 
sacB 
GmR 
wblK 
Ori T 
Ori V 
traJ 
sacB 
GmR 
Cut pJQ200sk+ and wblK1 with 
BamHI and PstI and ligate 
wblK 
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Figure 5.13 Plasmid DNA prepared from E. coli XL1-Blue cells transformed with pMF2.0 B/P 
Plasmid DNA was prepared using the 1, 2, 3 method described in section 2.7. The DNA samples were 
separated on a 0.7% agarose gel and stained with ethidium bromide. Lane 1 = Invitrogen 1 kb ladder, lane 
2 = pJQ200sk+ empty vector and lanes 3 – 14 = transformants 1 – 12.  
 
In figure 5.13 CCC and OC plasmid DNA is visible in lanes 3-14. Lane 2 contains 
pJQ200sk+ plasmid DNA and only the CCC form is visible. By comparing the sizes of 
the DNA bands obtained for the transformants to the empty vector it may be deduced 
that transformants 1 (lane 3), 6 (lane 8) and 9 (lane 11) do not contain the wblK1 insert 
as their CCC DNA form is migrating to the same region of the gel as the empty vector 
in lane 1. Transformants 2-5, 7, 8 and 10-12 do contain the wblK1 insert. Their plasmid 
DNA is larger than the empty vector. Nine of the twelve transformants appeared to have 
the correct wblK1 insert. This was confirmed by restriction analysis. Transformant four 
was digested with BamHI and PstI. The results are shown in figure 5.14. 
 1    2     3     4    5     6    7    8     9   10   11  12  13  14 
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Figure 5.14 BamHI / PstI restriction digest of the plasmid pMF2.0 B/P to confirm that it contained 
the wblK1 insert 
Restriction analysis was carried out and DNA fragments were separated on an agarose gel and stained 
with ethidium bromide. Lane 1 = Invitrogen 1 kb ladder, lane 2 = uncut pMF2.0 B/P, lane 3 = pMF2.0 
B/P cut with BamHI only, lane 4 = pMF2.0 B/P cut with PstI only and lane 5 = pMF2.0 B/P cut with 
BamHI and PstI.  
 
The CCC form of uncut pMF2.0 B/P is showing up strongly in lane 2. When cut with 
BamHI only (lane 3) and PstI only (lane 4) pMF2.0 B/P is linearised as there is only one 
restriction site in the plasmid for each of these enzymes. The linearised pMF2.0 B/P 
appears at the expected size of ~7.5 kb. When pMF2.0 B/P is cut with BamHI and PstI, 
two fragments are seen, one at 2 kb (the wblK1 insert) and one at ~5.5 kb. The 
restriction analysis shown in figure 5.14 confirms that the pMF2.0 B/P clone does 
contain wblK1. This was further confirmed by carrying out a PCR on pMF2.0 B/P using 
the primers wblK_F1 and wblK_R1. The PCR yielded a 2 kb fragment, the wblK1 
insert (results not shown). 
 
Because directional cloning was used it was expected that the insert wblK1 should have 
ligated to pJQ200sk+ in the desired orientation. In order to confirm this, restriction 
analysis using the enzyme BglII was carried out. It can be seen from figure 5.12 that 
pJQ200sk+ contains one BglII site and wblK1 also contains one BglII site. Restriction 
of pMF2.0 B/P with this enzyme should therefore cut the plasmid twice yielding two 
fragments of 1211 bp and 6193 bp if the insert is in the correct orientation. Figure 5.15 
shows the result of the restriction analysis. 
 
 
8 kb 
7 kb 
 
6 kb 
 
5 kb 
 
 
4 kb 
 
3 kb 
 
2 kb 
  1        2        3         4        5 
 174 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 BglII restriction digest of pMF2.0 B/P to confirm orientation of wblK1 
DNA fragments generated from the restriction analysis using BglII were visualised on an agarose gel that 
had been stained with ethidium bromide. Lane 1 = Invitrogen 1 kb DNA ladder, lane 2 = uncut pMF2.0 
B/P, lane 3 = pMF2.0 B/P cut with BglII and lane 4 = pJQ200sk+ cut with BglII.  
 
pMF2.0 B/P cut with BglII yielded two fragments of ~1.2 kb and 6.2 kb in size (lane 3). 
These were the sizes expected if the fragment was in the correct orientation. BglII cuts 
pJQ200sk+ only once as expected giving a linear fragment of 5.5 kb in size (lane 4). 
 
The next step in the mutagenesis strategy was the construction of the second construct, 
pMF2.1 P/X. Plasmid DNA from pMF2.0 B/P and the purified PCR product wblK2, 
containing the 3′ region of the wblK gene were restricted with the enzymes PstI and 
XhoI. The digests were gel extracted as before and ligated together to create pMF2.1 
P/X as shown in figure 5.16. 
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Figure 5.16 The construction of pMF2.1 P/X 
pMF2.1 P/X was constructed by ligation of PstI/XhoI restricted wblK2 and pMF2.0 B/P. wblK2 contains 
the 3′ region of the wblK gene. 
 
Electrocompetent E. coli XL1-Blue cells were transformed with the clone pMF2.1 P/X 
using electroporation and transformants were visible following overnight incubation on 
LB agar containing gentamicin. Plasmid DNA from eight transformants was prepared 
using the 1, 2, 3 method to confirm if they contained the wblK2 insert. The results are 
shown in figure 5.17. 
Ori T Ori V 
traJ 
sacB 
GmR 
wblK 
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Ori V traJ 
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GmR 
wblK 
Cut pMF2.0 B/P and wblK2 
with PstI and XhoI and ligate 
wblK 
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Figure 5.17 Plasmid DNA prepared from E. coli XL1-Blue cells transformed with pMF2.1 P/X 
Plasmid DNA was prepared using the 1, 2, 3 method and separated on an agarose gel. DNA was 
visualised on a UV transilluminator following staining with ethidium bromide. Lane 1 = Invitrogen 1 kb 
DNA ladder, lanes 2 – 9 = Transformants 1 – 8, lane 10 = pMF2.0 B/P.  
 
From figure 5.17 it can be deduced that transformants 5 (lane 6) and 8 (lane 10) do not 
contain the wblK2 insert as their CCC DNA form is migrating to the same region of the 
gel as pMF2.0 B/P in lane 10. Transformants 1 – 4, 6 and 7 do contain the wblK2 insert. 
Their DNA is larger than that obtained for pMF2.0 B/P.  
 
One of the transformants was chosen for restriction analysis to confirm that wblK2 was 
present and that it was in the correct orientation. Again, directional cloning was used so 
it is expected that wblK2 should have ligated to pMF2.0 B/P in the desired direction. 
SacI and BglII restriction digests were carried out. pMF2.0 B/P was also digested as a 
control. The results of the restriction analysis are shown in figure 5.18. 
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Figure 5.18 SacI and BglII restriction digests of the plasmid pMF2.1 P/X to confirm the presence 
and orientation of wblK2 in the plasmid 
DNA fragments generated from the restriction analysis using SacI and BglII were separated on an agarose 
gel and visualised after staining with ethidium bromide. Lane 1 = Invitrogen 1 kb DNA ladder, lane 2 = 
uncut pMF2.0 B/P, lane 3 = pMF2.0 B/P cut with SacI, lane 4 = pMF2.0 B/P cut with BglII, lane 5 = 
uncut pMF2.1 P/X, lane 6 = pMF2.1 P/X cut with SacI (partial digestion), lane 7 = pMF2.1 P/X cut with 
BglII. 
 
SacI cuts pMF2.0 B/P only once to yield a linear fragment of DNA with a size of 7.5 kb 
(lane 2). pMF2.0 B/P contains two BglII restriction sites and is cut twice to yield 
fragments of the expected sizes of 6.5 kb and 1.2 kb. The insertion of wblK2 introduces 
one extra SacI site and two extra BglII sites. In lane 6, four bands are visible. The bands 
migrating at 7.5 kb and 2 kb are the SacI digestion fragments. However incomplete 
digestion occurred and bands containing unrestricted OC and CCC pMF2.1 P/X DNA 
are also still visible. In lane 7 three fragments are visible. BglII cuts pMF2.1 P/X four 
times but one of these fragments is only 314 bp in size and so is not visible on this gel. 
The other three fragments are at 1.2 kb, 2.7 kb and 5.2 kb and these are the expected 
size. 
 
This restriction analysis confirms that the wblK2 insert is present in pMF2.1 P/X and is 
in the correct orientation because restriction sites for SacI and BglII lie inside the insert 
and following digestion the correct sized fragments were obtained.  
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A final confirmation was carried out on pMF2.1 P/X. The primers that were used to 
initially amplify wblK2 were used in a PCR with pMF2.1 P/X DNA as the template 
(figure 5.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 PCR products generated from the amplification of the wblK gene 
A PCR reaction was carried out to confirm that the complete wblK gene was present in pMF2.1 P/X. PCR 
DNA was run on an agarose gel, stained with ethidium bromide and visualised. Lane 1 = Invitrogen 1 kb 
DNA ladder, lane 2 = PCR on pMF2.1 P/X, lane 3 = PCR on P. luminescens genomic DNA (positive 
control), lane 4 = PCR on pMF2.0 B/P (negative control).  
 
The PCR produced a 2 kb DNA fragment for pMF2.1 P/X DNA (lane 2) and P. 
luminescens genomic DNA (lane 3), which was used as a positive control. No PCR 
product was formed using pMF2.0 B/P as template DNA (lane 4) because the wblK2 
insert is not present. 
 
The restriction analysis and PCR results confirmed conclusively that pMF2.1 P/X 
contains wblK2. This construct now contained the entire wblK gene. The next step in 
the mutagenesis process was to mutate this gene by insertional inactivation with a KanR 
cassette. The KanR cassette was isolated from the pUK4K vector (figure 2.3, Amersham 
Pharmacia) by restriction with PstI as shown in figure 5.20. 
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Figure 5.20 Schematic representation of how the kanamycin resistance cassette was isolated from 
the pUK4K plasmid 
PstI was used to isolate the KanR cassette (1240 bp) which contained the kanR gene (brown). The kanR 
gene contains an XhoI site near its 5′ end. 
 
pMF2.1 P/X was restricted with PstI. The pMF2.1 P/X digestion and the isolated KanR 
cassette were purified by gel extraction and ligated together to yield the final construct 
for the mutagenesis of wblK, pMF2.2 P, as shown in figure 5.21. 
Cut with PstI 
AmpR 
KanR 
kanR
 180 
 
 
Figure 5.21 The construction of pMF2.2 P 
pMF2.1 P/X was cut with PstI to generate cohesive ends so that the KanR cassette could be ligated to it. 
The KanR cassette interrupts the wblK gene (green). The kanR gene (brown) is in the opposite orientation 
to wblK to ensure that transcriptional read-through does not occur. 
 
pMF2.2 P was transformed into chemically competent E. coli XL10-Gold cells (section 
2.11.4) and transformants were selected as before and screened for the correct insert. 
Transformants are shown in figure 5.22. 
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cassette with PstI and ligate 
Ori T Ori V 
traJ 
sacB 
GmR 
wblK 
wblK 
Ori T Ori V traJ 
sacB 
GmR 
kanR 
 181 
 
Figure 5.22 Plasmid DNA prepared from E. coli XL10-Gold cells transformed with pMF2.2 P 
Plasmid DNA was prepared using the 1, 2, 3 method described in section 2.7. The DNA samples were 
separated on an agarose gel and DNA was stained using ethidium bromide. Lanes 1, 15 = Invitrogen 1 kb 
DNA ladder, lanes 2 – 13 = transformants 1-12, lane 14 = pMF2.1 X/P.  
 
By comparing the sizes of the DNA fragments obtained for the transformants to the size 
of pMF2.1 P/X, it appears that all transformants contain an insert. Transformants 1-4, 7, 
8 and 11 have the correct insert. Transformants 5, 6, 9, 10 and 12 have more than one 
insert. 
 
In the case of pMF2.2 P it is very important to confirm the orientation of the kanR gene 
as the KanR cassette may ligate to pMF2.1 P/X in either orientation. The XhoI site in the 
kanR gene was used to confirm the orientation as shown in figure 5.23. Restriction 
analysis was also carried out on pJQ200sk+ DNA as a control. 
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Figure 5.23 XhoI restriction digest of the plasmid pMF2.2 P to confirm that it contained the KanR 
cassette in the correct orientation 
Following restriction analysis, DNA fragments were visualised by separating them on a 0.7% agarose gel 
and staining them with ethidium bromide. Lane 1 = Invitrogen 1 kb DNA ladder, lane 2 = uncut 
pJQ200sk+, lane 3 = pJQ200sk+ digested with XhoI, lane 4 = uncut pMF2.2 P, lane 5 = pMF2.2 P 
digested with XhoI.  
 
XhoI cuts pJQ200sk+ once yielding a linear DNA fragment of 5.5 kb in size (lane 3). 
XhoI cuts pMF2.2 P twice, once inside the kanR gene, yielding two fragments of 8.5 kb 
and 2.2 kb in size (lane 5). These are the expected sizes and thus confirm that the 
orientation of the KanR cassette is correct. 
 
The final construct pMF2.2 P contained the wblK gene interrupted by kanR in the 
opposite orientation. This plasmid was used to introduce the mutation into P. 
luminescens. The plasmid was introduced into P. luminescens by tri-parental mating. 
Transconjugates were selected by growing on LB agar containing rifampicin and 
kanamycin (section 2.4).  
 
Homologous recombination occurred as described in section 5.2. One transconjugate 
colony was chosen and used to test for 2nd recombinants. The colony was grown in LB 
broth containing kanamycin. The following day, serial dilutions were performed on the 
culture and the dilutions were plated on media containing 5% sucrose and kanamycin. 
Any colonies that grew on these plates did not contain the sacB gene and so were able 
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to survive in the presence of sucrose. This meant that they were 2nd recombinants 
because the sacB gene had been excised from the chromosomal DNA.  
 
As a final test, any colonies that grew on sucrose media were transferred to replica 
plates. One plate contained kanamycin and the other contained gentamicin. The 
gentamicin resistance gene should also be excised in 2nd recombinants and so the 
colonies should grow on the plates containing kanamycin and not on the ones 
containing gentamicin. Ten colonies were chosen for replica plating and all ten grew in 
the presence of kanamycin and not gentamicin.  
 
Genomic DNA was prepared from the P. luminescens wblK mutant strain (section 2.6). 
Two separate PCRs were carried out using P. luminescens wildtype DNA and P. 
luminescens wblK mutant DNA as templates. The primers wblK_F1 and wblK_R2 were 
used in the reactions. wblK_F1 was the forward primer initially used to amplify the 
wblK1 fragment and wblK_R2 was the reverse primer used to amplify the wblK2 
fragment. Using these primers together should amplify the entire 4080 base region of 
DNA in the wildtype strain containing the complete wblK gene. In the mutant strain the 
wblK gene is interrupted with the KanR cassette and so the size of the PCR product 
should be 5320 bases. The results of the PCRs are shown in figure 5.24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24 PCR products generated from the amplification of the entire wblK fragment from P. 
luminescens wildtype genomic DNA and P. luminescens wblK mutant genomic DNA 
PCR products were separated on an agarose gel and visualised after ethidium bromide staining. Lane 1 = 
Invitrogen 1 kb DNA Ladder, lane 2 = wildtype PCR, lane 3 = wblK mutant PCR.  
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The size of the PCR fragment obtained for the wildtype (lane 2) is just over 4 kb and for 
the wblK mutant (lane 3) it is ~5.5 kb. The size of the KanR cassette is 1240 bp. This 
PCR analysis confirms unequivocally that in the strain P. luminescens wblK mutant, the 
wblK gene has been interrupted with a kanamycin resistance cassette. 
 
5.4 Analysis of glycoproteins from P. luminescens wblK mutant 
 
Once the P. luminescens wblK mutant was prepared, the next step was to analyse the 
mutant to examine how this mutation affects the glycan patterns of the glycoproteins 
produced by the organism.  
 
A 50 ml culture of P. luminescens wblK mutant was prepared as described in section 
2.5.1. Periplasmic, cytoplasmic and membrane proteins were isolated as before using 
the water lysis method (section 2.15). In order to examine the glycoproteins being 
produced by the wblK mutant similar methods were employed that had previously been 
used to analyse glycoproteins from the wildtype strain i.e. lectins were utilised in 
ELLAs, western blots and bound to agarose resins to detect and isolate glycoproteins. 
The anti-P.l. polyclonal antibody that had been prepared against whole cells of the P. 
luminescens wildtype strain (section 2.21) was also used to detect differences between 
the two strains. 
 
Initially a number of ELLAs were carried out to profile the interactions between the 
periplasmic, cytoplasmic and membrane proteins from both strains with a range of 
lectins (table 3.2). Proteins prepared from both the wildtype strain and the mutant strain 
were adjusted to the same concentration and used in the same experiment so that the 
results could be accurately compared. The results from this experiment were very 
similar to those in figure 3.5 and there was no significant difference seen between the 
two strains with regard to the intensity of the signal generated with each lectin (results 
not shown). 
 
Next western blots were carried out to compare the band pattern generated by proteins 
from the two strains when probed with the lectin SBA or anti-P.l. antibody. SBA was 
chosen as it gave a very strong response previously with P. luminescens proteins. 
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(WGA was not chosen as it tends to cause very high background staining and so does 
not work well in western blots). The anti-P.l. antibody was prepared against wildtype 
whole cells. The generated antibody would be specific for antigens from the surface of 
the cell including glycans on glycoproteins. If the wblK mutation affected the 
glycosylation of any surface proteins then this could affect the binding of the antibody 
to them. Figure 5.25 shows the result of the western blot analysis. 
 
 
Figure 5.25 Western blot analysis showing interactions between P. luminescens wildtype and wblK 
mutant protein fractions with anti-P.l. antibody (a) and SBA lectin (b) 
Lane 1 = NEB prestained protein marker, lane 2 = wildtype periplasmic proteins, lane 3 = wildtype 
cytoplasmic proteins, lane 4 = wildtype membrane proteins, lane 5 = wblK mutant periplasmic proteins, 
lane 6 = wblK mutant cytoplasmic proteins, lane 7 = wblK mutant membrane proteins.  
 
In figure 5.25 there were no significant differences detected in the band pattern between 
the wildtype and mutant strains on the anti-P.l. blot. However, on the SBA blot when 
the membrane proteins are compared for both strains, bands are visible at ~17 kDa in 
the wildtype (figure 5.25 (b), lane 4) that are not as clear in the mutant (figure 5.25 (b), 
lane 7). On the original blot there are some small proteins showing up in lane 7 (b) at 
~17 kDa that did not show up well when the blot was scanned. Therefore, from this blot 
it is not possible to conclude if protein glycosylation may have been affected by the 
mutation in wblK. For the initial ELLA and western blot analysis described above, 
crude periplasmic, cytoplasmic and membrane proteins were used.  If the wblK 
mutation is having any effect on the glycoproteins produced by the organism it was not 
immediately obvious when looking at the large mix of total proteins produced by P. 
luminescens. Because so many proteins are produced by the organism, the bands seen in 
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figure 5.25 could contain not just one but several proteins of the same molecular weight 
and so any differences in the band pattern may be hidden. In order to make the analysis 
simpler and get a more detailed look at glycoproteins specifically, LAC was used to 
isolate glycoproteins from the other proteins in the cell. 
 
5.4.1 Isolation of glycoproteins from P. luminescens wblK mutant periplasmic 
proteins using LAC 
 
LAC was carried out using WGA resin as before and periplasmic proteins were again 
used because they produced the protein profiles that were observed as being least 
complex. Samples from the crude proteins (periplasmic proteins before separation on 
the column), unbound proteins and eluted proteins were run on an SDS-PAGE gel and 
stained with silver stain (figure 5.26 (a)). A western blot was also carried out with these 
samples which was probed with anti-P.l. antibody (figure 5.26 (b)). 
 
Figure 5.26 P. luminescens wildtype and wblK mutant WGA LAC periplasmic protein fractions 
separated on a 15% SDS-PAGE gel (a) and on a western blot probed with anti-P.l. antibody (b) 
Lane 1 = NEB protein marker, lane 2 = crude wildtype periplasmic proteins, lane 3 = crude wblK mutant 
periplasmic proteins, lane 4 = unbound wildtype periplasmic proteins, lane 5 = unbound wblK mutant 
periplasmic proteins, lane 6 = eluted wildtype periplasmic proteins, lane 7 = eluted wblK mutant 
periplasmic proteins. Blue arrows indicate proteins that were isolated from the wblK mutant that were not 
present in the wildtype strain. 
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Many interesting observations may be made about the images in figure 5.27. Firstly, in 
the silver stained gel (a) there is a new band showing up in lane 3 (crude wblK mutant 
periplasmic proteins) at 34 kDa that is not visible in the wildtype (lane 2). There is also 
a band in lane 2 at ~40 kDa that appears to be absent in lane 3, although it is difficult to 
tell because of overlapping bands. It is possible that these bands are the same proteins 
and that mutating wblK could have altered the molecular weight of the protein from 40 
kDa to 34 kDa if its glycosylation was altered. Neither of these proteins bound to WGA 
and are both clearly visible in the unbound fractions (lanes 4 and 5).  
 
There is another band in lane 2 (a) at ~25 kDa that is not showing up in the mutant 
strain. Again this protein does not bind to WGA and is visible in the unbound fraction in 
lane 4. In the anti-P.l. blot there is a band visible just below the 25 kDa marker in lane 2 
that is absent in lane 3. This could be the same protein that is seen in the silver stained 
gel. The fact that this protein is absent in the anti-P.l. blot in the mutant strain suggests 
that it may have been altered in some way by the mutation. 
 
The most interesting difference between the two strains is seen when the eluted protein 
samples are compared (lanes 6 and 7). In the silver stained gel two new proteins are 
showing up at 30 kDa and 23 kDa (blue arrows) in the wblK mutant compared to the 
wildtype. The protein at 30 kDa is particularly strong. These new bands do not appear in 
the anti-P.l. blot. A number of possible scenarios could exist to explain the appearance 
of these new bands and the most likely scenario will now be explained. WGA binds 
terminal GlcNAc. WblK could be responsible for adding a further sugar moiety onto the 
glycan chain so that in the normal wildtype GlcNAc is not the terminating sugar and so 
it does not bind to WGA. However, when WblK is absent in the mutant, the glycan is 
not elongated any further and terminates with GlcNAc. 
 
One final observation to make about figure 5.27 is that the glycosylation of the protein 
identified as OmpN (chapter 4) has not been affected by the mutation of wblK. The 
band is showing up in both the wildtype and mutant strain at 40 kDa as before and is 
still able to bind to WGA in the mutant. This means that either WblK is not needed for 
the glycosylation of OmpN or perhaps OmpN is glycosylated by a completely different 
pathway altogether. Many instances of multiple glycosylation pathways in the same 
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bacterium have been discovered already (chapter 1) so there is no reason to believe that 
P. luminescens does not have more than one protein glycosylation system. 
 
In order to get a more detailed insight into the proteins eluted from the WGA resin in 
both the wildtype and mutant strain the proteins were run on a 2-D gel for better 
separation as shown in figure 5.27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.27 P. luminescens wildtype (a) and wblK mutant (b) periplasmic proteins eluted from 
WGA agarose and separated on a 2-dimensional gel 
Periplasmic proteins from P. luminescens wildtype and wblK mutant strains that bound to WGA in a LAC 
column, were eluted from the column and separated on 2-dimensional gels, which were subsequently 
stained with silver stain. 30 kDa proteins that are visible in the mutant and not the wildtype are 
highlighted by a red box. Proteins with a molecular mass of ~23 kDa that are visible in the mutant and not 
the wildtype are highlighted by blue arrows. 
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It can be seen from figure 5.27 that the 30 kDa band that appeared in the wblK mutant 
eluted proteins (figure 5.26, lane 7) that was not present in the wildtype (figure 5.26, 
lane 6) actually consists of four proteins with almost identical molecular weights but 
different pI values. These spots are highlighted by a red box in figure 5.27 (b). These 
spots are not visible in figure 5.27 (a). The 23 kDa band highlighted in figure 5.26, lane 
7, also seems to be made up of two proteins with very different pI values. These spots 
are highlighted by blue arrows in figure 5.27 (b) and again, these proteins are not seen 
in figure 5.27 (a). 
 
The proteins highlighted in the red box in figure 5.27 (b) could be the same protein with 
slightly different glycosylation patterns which would give them different pI values. In 
other words they could be glycoforms. In order to investigate this two of the spots, the 
first spot at pI 5.5 and the third spot at pI 6.1 were chosen for identification. 
 
5.4.2 Identification of the isolated 30 kDa glycoprotein from the periplasm of P. 
luminescens wblK mutant using peptide mass fingerprinting 
 
In order to deduce if the 30 kDa proteins highlighted in figure 5.28 (b) were different 
proteins or different glycoforms of the same protein, two of the protein spots were 
chosen for identification using PMF. The proteins were sent to the company Alphalyse 
for identification. The method used for the generation of peptides was similar to that 
outlined in section 2.25.5. MALDI-MS using a Bruker Autoflex III MALDI TOF/TOF 
instrument in positive ion mode was employed to analyse the digested protein. The first 
sample was called WM1 and the second sample was called WM2. The MALDI spectra 
generated for WM1 and WM2 are shown in figure 5.28. 
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Figure 5.28 Mass spectra generated from the trypsin digestion of WM1 (a) and WM2 (b), 30 kDa 
proteins isolated from the periplasm of P. luminescens wblK mutant by WGA LAC 
Peptides were analysed using a Bruker Autoflex III MALDI TOF/TOF mass spectrometer.  
 
It can be seen from analysing the spectra from both protein samples that they are almost 
identical suggesting that the samples contain the same protein. The company also chose 
four peptides from each sample for fragmentation analysis i.e. partial sequencing using 
MALDI MS/MS. The data from this analysis as well as the data from the MS spectra 
(figure 5.28) were combined and used for database searching using the MASCOT 
software. The data was searched against in-house protein databases containing over 12 
million known non-redundant protein sequences. The results from this analysis 
identified both samples to be the same protein. The protein was identified as plu3611, a 
hypothetical protein. The MASCOT score obtained for WM1 was 211 and for WM2 
was 303, values that are far above the threshold of 78 for a significant match. Tables 5.2 
and 5.3 show the peptides generated from the digestion of the WM1 and WM2 samples 
that matched to the sequence of plu3611. Those in bold were sequenced using MS/MS. 
(a) 
(b) 
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Figures 5.29 and 5.30 show the sequence of plu3611 and the peptides from the digested 
WM1 and WM2 samples that matched to it. 
 
Table 5.2 Peptides generated from the digestion of WM1 (from figure 5.28 (a)) 
that matched to the sequence of plu3611 
Residue Observed 
mass (Da) 
Expected 
Mr (Da) 
Calculated 
Mr (Da) 
Delta Miss Sequence 
       
73 - 78 832.43 831.42 831.42 0.00 0 K.YFDFLK.N 
73 - 84 1510.77 1509.76 1509.76 0.00 1 K.YFDFLKNHGIEK.K 
85 - 93 1015.56 1014.55 1014.55 0.00 1 K.KDIDAANLR.T 
86 - 93 887.49 886.48 886.45 +0.03 0 K.DIDAANLR.T 
94 - 106 1515.66 1514.66 1514.65 +0.01 0 R.TQPDYEYDNVSGK.S 
124 - 137 1555.87 1554.86 1554.86 0.00 1 R.KLDQLNDLLDGALK.A 
183 - 192 1171.63 1170.62 1170.60 +0.02 0 K.VGSIYSINYR.A 
193 - 201 1055.52 1054.52 1054.51 +0.01 0 R.APEVIDHMK.Y 
Oxidation (M) 
193 - 203 1358.70 1357.69 1357.68 +0.01 1 R.APEVIDHMKYR.N 
193 - 203 1374.69 1373.69 1373.68 +0.01 1 R.APEVIDHMKYR.N 
Oxidation (M) 
 
  1 MKLKSLGLAA MLSAGVPLAA QAADLPGVPH VITSGNAVVK AEPDIATLLI 
 51 NVNIAAKDAS GAKKQVDELV AKYFDFLKNH GIEKKDIDAA NLRTQPDYEY 
101 DNVSGKSVLK GYRAIRSVEV KVRKLDQLND LLDGALKAGL NEIVSVQFGV 
151 DNPQKYRDEA RQKAIENAIE QAGALAKGFN SKVGSIYSIN YRAPEVIDHM 
201 KYRNTDVMMS GGAAAGVGET YQQDSINFSD QVDVVFELKP 
 
Figure 5.29 The sequence of plu3611, a hypothetical protein from P. luminescens 
The peptides that were generated from the digestion of WM1 that matched to the sequence of plu3611 are 
shown in bold red. The percentage sequence coverage was 28%. 
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Table 5.3 Peptides generated from the digestion of WM2 (from figure 5.28 (b)) 
that matched to the sequence of plu3611 
Residue Observed 
mass (Da) 
Expected 
Mr (Da) 
Calculated 
Mr (Da) 
Delta Miss Sequence 
       
64 - 72 1029.56 1028.55 1028.59 -0.04 1 K.KQVDELVAK.Y 
73 - 78 832.39 831.39 831.42 -0.03 0 K.YFDFLK.N 
73 - 84 1510.74 1509.73 1509.76 -0.03 1 K.YFDFLKNHGIEK.K 
85 - 93 1015.51 1014.51 1014.55 -0.04 1 K.KDIDAANLR.T 
86 - 93 887.44 886.43 886.45 -0.02 0 K.DIDAANLR.T 
94 - 106 1515.63 1514.62 1514.65 -0.03 0 R.TQPDYEYDNVSGK.S 
94 - 110 1942.90 1941.89 1941.93 -0.04 1 R.TQPDYEYDNVSGKSVLK.G 
107 - 113 822.47 821.46 821.48 -0.02 1 K.SVLKGYR.A 
124 - 137 1555.84 1554.83 1554.86 -0.03 1 R.KLDQLNDLLDGALK.A 
183 - 192 1171.58 1170.57 1170.60 -0.03 0 K.VGSIYSINYR.A 
193 - 201 1039.47 1038.46 1038.52 -0.06 0 R.APEVIDHMK.Y 
193 - 201 1055.48 1054.48 1054.51 -0.03 0 R.APEVIDHMK.Y 
Oxidation (M) 
193 - 203 1358.67 1357.66 1357.68 -0.02 1 R.APEVIDHMKYR.N 
193 - 203 1374.66 1373.65 1373.68 -0.03 1 R.APEVIDHMKYR.N 
Oxidation (M) 
 
  1 MKLKSLGLAA MLSAGVPLAA QAADLPGVPH VITSGNAVVK AEPDIATLLI  
 51 NVNIAAKDAS GAKKQVDELV AKYFDFLKNH GIEKKDIDAA NLRTQPDYEY  
101 DNVSGKSVLK GYRAIRSVEV KVRKLDQLND LLDGALKAGL NEIVSVQFGV  
151 DNPQKYRDEA RQKAIENAIE QAGALAKGFN SKVGSIYSIN YRAPEVIDHM  
201 KYRNTDVMMS GGAAAGVGET YQQDSINFSD QVDVVFELKP  
 
Figure 5.30 The sequence of plu3611, a hypothetical protein from P. luminescens 
The peptides that were generated from the digestion of WM2 that matched to the sequence of plu3611 are 
shown in bold red. The percentage sequence coverage was 35%. 
 
It can be seen from the above data that both digested samples matched very well to 
plu3611. The percentage sequence coverage obtained for the WM2 sample was a little 
higher than for WM1 probably because the protein spot that contained WM2 was much 
bigger than WM1 and so would have had a higher concentration of sample. 
 
plu3611 is a hypothetical protein. Cellular roles have been assigned to this protein by 
the JCVI. It is stated as being involved in electron transport, ribosomal protein synthesis 
and to have other regulatory functions.  
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The BlastP program (NCBI, section 2.12) was used to search for other proteins 
homologous to plu3611. The search returned many matches that were very similar to 
plu3611. The closest matches were seen in P. asymbiotica, Xenorhabdus spp. and 
Yersinia spp. However all of the matches to plu3611 came back as hypothetical proteins 
or proteins of unknown function or uncharacterised proteins so orthologues to plu3611 
have not been well studied in any organism. 
 
Searches were also carried out to identify conserved domains in this protein. plu3611 
was found to have a conserved domain from oxidative stress defence proteins. It also 
contains two other conserved domains that have not been characterised. All three 
conserved domains are found in proteins from the SIMPL superfamily. Members from 
this superfamily have so far only been well studied in mice. 
 
Although nothing is known about the function of the protein plu3611, this study shows 
that the protein is most likely glycosylated. Aberrant glycosylation of plu3611 was 
caused by mutating the wblK gene suggesting that the WblK protein (or WblF/WblM or 
all three proteins) is involved in normal glycosylation of this protein. Also, at least two 
different glycoforms exist in the wblK mutant as the two spots from figure 5.28 that 
were identified had different pI values. The calculated pI of the protein backbone of 
plu3611 is 5.97. On the 2-D gel WM1 and WM2 were shown to have pIs of 5.5 and 6.1. 
Also the molecular weight of the protein backbone is 25893 Da. The protein appears to 
have a molecular weight of ~30 kDa on a protein gel. The significant difference 
between the calculated and observed molecular weights may be accounted for by 
glycosylation. No other post translational modification could cause a difference of ~4 
kDa in size. The work presented here also shows that it is likely that more than one 
glycosylation system could exist in P. luminescens since the mutation of wblK did not 
seem to alter the glycosylation of OmpN.   
 
5.4.3 O-deglycosylation of glycoproteins from the periplasm of P. luminescens 
wildtype and wblK mutant strains 
 
Proteins isolated from the periplasm of the two P. luminescens strains using LAC were 
treated with β-elimination reagent in order to remove any O-linked glycans. The 
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procedure for O-deglycosylation is found in section 2.26. Untreated and treated proteins 
were analysed by ELLA analysis to see if they still bound to the lectin WGA, which 
was initially used to isolate them. The results of the ELLA analysis are shown in figure 
5.31. 
 
 
Figure 5.31 ELLA profiling interactions between O-deglycosylated P. luminescens wildtype (a) and 
wblK mutant (b) periplasmic proteins eluted from a WGA LAC column with the lectin WGA 
Green bars represent proteins eluted from the WGA LAC column that were not treated with β-elimination 
reagent (crude sample). The light blue bars represent proteins that were O-deglycosylated (β-Elimination 
+). A control reaction was done where all of the steps of the β-elimination reaction were carried out 
except that dH2O was used instead of β-elimination reagent (yellow bars, β-Elimination -).   
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It can be seen from the results shown in figure 5.31 that in both wildtype and wblK 
mutant samples, treatment with β-elimination reagent dramatically reduced the signal 
produced with the lectin WGA. These data provide strong evidence that most of the 
proteins isolated from the periplasm of P. luminescens using WGA LAC are O-
glycosylated. Treatment with β-elimination reduced the ELLA signal generated with 
WGA almost down to baseline levels. In chapter 3, β-elimination was carried out on 
crude periplasmic, cytoplasmic and membrane proteins isolated from P. luminescens 
wildtype. It was also shown to significantly reduce the binding of the lectin WGA to 
proteins in each of the fractions (figure 3.22). Although some of the proteins produced 
by P. luminescens may be N-glycosylated it appears so far that O-linked glycosylation 
prevails, however, this requires further investigation. 
 Chapter 6 
Concluding remarks 
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Interest in the area of bacterial glycoproteomics has increased significantly in the past 
twenty years especially since the breakthrough discovery of the N-linked general protein 
glycosylation pathway in C. jejuni in 2002 (Young et al. 2002). The types of bacterial 
glycans that have been discovered are very varied and complex in terms of the 
monosaccharide units that they consist of and the linkages between them. Many unusual 
monosaccharides have been found in bacterial systems that are not present in eukaryotic 
glycoproteins. It also appears that different bacterial organisms have evolved diverse 
glycosylation pathways, for example the stepwise N-linked glycosylation system seen in 
H. influenzae (Gross et al. 2008) and OT mediated O-linked glycosylation in Neisseria 
spp. (Faridmoayer et al. 2007) and P. aeruginosa (Smedley III et al. 2005). These types 
of glycosylation pathways have not been seen in any eukaryotic system. There is no 
doubt that what is known so far in the area of bacterial glycoproteomics is only the tip 
of the iceberg and there is much more that remains to be discovered.  
 
The focus of this research was to investigate protein glycosylation in the Gram-
negative, Gammaproteobacterium, P. luminescens. Analysis of the P. luminescens 
genome revealed genes encoding proteins homologous to Pgl proteins from C. jejuni 
involved in the general OT mediated N-linked protein glycosylation pathway (Linton et 
al. 2005) and Pgl proteins from N. meningitidis involved in the OT mediated O-linked 
protein glycosylation pathway (Power et al. 2003a). This information combined with 
knowledge about how adhesion and invasion play a crucial role in the life cycle of P. 
luminescens provided strong evidence to suggest that the organism does produce 
glycosylated proteins. 
 
Lectins (carbohydrate binding proteins) were employed to analyse the entire pool of 
proteins produced by P. luminescens for the presence of glycoproteins. Initial screening 
of extracellular proteins and proteins from the cytoplasm, periplasm and membrane of 
the bacterium with various lectins in ELLAs and western blots revealed that many 
proteins from each fraction were interacting with a range of lectins especially mannose, 
galactose, GalNAc and GlcNAc binding lectins. This was consistent with the types of 
glycans that had already been discovered in other bacterial glycoproteins. In order to 
validate the results obtained for P. luminescens similar experiments were carried out 
using C. jejuni proteins. The results obtained for the C. jejuni proteins were consistent 
with what was already presented previously in the literature (Linton et al. 2002).  
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Lectin affinity chromatography, using a range of agarose bound lectins, Con A, GSL I 
and WGA was used to isolate putative glycoproteins from the cytoplasm and periplasm 
of P. luminescens. The addition of free sugar, known to inhibit glycan-binding of the 
particular lectin, was used to elute putative glycoproteins from the resin. This strongly 
suggests that that the binding of putative glycoproteins from P. luminescens to lectins is 
occurring through glycan-protein interaction rather than protein-protein or other non-
specific interactions. Putative glycoproteins that were isolated in this way produced 
strong signals in western blots and ELLAs with the lectin that was used to isolate them 
initially, as well as with other lectins, suggesting that they are modified with more that 
one monosaccharide.  
 
Two putative glycoproteins that had been isolated from the periplasm of P. luminescens 
by LAC using WGA agarose were identified by mass spectrometry. Peptide mass 
fingerprinting was the technique employed to identify the proteins. Bands containing 
the two proteins were excised from an SDS-PAGE gel and digested into peptides using 
the enzyme trypsin and the masses of the generated peptides were found using MALDI-
MS. One putative glycoprotein was identified as plu3795, a hypothetical protein. No 
information was available about that protein and so it was not pursued any further. The 
second putative glycoprotein to be identified was an outer membrane porin, OmpN. The 
OmpN protein sample that had been digested with trypsin was also treated with the 
enzyme PNGaseF to remove any N-linked glycans and the sample was re-analysed by 
MALDI-MS. The PNGaseF treated sample contained no new peptides in its spectrum 
compared to the non-treated sample and so it was assumed that the glycosylation was 
not N-linked but possibly O-linked.  The glycosylation of many structural outer 
membrane proteins has been discussed in the literature however no instances were 
found where an outer membrane porin was shown to be glycosylated. 
 
In order to carry out further analysis of the OmpN protein, the ompN gene was cloned 
with a histidine tag, ligated to a broad host range plasmid and expressed in its natural 
background, P. luminescens. This enabled purification of OmpN using immobilised 
metal affinity chromatography. The plasmid containing the recombinant ompN gene 
was also transformed into E. coli and expressed in order to have a non-glycosylated 
form of the protein for comparison. Expression of OmpN in both E. coli and P. 
luminescens was found to be very low, however, a pure sample of OmpN was isolated 
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from both strains for analysis. Purified OmpN from P. luminescens retained its ability to 
bind WGA in LAC indicating that glycosylation of the recombinant protein was still 
occurring. OmpN purified from P. luminescens was also shown to bind WGA in an 
ELLA. It was also shown to bind the lectin GSL I. In contrast, OmpN purified from E. 
coli did not bind either of these lectins in an ELLA. The E. coli stain used does not 
contain the same glycosylation machinery as P. luminescens, therefore the only 
difference between the proteins produced in the two stains should be in how they are 
glycosylated. This fact and the results from the ELLA analysis of OmpN from both 
species strongly indicates that OmpN is glycosylated in P. luminescens. 
 
The glycosylation of the porin OmpN could possibly be significant in enabling P. 
luminescens carry out its life cycle. Following the sequencing of the genome of P. 
luminescens many genes encoding proteins that are likely to be involved in host 
colonisation and invasion of the insect were identified. These proteins include a number 
of adhesins, lectins and fimbrial genes (Duchaud et al. 2003). The mechanisms for how 
P. luminescens colonises the host and infects the insect are not entirely understood. 
Because OmpN is an outer membrane, surface exposed protein, it is possible that it 
could also play a role in colonisation and adhesion and that the glycosylation of this 
protein is aiding in these processes. The best way to discover if this is true would be to 
mutate the genes that are involved in glycosylating OmpN and carry out in vivo studies 
using the mutant organism to investigate if it is still capable of colonising the nematode 
and infecting the insect. 
 
As previously stated a number of genes encoding proteins homologous to genes 
involved in protein glycosylation in C. jejuni and N. meningitidis were identified in P. 
luminescens. One such gene, wblK, was mutated by insertional inactivation. From 
analysis of the genome of P. luminescens it appeared that wblK was part of an operon, 
with the genes wblF and wblM lying adjacent to it, with no gaps between the genes. 
Therefore it was anticipated that if wblK was knocked out, wblF and wblM would also 
be mutated. The wblK mutant was constructed and verified. Initial analysis of proteins 
isolated from the cytoplasm, periplasm and membrane of the wblK mutant showed no 
significant variations in the binding to a range of lectins in ELLAs compared to the 
wildtype. Proteins from the various cell fractions were also examined on a western blot 
and probed with anti-P.l. antibody, a polyclonal antibody raised against P. luminescens 
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wildtype whole cells. Again no changes in the protein band pattern were observed. 
However, when proteins from the wblK mutant periplasm were passed over a WGA 
LAC column and bound proteins were eluted with GlcNAc, two new proteins were 
visible on an SDS-PAGE gel in the eluted protein fraction compared to the wildtype. 
 
The eluted proteins from the wblK mutant were further separated using 2-D gel 
electrophoresis. It was found that the 30 kDa band that appeared on the 1-D gel actually 
comprised four different spots on the 2-D gel. It was proven that at least two of the 
spots consisted of the same protein as they were both identified to be the protein 
plu3611 using peptide mass fingerprinting. Plu3611 is a hypothetical protein with very 
little information available about it. The molecular weight of the protein backbone is 26 
kDa and the observed molecular weight on a protein gel is ~30 kDa. This large variation 
of molecular weight can be accounted for by glycosylation. The fact that at least two 
forms of the same protein with slight variations in their pI values were isolated through 
their binding to the lectin WGA suggests that these proteins are glycoforms of each 
other.  
 
The mutation of wblK caused a change in the glycosylation of plu3611 and at least one 
other protein with a molecular weight of ~23 kDa. These proteins were not isolated by 
WGA LAC in the wildtype strain. However, mutating wblK did not seem to alter the 
glycosylation of OmpN as this protein was still isolated from the periplasm of the wblK 
mutant. This suggests that OmpN is being glycosylated through a different 
glycosylation system. This is not unreasonable to imagine as many other bacteria have 
been shown to contain more than one protein glycosylation system. 
 
At present it appears more likely that proteins that are glycosylated in P. luminescens 
are modified with O-linked glycans rather than N-linked glycans. P. luminescens 
putative glycoproteins isolated by WGA LAC were treated with β-elimination reagent 
(an O-deglycosylation agent). The signal observed with the binding of WGA in an 
ELLA was dramatically reduced in treated samples compared to untreated samples. It is 
also more likely that the glycosylation is not OT mediated. No orthologues to known 
OT enzymes (PglB from C. jejuni, PglL from N. meningitidis, PilO from P. aeruginosa 
and HMW1C from H. influenzae) have been found in P. luminescens. 
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A number of interesting experiments could be carried out in order to continue forward 
from the work outlined in this thesis. For example, the protein plu3611, which was 
isolated from P. luminescens wblK mutant could be analysed further with respect to its 
glycan content and its function. Glycan analysis could be carried out using NMR 
spectroscopy and mass spectrometry. The function of plu3611 could be elucidated by 
knocking out the gene encoding plu3611 and analysing its phenotype. The gene could 
also be cloned and expressed and the protein purified. The purified protein could be 
analysed using two-hybrid screening or immunoprecipitation to discover protein-protein 
interactions.  
 
The wblK mutation could also be complemented to see if the phenotype is restored to 
that which is seen in the wildtype. This may be done by cloning the wblK gene and 
ligating it to a plasmid such as pBBR1MSC-5 and expressing it in P. luminescens wblK 
mutant. It could also be complemented with pglE from C. jejuni in order to ascertain if 
PglE could carry out the same function in P. luminescens as it does in C. jejuni. 
 
In vivo studies could be carried out to examine the effect of the wblK mutation on the 
life cycle and/or pathogenesis of P. luminescens. The organism can be injected directly 
into insect larva. Parameters such as numbers of bacteria and time taken for death of the 
insect to occur could be compared to the wildtype. Random mutagenesis could be used 
to find other glycosylation genes, for example those that may be involved in OmpN 
glycosylation. Again these mutants could be analysed using in vivo studies. 
 
Research in the area of bacterial glycoproteomics is now proving to be very important 
for the biopharmaceutical industry. As discussed in section 1.5, scientists are now 
looking to prokaryotes as new expression systems for glycoprotein therapeutics, 
because of the ease with which they can be grown, maintained and manipulated 
compared to eukaryotic organisms (Pandhal and Wright 2010). Any knowledge that can 
be gained about the components of a bacterial glycosylation system would be very 
useful and could open up the potential to undertake the production of biotherapeutics in 
bacteria, where effective glycosylation could be engineered (Langdon et al. 2009).  
 
Another reason for the interest in bacterial glycoproteomics is that it has been realised 
that glycoproteins can play a huge role in the pathogenicity of an organism. Knowledge 
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about the glycome of a pathogenic organism can be used to help prevent and treat 
infection from medically relevant pathogens. P. luminescens is not considered a human 
pathogen but its close relative P. asymbiotica is an opportunistic pathogen of humans 
(Gerrard et al. 2004). P. luminescens is also a promising natural insecticide (Blackburn 
et al. 2005), therefore knowledge of the mechanisms this organism uses to invade the 
insect could be valuable. Glycosylation may play a role in invasion by P. luminescens. 
 
In eukaryotes protein glycosylation is essential for the correct function of many 
proteins. Glycosylation can be essential for protein trafficking in eukaryotes and 
changes in the glycosylation pattern of some eukaryotic glycoproteins have been 
directly implicated in certain diseases (Taylor and Drickamer 2006, Varki 1999). While 
it is not likely that glycosylation is of equal relevance in prokaryotes, the discovery of 
glycosylation systems in bacteria is likely to open up new insights into how bacterial 
cells function. 
 203 
References 
 
1. Abu-Qarn, M., Eichler, J. and Sharon, N. 2008. Not just for Eukarya anymore: 
protein glycosylation in Bacteria and Archaea. Curr. Opin. Struct. Biol. 18 (5), 
pp544-550.  
2. Aebi, M. and Hennet, T. 2001. Congenital disorders of glycosylation: genetic 
model systems lead the way. Trends Cell. Biol. 11 (3), pp136-141.  
3. Ambrosi, M., Cameron, N. R. and Davis, B. G. 2005. Lectins: tools for the 
molecular understanding of the glycocode. Org. Biomol Chem. 3 (9), pp1593-1608.  
4. Anttinen, H. and Hulkko, A. 1980. Regulation of the glycosylations of collagen 
hydroxylysine in chick embryo tendon and cartilage cells. Biochimica et 
Biophysica Acta (BBA) - General Subjects 632 (3), pp417-427.  
5. Apweiler, R., Hermjakob, H. and Sharon, N. 1999. On the frequency of protein 
glycosylation, as deduced from analysis of the SWISS-PROT database. Biochimica 
et Biophysica Acta (BBA) - General Subjects 1473 (1), pp4-8.  
6. Arora, S. K., Bangera, M., Lory, S. and Ramphal, R. 2001. A genomic island in 
Pseudomonas aeruginosa carries the determinants of flagellin glycosylation. Proc. 
Natl. Acad. Sci. U.S.A. 98 (16), pp9342-9347.  
7. Barondes, S. H. 1988. Bifunctional properties of lectins: lectins redefined. Trends 
Biochem. Sci. 13 (12), pp480.  
8. Bartels, K., Funken, H., Knapp, A. 2011. Glycosylation Is Required for Outer 
Membrane Localization of the Lectin LecB in Pseudomonas aeruginosa. J. 
Bacteriol. 193 (5), pp1107-1113.  
9. Baumeister, W. and Lembcke, G. 1992. Structural features of archaebacterial cell 
envelopes. J. Bioenerg. Biomembr. 24 (6), pp567-575.  
10. Beeley, J. G. 1977. Peptide chain conformation and the glycosylation of 
glycoproteins. Biochem. Biophys. Res. Commun. 76 (4), pp1051.  
11. Benz, I. and Schmidt, M. A. 2002. Never say never again: protein glycosylation in 
pathogenic bacteria. Mol. Microbiol. 45 (2), pp267-276.  
12. Benz, I. and Schmidt, M. A. 2001. Glycosylation with heptose residues mediated 
by the aah gene product is essential for adherence of the AIDA-I adhesin. Mol. 
Microbiol. 40 (6), pp1403-1413. 
 204 
13. Bernatchez, S., Szymanski, C. M., Ishiyama, N. 2005. A Single Bifunctional UDP-
GlcNAc/Glc 4-Epimerase Supports the Synthesis of Three Cell Surface 
Glycoconjugates in Campylobacter jejuni. J. Biol. Chem. 280 (6), pp4792-4802.  
14. Birnboim, H. C. and Doly, J. 1979. A rapid alkaline extraction procedure for 
screening recombinant plasmid DNA. Nucl. Acids Res. 7 (6), pp1513-1523.  
15. Blackburn, M. B., Domek, J. M., Gelman, D. B. and Hu, J. S. 2005. The broadly 
insecticidal Photorhabdus luminescens toxin complex a (Tca): activity against the 
Colorado potato beetle, Leptinotarsa decemlineata, and sweet potato whitefly, 
Bemisia tabaci. J.Insect Sci. 5, pp32-42.  
16. Böhme, U. and Cross, G. A. M. 2002. Mutational analysis of the variant surface 
glycoprotein GPI-anchor signal sequence in Trypanosoma brucei. J. Cell. Sci. 115 
(4), pp805-816.  
17. Bolivar, F., Rodriguez, R. L., Greene, P. J. 1977. Construction and characterization 
of new cloning vehicles. II. A multipurpose cloning system. Gene 2 (2), pp95-113.  
18. Bugg, T. D. H. and Brandish, P. E. 1994. From peptidoglycan to glycoproteins: 
Common features of lipid-linked oligosaccharide biosynthesis. FEMS Microbiol. 
Lett. 119 (3), pp255-262.  
19. Campbell, C. and Yarema, K. 2005. Large-scale approaches for glycobiology. 
Genome Biol. 6 (11), pp236.  
20. Carlson, D. M. 1968. Structures and Immunochemical Properties of 
Oligosaccharides Isolated from Pig Submaxillary Mucins. J. Biol. Chem. 243 (3), 
pp616-626.  
21. Caroff, M. and Karibian, D. 2003. Structure of bacterial lipopolysaccharides. 
Carbohydr. Res. 338 (23), pp2431.  
22. Castric, P. 1995. pilO, a gene required for glycosylation of Pseudomonas 
aeruginosa 1244 pilin. Microbiology 141 (5), pp1247-1254.  
23. Castric, P., Cassels, F. J. and Carlson, R. W. 2001. Structural Characterization of 
the Pseudomonas aeruginosa 1244 Pilin Glycan. J. Biol. Chem. 276 (28), 
pp26479-26485.  
24. Comer, J. E., Marshall, M. A., Blanch, V. J. 2002. Identification of the 
Pseudomonas aeruginosa 1244 Pilin Glycosylation Site. Infect. Immun. 70 (6), 
pp2837-2845.  
 205 
25. Dell, A., Galadari, A., Sastre, F. and Hitchen, P. 2010. Similarities and differences 
in the glycosylation mechanisms in prokaryotes and eukaryotes. Int. J. Microbiol. 
2010pp148178.  
26. DiGiandomenico, A., Matewish, M. J., Bisaillon, A. 2002. Glycosylation of 
Pseudomonas aeruginosa 1244 pilin: glycan substrate specificity. Mol. Microbiol. 
46 (2), pp519-530.  
27. Dobos, K. M., Khoo, K. H., Swiderek, K. M. 1996. Definition of the full extent of 
glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. J. 
Bacteriol. 178 (9), pp2498-2506.  
28. Doig, P., Kinsella, N., Guerry, P. and Trust, T. J. 1996. Characterization of a post-
translational modification of Campylobacter flagellin: identification of a sero-
specific glycosyl moiety. Mol. Microbiol. 19 (2), pp379-387.  
29. Duchaud, E., Rusniok, C., Frangeul, L. 2003. The genome sequence of the 
entomopathogenic bacterium Photorhabdus luminescens. Nat. Biotech. 21 (11), 
pp1307.  
30. Duchene, M., Schweizer, A., Lottspeich, F. 1988. Sequence and transcriptional 
start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J. 
Bacteriol. 170 (1), pp155-162.  
31. Endo, T. 1999. O-Mannosyl glycans in mammals. Biochimica et Biophysica Acta 
(BBA) - General Subjects 1473 (1), pp237-246.  
32. Evans, J. N. S. 1995. Biomolecular NMR spectroscopy. Oxford ; New York: 
Oxford University Press.  
33. Fan, X., She, Y., Bagshaw, R. D. 2004. A method for proteomic identification of 
membrane-bound proteins containing Asn-linked oligosaccharides. Anal. Biochem. 
332 (1), pp178-186.  
34. Faridmoayer, A., Fentabil, M. A., Mills, D. C. 2007. Functional Characterization 
of Bacterial Oligosaccharyltransferases Involved in O-Linked Protein 
Glycosylation. J. Bacteriol. 189 (22), pp8088-8098.  
35. Feldman, M. F., Wacker, M., Hernandez, M. 2005. Engineering N-linked protein 
glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia 
coli. Proc. Natl. Acad. Sci. U.S.A. 102 (8), pp3016-3021.  
36. Finan, T. M., Kunkel, B., De Vos, G. F. and Signer, E. R. 1986. Second symbiotic 
megaplasmid in Rhizobium meliloti carrying exopolysaccharide and thiamine 
synthesis genes. J. Bacteriol. 167 (1), pp66-72.  
 206 
37. Fletcher, C. M., Coyne, M. J., Villa, O. F. 2009. A General O-Glycosylation 
System Important to the Physiology of a Major Human Intestinal Symbiont. Cell, 
137 (2), pp321-331.  
38. Forst, S. and Nealson, K. 1996. Molecular biology of the symbiotic-pathogenic 
bacteria Xenorhabdus spp. and Photorhabdus spp. Microbiol. Rev. 60 (1), pp21-43.  
39. Forst, S., Dowds, B., Boemare, N. and Stackebrandt, E. 1997. Xenorhabdus and 
Photorhabdus spp. :Bugs That Kill Bugs. Ann.l Rev. Microbiol. 51 (1), pp47-72.  
40. Fry, B. N., Feng, S., Chen, Y. 2000. The galE Gene of Campylobacter jejuni Is 
Involved in Lipopolysaccharide Synthesis and Virulence. Infect. Immun. 68 (5), 
pp2594-2601.  
41. Gaastra, W. and Svennerholm, A. 1996. Colonization factors of human 
enterotoxigenic Escherichia coli (ETEC). Trends Microbiol. 4 (11), pp444-452.  
42. Gabius, H., André, S., Jiménez-Barbero, J. 2011. From lectin structure to 
functional glycomics: principles of the sugar code. Trends Biochem. Sci. 36 (6), 
pp298-313.  
43. Gerrard, J., Waterfield, N., Vohra, R. and ffrench-Constant, R. 2004. Human 
infection with Photorhabdus asymbiotica: an emerging bacterial pathogen. 
Microbes Infect. 6 (2), pp229-237.  
44. Geyer, H. and Geyer, R. 2006. Strategies for analysis of glycoprotein 
glycosylation. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1764 
(12), pp1853.  
45. Glover, K. J., Weerapana, E. and Imperiali, B. 2005. In vitro assembly of the 
undecaprenylpyrophosphate-linked heptasaccharide for prokaryotic N-linked 
glycosylation. Proc. Natl. Acad. Sci. U.S.A. 102 (40), pp14255-14259.  
46. Goon, S., Kelly, J. F., Logan, S. M. 2003. Pseudaminic acid, the major 
modification on Campylobacter flagellin, is synthesized via the Cj1293 gene. Mol. 
Microbiol. 50 (2), pp659-671.  
47. Grass, S., Buscher, A. Z., Swords, W. E. 2003. The Haemophilus influenzae 
HMW1 adhesin is glycosylated in a process that requires HMW1C and 
phosphoglucomutase, an enzyme involved in lipooligosaccharide biosynthesis. 
Mol. Microbiol. 48 (3), pp737-751.  
48. Gross, J., Grass, S., Davis, A. E. 2008. The Haemophilus influenzae HMW1 
Adhesin Is a Glycoprotein with an Unusual N-Linked Carbohydrate Modification. 
J. Biol. Chem. 283 (38), pp26010-26015.  
 207 
49. Grünewald, S., Matthijs, G. and Jaeken, J. 2002. Congenital Disorders of 
Glycosylation: A Review. Pediatr. Res. 52 (5), pp618-624. 
50. Haltiwanger, R. S. and Stanley, P. 2002. Modulation of receptor signaling by 
glycosylation: fringe is an O-fucose-[beta]1,3-N-acetylglucosaminyltransferase. 
Biochimica et Biophysica Acta (BBA) - General Subjects 1573 (3), pp328-335.  
51. Hamilton, S. R. and Gerngross, T. U. 2007. Glycosylation engineering in yeast: the 
advent of fully humanized yeast. Curr. Opin. Biotechnol. 18 (5), pp387-392.  
52. Henzel, W. J., Billeci, T. M., Stults, J. T. 1993. Identifying proteins from two-
dimensional gels by molecular mass searching of peptide fragments in protein 
sequence databases. Proc. Natl. Acad. Sci. U.S.A. 90 (11), pp5011-5015.  
53. Hillenkamp, F. andPeter-Katalinić, J. 2007. MALDI MS: A practical guide to 
instrumentation, methods and applications. Wiley-Vch Verlagsgesellschaft Mbh : 
Weinheim.  
54. Hitchen, P. G. and Dell, A. 2006. Bacterial glycoproteomics. Microbiology 152 
(6), pp1575-1580.  
55. Horzempa, J., Dean, C. R., Goldberg, J. B. and Castric, P. 2006. Pseudomonas 
aeruginosa 1244 Pilin Glycosylation: Glycan Substrate Recognition. J. Bacteriol. 
188 (12), pp4244-4252.  
56. Inokuchi, K., Mutoh, N., Matsuyama, S. and Mizushima, S. 1982. Primary 
structure of the ompF gene that codes for a major outer membrane protein of 
Escherichia coli K-12. Nucl. Acids Res. 10 (21), pp6957-6968.  
57. Inoue, H., Nojima, H. and Okayama, H. 1990. High efficiency transformation of 
Escherichia coli with plasmids. Gene, 96 (1), pp23-28.  
58. Jennings, M. P., Virji, M., Evans, D. 1998. Identification of a novel gene involved 
in pilin glycosylation in Neisseria meningitidis. Mol. Microbiol. 29 (4), pp975-984.  
59. Kahler, C. M., Martin, L. E., Tzeng, Y. 2001. Polymorphisms in Pilin 
Glycosylation Locus of Neisseria meningitidis Expressing Class II Pili. Infect. 
Immun. 69 (6), pp3597-3604.  
60. Karlyshev, A. V., Champion, O. L., Churcher, C. 2005. Analysis of 
Campylobacter jejuni capsular loci reveals multiple mechanisms for the generation 
of structural diversity and the ability to form complex heptoses. Mol. Microbiol. 55 
(1), pp90-103.  
61. Karlyshev, A. V., Ketley, J. M. and Wren, B. W. 2005a. The Campylobacter jejuni 
glycome. FEMS Microbiol. Rev. 29 (2), pp377-390.  
 208 
62. Kawamura, T. and Shockman, G. D. 1983. Purification and some properties of the 
endogenous, autolytic N-acetylmuramoylhydrolase of Streptococcus faecium, a 
bacterial glycoenzyme. J. Biol. Chem. 258 (15), pp9514-9521.  
63. Kaya, H. K. and Gaugler, R. 1993. Entomopathogenic Nematodes. Annu. Rev. 
Entomol. 38 (1), pp181-206.  
64. Keeler, J. 2005. Understanding NMR spectroscopy. Chichester, England ; 
Hoboken, NJ: Wiley.  
65. Ketley, J. M. 1997. Pathogenesis of enteric infection by Campylobacter. 
Microbiology 143 (1), pp5-21.  
66. Kilpatrick, D. C. 2002. Animal lectins: a historical introduction and overview. 
Biochimica et Biophysica Acta (BBA) - General Subjects 1572 (2-3), pp187.  
67. Konami, Y., Yamamoto, K., Osawa, T. and Irimura, T. 1995. A putative 
carbohydrate-binding domain of the lactose binding Cytisus sessilifolius anti-H(O) 
lectin has a similar amino acid sequence to that of the L-fucose-binding Ulex 
europaeus anti-H(O) lectin. Glycoconj. J. 12 (2), pp128.  
68. Kovach, M. E., Elzer, P. H., Hill, D. S. 1995. Four new derivatives of the broad-
host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance 
cassettes. Gene 166, pp175–176.  
69. Kowarik, M., Numao, S., Feldman, M. F. 2006a. N-Linked Glycosylation of 
Folded Proteins by the Bacterial Oligosaccharyltransferase. Science 314 (5802), 
pp1148-1150.  
70. Kowarik, M., Young, N. M., Numao, S. 2006b. Definition of the bacterial N-
glycosylation site consensus sequence. EMBO J. 25 (9), pp1957-1966.  
71. Krinos, C. M., Coyne, M. J., Weinacht, K. G. 2001. Extensive surface diversity of 
a commensal microorganism by multiple DNA inversions. Nature 414 (6863), 
pp555-558.  
72. Ku, S. C., Schulz, B. L., Power, P. M. and Jennings, M. P. 2009. The pilin O-
glycosylation pathway of pathogenic Neisseria is a general system that 
glycosylates AniA, an outer membrane nitrite reductase. Biochem. Biophys. Res. 
Commun. 378 (1), pp84-89.  
73. Kuno, A., Uchiyama, N., Koseki-Kuno, S. 2005. Evanescent-field fluorescence-
assisted lectin microarray: a new strategy for glycan profiling. Nat. Meth. 2 (11), 
pp851.  
 209 
74. Kuo, C., Takahashi, N., Swanson, A. F. 1996. An N-linked high-mannose type 
oligosaccharide, expressed at the major outer membrane protein of Chlamydia 
trachomatis, mediates attachment and infectivity of the microorganism to HeLa 
cells. J. Clin. Invest. 98 (12), pp2813-2818.  
75. Laemmli, U. K. 1970. Cleavage of Structural Proteins during the Assembly of the 
Head of Bacteriophage T4. Nature 227 (5259), pp680-685.  
76. Laine, R. A. 1997. The Information Storing Potential of the Sugar Code. 
Glycosciences By: Gabius H. J, Gabius, S. (eds), London : Weinheim : Chapman 
and Hall, pp1-14.  
77. Lamblin, G., Degroote, S., Perini, J. 2001. Human airway mucin glycosylation: A 
combinatory of carbohydrate determinants which vary in cystic fibrosis. 
Glycoconj. J. 18 (9), pp661-684.  
78. Langdon, R. H., Cuccui, J. and Wren, B. W. 2009. N-linked glycosylation in 
bacteria: an unexpected application. Future Microbiology 4 (4), pp401-412.  
79. Lengeler, J.W., Drews, G. and Schlegel, H.G. 1999. Biology of the prokaryotes. 
Stuttgart : Blackwell Science.  
80. Lindenthal, C. and Elsinghorst, E. A. 1999. Identification of a glycoprotein 
produced by enterotoxigenic Escherichia coli. Infect. Immun. 67 (8), pp4084-4091.  
81. Linton, D., Allan, E., Karlyshev, A. V. 2002. Identification of N-
acetylgalactosamine-containing glycoproteins PEB3 and CgpA in Campylobacter 
jejuni. Mol. Microbiol. 43 (2), pp497-508.  
82. Linton, D., Dorrell, N., Hitchen, P. G. 2005. Functional analysis of the 
Campylobacter jejuni N-linked protein glycosylation pathway. Mol. Microbiol. 55 
(6), pp1695-1703.  
83. Lis, H. and Sharon, N. 1998. Lectins: Carbohydrate-Specific Proteins That Mediate 
Cellular Recognition. Chem. Rev. 98 (2), pp637-674.  
84. Logan, S. M., Kelly, J. F., Thibault, P. 2002. Structural heterogeneity of 
carbohydrate modifications affects serospecificity of Campylobacter flagellins. 
Mol. Microbiol. 46 (2), pp587-597.  
85. Lommel, M. and Strahl, S. 2009. Protein O-mannosylation: Conserved from 
bacteria to humans. Glycobiology 19 (8), pp816-828.  
86. Madera, M., Mechref, Y., Klouckova, I. and Novotny, M. V. 2006. Semiautomated 
High-Sensitivity Profiling of Human Blood Serum Glycoproteins through Lectin 
 210 
Preconcentration and Multidimensional Chromatography/Tandem Mass 
Spectrometry. J. Proteome Res. 5 (9), pp2348-2363.  
87. Marceau, M., Forest, K., Beretti, J. 1998. Consequences of the loss of O-linked 
glycosylation of meningococcal type IV pilin on piliation and pilus-mediated 
adhesion. Mol. Microbiol. 27 (4), pp705-715.  
88. Marth, J. D. and Grewal, P. K. 2008. Mammalian glycosylation in immunity. Nat. 
Rev. Immunol. 8 (11), pp874-887.  
89. Mattick, J. S. 2002. Type IV Pili and Twitching Motility. Annu. Rev. of Microbiol. 
56 (1), pp289-314.  
90. McGuckin, W. F. and McKenzie, B. F. 1958. An Improved Periodic Acid Fuchsin 
Sulfite Staining Method for Evaluation of Glycoproteins. Clin. Chem. 4 (6), pp476-
483.  
91. Medzihradszky, K. F., Campbell, J. M., Baldwin, M. A. 2000. The Characteristics 
of Peptide Collision-Induced Dissociation Using a High-Performance MALDI-
TOF/TOF Tandem Mass Spectrometer. Anal. Chem. 72 (3), pp552-558.  
92. Mescher, M. F. and Strominger, J. L. 1976. Purification and characterization of a 
prokaryotic glucoprotein from the cell envelope of Halobacterium salinarium. J. 
Biol. Chem. 251 (7), pp2005-2014.  
93. Mescher, M. F., Strominger, J. L. and Watson, S. W. 1974. Protein and 
Carbohydrate Composition of the Cell Envelope of Halobacterium salinarium. J. 
Bacteriol. 120 (2), pp945-954.  
94. Michell, S. L., Whelan, A. O., Wheeler, P. R. 2003. The MPB83 Antigen from 
Mycobacterium bovis Contains O-Linked Mannose and (1→3)-Mannobiose 
Moieties. J. Biol. Chem. 278 (18), pp16423-16432.  
95. Nakamura, N., Lyalin, D. and Panin, V. M. 2010. Protein O-mannosylation in 
animal development and physiology: From human disorders to Drosophila 
phenotypes. Semin. Cell. Dev. Biol. 21 (6), pp622-630.  
96. Nita-Lazar, M., Wacker, M., Schegg, B. 2005. The N-X-S/T consensus sequence is 
required but not sufficient for bacterial N-linked protein glycosylation. 
Glycobiology 15 (4), pp361-367.  
97. North, S. J., Hitchen, P. G., Haslam, S. M. and Dell, A. 2009. Mass spectrometry 
in the analysis of N-linked and O-linked glycans. Curr. Opin. Struct. Biol. 19 (5), 
pp498-506.  
 211 
98. Nothaft, H. and Szymanski, C. M. 2010. Protein glycosylation in bacteria: sweeter 
than ever. Nat. Rev. Micro. 8 (11), pp765-778.  
99. Pandhal, J. and Wright, P. 2010. N-Linked glycoengineering for human therapeutic 
proteins in bacteria. Biotechnol. Lett. 32 (9), pp1189-1198.  
100. Pappin, D. J. C., Hojrup, P. and Bleasby, A. J. 1993. Rapid identification of 
proteins by peptide-mass fingerprinting. Curr. Biol. 3 (6), pp327-332.  
101. Parge, H. E., Forest, K. T., Hickey, M. J. 1995. Structure of the fibre-forming 
protein pilin at 2.6 A resolution. Nature 378 (6552), pp32.  
102. Paulson, J. C. 1989. Glycoproteins: what are the sugar chains for? Trends Biochem. 
Sci. 14 (7), pp272-276.  
103. Poretz, R. D. and Goldstein, I. J. 1971. Protein-carbohydrate interaction : On the 
mode of binding of aromatic moieties to concanavalin A, the phytohemagglutinin 
of the jack bean. Biochem. Pharmacol. 20 (10), pp2727-2739.  
104. Power, P. M. and Jennings, M. P. 2003. The genetics of glycosylation in Gram-
negative bacteria. FEMS Microbiol. Lett. 218 (2), pp211-222.  
105. Power, P. M., Roddam, L. F., Rutter, K. 2003a. Genetic characterization of pilin 
glycosylation and phase variation in Neisseria meningitidis. Mol. Microbiol. 49 
(3), pp833-847.  
106. Power, P. M., Roddam, L. F., Rutter, K. 2000. Genetic characterization of pilin 
glycosylation in Neisseria meningitidis. Mol. Microbiol. 49 (3), pp833-847.  
107. Power, P. M., Seib, K. L. and Jennings, M. P. 2006. Pilin glycosylation in 
Neisseria meningitidis occurs by a similar pathway to wzy-dependent O-antigen 
biosynthesis in Escherichia coli. Biochem. Biophys. Res. Commun. 347 (4), pp904-
908.  
108. Quandt, J. and Hynes, M. F. 1993. Versatile suicide vectors which allow direct 
selection for gene replacement in Gram-negative bacteria. Gene 127 (1), pp15-21.  
109. Roberts, I. S. 1996. The biochemistry and genetics of capsular polysaccharide 
production in bacteria. Annu. Rev. Microbiol. 50pp285-315.  
110. Samuel, G. and Reeves, P. 2003. Biosynthesis of O-antigens: genes and pathways 
involved in nucleotide sugar precursor synthesis and O-antigen assembly. 
Carbohydr. Res. 338 (23), pp2503.  
111. Schaffer, C. and Messner, P. 2004. Surface-layer glycoproteins: an example for the 
diversity of bacterial glycosylation with promising impacts on nanobiotechnology. 
Glycobiology 14 (8), pp31R-42.  
 212 
112. Schirm, M., Arora, S. K., Verma, A. 2004. Structural and genetic characterization 
of glycosylation of type a flagellin in Pseudomonas aeruginosa. J. Bacteriol. 186 
(9), pp2523.  
113. Schirm, M., Soo, E. C., Aubry, A. J. 2003. Structural, genetic and functional 
characterization of the flagellin glycosylation process in Helicobacter pylori. Mol. 
Microbiol. 48 (6), pp1579-1592.  
114. Schmidt, M. A., Riley, L. W. and Benz, I. 2003. Sweet new world: glycoproteins 
in bacterial pathogens. Trends Microbiol. 11 (12), pp554-561.  
115. Schwan, T. G. and Piesman, J. 2002. Vector interactions and molecular adaptations 
of Lyme disease and relapsing fever spirochetes associated with transmission by 
ticks. Emerg. Infect. Dis. 8 (2), pp115-121.  
116. Sharon, N. and Lis, H. 1990. Legume lectins-a large family of homologous 
proteins. FASEB J. 4 (14), pp3198-3208.  
117. Sherlock, O., Dobrindt, U., Jensen, J. B. 2006. Glycosylation of the Self-
Recognizing Escherichia coli Ag43 Autotransporter Protein. J. Bacteriol. 188 (5), 
pp1798-1807.  
118. Shevchenko, A., Tomas, H., Havlis, J. 2007. In-gel digestion for mass 
spectrometric characterization of proteins and proteomes. Nat. Protocols 1 (6), 
pp2856-2860.  
119. Siuti, N. and Kelleher, N. L. 2007. Decoding protein modifications using top-down 
mass spectrometry. Nat. Meth. 4 (10), pp817-821.  
120. Sleytr, U. B. and Thorne, K. J. 1976. Chemical characterization of the regularly 
arranged surface layers of Clostridium thermosaccharolyticum and Clostridium 
thermohydrosulfuricum. J. Bacteriol. 126 (1), pp377-383.  
121. Smedley III, J. G., Jewell, E., Roguskie, J. 2005. Influence of Pilin Glycosylation 
on Pseudomonas aeruginosa 1244 Pilus Function. Infect. Immun. 73 (12), pp7922-
7931.  
122. Sojar, H.T., Bahl, O.P. and Victor, G.1987. [27] Chemical deglycosylation of 
glycoproteins. Methods in Enzymology. Academic Press. pp341-350.  
123. Stimson, E., Virji, M., Makepeace, K. 1995. Meningococcal pilin: a glycoprotein 
substituted with digalactosyl 2,4-diacetamido-2,4,6-trideoxyhexose. Mol. 
Microbiol. 17 (6), pp1201-1214.  
124. Sumner, J. B. 1919. The Globulins of the Jack Bean, Canavalia ensiformis. 
Preliminary Paper. J. Biol. Chem. 37 (1), pp137-142.  
 213 
125. Sumner, J. B. and Howell, S. F. 1936. Identification of Hemagglutinin of Jack 
Bean with Concanavalin A. J. Bacteriol. 32 (2), pp227-237.  
126. Swanson, A. F. and Kuo, C. C. 1991. Evidence that the major outer membrane 
protein of Chlamydia trachomatis is glycosylated. Infect. Immun. 59 (6), pp2120-
2125.  
127. Szymanski, C. M., Burr, D. H. and Guerry, P. 2002. Campylobacter Protein 
Glycosylation Affects Host Cell Interactions. Infect. Immun. 70 (4), pp2242-2244.  
128. Szymanski, C. M., Logan, S. M., Linton, D. and Wren, B. W. 2003. 
Campylobacter - a tale of two protein glycosylation systems. Trends Microbiol. 11 
(5), pp233-238.  
129. Szymanski, C. M. and Wren, B. W. 2005. Protein glycosylation in bacterial 
mucosal pathogens. Nat. Rev. Micro. 3 (3), pp225-237.  
130. Szymanski, C. M., Yao, R., Ewing, C. P. 1999. Evidence for a system of general 
protein glycosylation in Campylobacter jejuni. Mol. Microbiol. 32 (5), pp1022-
1030.  
131. Taylor, M.E. and Drickamer, K. 2006. Introduction to glycobiology. 2nd. Oxford ; 
New York: Oxford University Press.  
132. Thibault, P., Logan, S. M., Kelly, J. F. 2001. Identification of the carbohydrate 
moieties and glycosylation motifs in Campylobacter jejuni flagellin. J. Biol. Chem. 
276 (37), pp34862-34870.  
133. Twine, S. M., Paul, C. J., Vinogradov, E. 2008. Flagellar glycosylation in 
Clostridium botulinum. FEBS J. 275 (17), pp4428-4444.  
134. Twine, S. M., Reid, C. W., Aubry, A. 2009. Motility and Flagellar Glycosylation 
in Clostridium difficile. J. Bacteriol. 191 (22), pp7050-7062.  
135. University of Bath 2004. (News). [Online]. Available from : 
<http://www.bath.ac.uk/pr/releases/humaninfectionsfrominsects.htm> [Accessed 
21 January 2008]. 
136. Upreti, R. K., Kumar, M. and Shankar, V. 2003. Bacterial glycoproteins: 
Functions, biosynthesis and applications. Proteomics 3 (4), pp363-379.  
137. USDA Agricultural Research Service. [Online]. Available from : 
<http://www.ars.usda.gov/is/kids/insects/story12/nematodes.htm> [Accessed 21 
January 2008]. 
138. Varki, A. 1999. Essentials of glycobiology. Cold Spring Harbor, NY: Cold Spring 
Harbor Laboratory.  
 214 
139. Verma, A., Schirm, M., Arora, S. K. 2006. Glycosylation of b-Type Flagellin of 
Pseudomonas aeruginosa: Structural and Genetic Basis. J. Bacteriol. 188 (12), 
pp4395-4403.  
140. Vik, A., Aas, F. E., Anonsen, J. H. 2009. Broad spectrum O-linked protein 
glycosylation in the human pathogen Neisseria gonorrhoeae. Proc. Natl. Acad. Sci. 
U.S.A. 106 (11), pp4447-4452.  
141. Virji, M., Kayhty, H., Ferguson, D. J. P. 1991. The role of pili in the interactions of 
pathogenic Neisseria with cultured human endothelial cells. Mol. Microbiol. 5 (8), 
pp1831-1841.  
142. Wacker, M., Feldman, M. F., Callewaert, N. 2006. Substrate specificity of bacterial 
oligosaccharyltransferase suggests a common transfer mechanism for the bacterial 
and eukaryotic systems. Proc. Natl. Acad. Sci. U.S.A. 103 (18), pp7088-7093.  
143. Wacker, M., Linton, D., Hitchen, P. G. 2002. N-Linked Glycosylation in 
Campylobacter jejuni and its Functional Transfer into E. coli. Science 298 (5599), 
pp1790-1793.  
144. Walsh, G. and Jefferis, R. 2006. Post-translational modifications in the context of 
therapeutic proteins. Nat. Biotech. 24 (10), pp1241-1252.  
145. Wang, Y., Wu, S. and Hancock, W. S. 2006. Approaches to the study of N-linked 
glycoproteins in human plasma using lectin affinity chromatography and nano-
HPLC coupled to electrospray linear ion trap-Fourier transform mass spectrometry. 
Glycobiology 16 (6), pp514-523.  
146. Ward, A., Sanderson, N. M., O'Reilly, J. 2000. The amplified expression, 
identification, purification, assay, and properties of hexahistidine-tagged bacterial 
membrane transport proteins. Membrane transport—a practical approach. Oxford, 
United Kingdom : Oxford University Press, pp141-166.  
147. Waterfield, N. R., Ciche, T. and Clarke, D. 2009. Photorhabdus and a Host of 
Hosts. Annu. Rev. Microbiol. 63 (1), pp557-574.  
148. Weerapana, E., Glover, K. J., Chen, M. M. and Imperiali, B. 2005. Investigating 
Bacterial N-Linked Glycosylation: Synthesis and Glycosyl Acceptor Activity of 
the Undecaprenyl Pyrophosphate-Linked Bacillosamine. J. Am. Chem. Soc. 127 
(40), pp13766-13767.  
149. Weerapana, E. and Imperiali, B. 2006. Asparagine-linked protein glycosylation: 
from eukaryotic to prokaryotic systems. Glycobiology 16 (6), pp91R-101.  
 215 
150. Wehmeier, S., Varghese, A. S., Gurcha, S. S. 2009. Glycosylation of the phosphate 
binding protein, PstS, in Streptomyces coelicolor by a pathway that resembles 
protein O-mannosylation in eukaryotes. Mol. Microbiol. 71 (2), pp421-433.  
151. Werner, R. G., Kopp, K. and Schlueter, M. 2007. Glycosylation of therapeutic 
proteins in different production systems. Acta Paediatr. 96, pp17-22.  
152. Whitfield, C. 1995. Biosynthesis of lipopolysaccharide O antigens. Trends 
Microbiol. 3 (5), pp178-185.  
153. Young, N. M., Brisson, J., Kelly, J. 2002. Structure of the N-Linked Glycan 
Present on Multiple Glycoproteins in the Gram-negative Bacterium, 
Campylobacter jejuni. J. Biol. Chem. 277 (45), pp42530-42539.  
154. Zarembinski, T. I., Hung, L., Mueller-Dieckmann, H. 1998. Structure-based 
assignment of the biochemical function of a hypothetical protein: A test case of 
structural genomics. Proc. Natl. Acad. Sci. U.S.A. 95 (26), pp15189-15193.  
155. Zeituni, A. E., McCaig, W., Scisci, E. 2010. The Native 67-Kilodalton Minor 
Fimbria of Porphyromonas gingivalis Is a Novel Glycoprotein with DC-SIGN-
Targeting Motifs. J. Bacteriol. 192 (16), pp4103-4110.  
156. Zhang, L. and Reilly, J. P. 2009. Extracting both peptide sequence and glycan 
structural information by 157 nm photodissociation of N-linked glycopeptides. J. 
Proteome Res. 8 (2), pp734-742.  
157. Zhang, Y., Go, E. P. and Desaire, H. 2008. Maximizing Coverage of Glycosylation 
Heterogeneity in MALDI-MS Analysis of Glycoproteins with Up to 27 
Glycosylation Sites. Anal. Chem. 80 (9), pp3144-3158.  
